

CITATION REPORT

List of articles citing

Ig V Gene Mutation Status and CD38 Expression As Novel Prognostic Indicators in Chronic Lymphocytic Leukem

DOI: 10.1182/blood.v94.6.1840
Blood, 1999, 94, 1840-1847.

Source: <https://exaly.com/paper-pdf/30046268/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2165	Mature B-cell leukemias. 171-190		
2164	Frequent occurrence of deletions and duplications during somatic hypermutation: implications for oncogene translocations and heavy chain disease. 1998 , 95, 2463-8		288
2163	Unmutated Ig VH Genes Are Associated With a More Aggressive Form of Chronic Lymphocytic Leukemia. <i>Blood</i> , 1999 , 94, 1848-1854	2.2	2095
2162	Mutational Status of Ig VH Genes Provides Clinically Valuable Information in B-Cell Chronic Lymphocytic Leukemia. <i>Blood</i> , 1999 , 94, 1837-1839	2.2	48
2161	Clinical relevance of immunoglobulin mutation analysis. 2000 , 12, 395-402		6
2160	Lymphomas: complexity, not chaos. 2000 , 12, 379-82		2
2159	Chronic lymphocytic leukemia. 2000 , 7, 223-34		84
2158	Update on the biology of chronic lymphocytic leukemia. 2000 , 12, 22-9		66
2157	IgG-secreting lymphoplasmacytoid leukaemia: a B-cell disorder with extensively mutated VH genes undergoing Ig isotype-switching frequently associated with trisomy 12. <i>British Journal of Haematology</i> , 2000 , 109, 71-80	4.5	14
2156	MUM1/IRF4 expression as a frequent event in mature lymphoid malignancies. <i>Leukemia</i> , 2000 , 14, 449-560.7	10.7	146
2155	MUM1: a step ahead toward the understanding of lymphoma histogenesis. <i>Leukemia</i> , 2000 , 14, 563-6	10.7	62
2154	Identification of three subgroups of B cell chronic lymphocytic leukemia based upon mutations of BCL-6 and IgV genes. <i>Leukemia</i> , 2000 , 14, 811-5	10.7	42
2153	Historical aspects of chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2000 , 111, 1023-1034	4.5	45
2152	Autologous T lymphocytes recognize the tumour-derived immunoglobulin VH-CDR3 region in patients with B-cell chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2000 , 111, 230-238	4.5	45
2151	Biology of chronic lymphocytic leukemia. 2000 , 4, 5-21		54
2150	Morphological and immunophenotypic features of chronic lymphocytic leukemia. 2000 , 4, 22-47		82
2149	Genetic features of B-cell chronic lymphocytic leukemia. 2000 , 4, 48-72		49

2148	New Concepts in the Pathogenesis, Diagnosis, Prognostic Factors and Clinical Presentation of Chronic Lymphocytic Leukemia. 2000 , 4, 103-117		7
2147	Hematopoietic Stem-Cell Transplantation for B-Cell Chronic Lymphocytic Leukemia: Current Status. 2000 , 4, 167-178		5
2146	Immunophenotyping of leukemia. 2000 , 243, 59-75		112
2145	Cellular interactions, immunodeficiency and autoimmunity in CLL. 2000 , 42, 21-5		6
2144	Somatic mutation of bcl-6 genes can occur in the absence of VH mutations in chronic lymphocytic leukemia. <i>Blood</i> , 2000 , 95, 3534-3540	2.2	39
2143	Apoptosis or plasma cell differentiation of CD38-positive B-chronic lymphocytic leukemia cells induced by cross-linking of surface IgM or IgD. <i>Blood</i> , 2000 , 95, 1199-1206	2.2	72
2142	HFE polymorphism and accurate diagnosis of C282Y hereditary hemochromatosis carriers. <i>Blood</i> , 2000 , 95, 2453-2455	2.2	2
2141	Immunoglobulin V genes and CD38 expression in CLL. <i>Blood</i> , 2000 , 95, 2455-2457	2.2	137
2140	Expression of Ig- λ (CD79b) by chronic lymphocytic leukemia B cells that lack immunoglobulin heavy-chain allelic exclusion. <i>Blood</i> , 2000 , 95, 2725-2727	2.2	12
2139	Expression of unmutated VH genes is a detrimental prognostic factor in chronic lymphocytic leukemia. <i>Blood</i> , 2000 , 96, 377-379	2.2	108
2138	High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH. <i>Blood</i> , 2000 , 96, 1505-1511	2.2	135
2137	Neue Methoden in Diagnostik und Therapie: Kostensteigerung oder Kostenverminderung?. 2000 , 45-47		
2136	Hematopoietic and lymphoid tumors. 2000 , 304-388		
2135	Biclonal chronic lymphocytic leukemia. 2000 , 113, 798-804		24
2134	Aberrant B cell receptor signaling from B29 (Igbeta, CD79b) gene mutations of chronic lymphocytic leukemia B cells. 2000 , 97, 5504-9		29
2133	Ongoing immunoglobulin somatic mutation in germinal center B cell-like but not in activated B cell-like diffuse large cell lymphomas. 2000 , 97, 10209-13		188
2132	When and how to treat chronic lymphocytic leukemia. 2000 , 343, 1799-801		106
2131	The indispensable role of microenvironment in the natural history of low-grade B-cell neoplasms. 2000 , 79, 157-73		82

2130	Differential diagnosis of malignant lymphomas and related disorders by specific pattern of expression of immunophenotypic markers revealed by multiparameter flow cytometry (Review). 2000 , 17, 1165-77		3
2129	Histological and immunoglobulin VH gene analysis of interfollicular small lymphocytic lymphoma provides evidence for two types. 2000 , 157, 1063-70		27
2128	Genomic aberrations and survival in chronic lymphocytic leukemia. 2000 , 343, 1910-6		2573
2127	CD40 ligand in CLL pathogenesis and therapy. <i>Leukemia and Lymphoma</i> , 2000 , 37, 461-72	1.9	46
2126	Achieving optimal outcomes in chronic lymphocytic leukaemia. 2001 , 61, 593-611		14
2125	CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. <i>Blood</i> , 2001 , 98, 181-6	2.2	348
2124	Adhesion molecule expression in CD5-negative/CD10-negative chronic B-cell leukemias: comparison with non-Hodgkin's lymphomas and CD5-positive B-cell chronic lymphocytic leukemia. 2001 , 32, 66-73		12
2123	Secondary ocular involvement in systemic "memory" B-cell lymphocytic leukemia. 2001 , 108, 1289-95		21
2122	Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. <i>Blood</i> , 2001 , 98, 29-35	2.2	215
2121	How immunology is reshaping clinical disciplines: the example of haematology. 2001 , 358, 49-55		13
2120	Broad alterations of self-reactive antibody-repertoires of plasma IgM and IgG in B-cell chronic lymphocytic leukemia (B-CLL) and B-CLL related target-restricted autoimmunity. <i>Leukemia and Lymphoma</i> , 2001 , 42, 163-76	1.9	7
2119	Morphometric and colorimetric analysis of peripheral blood smears lymphocytes in B-cell disorders: proposal for a scoring system. <i>Leukemia and Lymphoma</i> , 2001 , 42, 29-40	1.9	8
2118	CD38 expression correlates with adverse biological features and predicts poor clinical outcome in B-cell chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2001 , 42, 109-14	1.9	72
2117	Immunophenotypic analysis of leukocytes in disease. 2001 , 138-164		
2116	Gene expression profiling in lymphoid malignancies. 2001 , 162-186		
2115	Chronic lymphocytic leukemia: case-based session. 2001 , 2001, 140-56		16
2114	Common Germinal-Center B-Cell Origin of the Malignant Cells in Two Composite Lymphomas, Involving Classical Hodgkin's Disease and Either Follicular Lymphoma or B-CLL. 2001 , 7, 285-292		71
2113	Pathology and cytogenetics. 2001 , 12-18		

2112 Small lymphocytic lymphoma and its variants. **2001**, 141-153

2111 CD38 expression is a poor predictor for VH gene mutational status and prognosis in chronic lymphocytic leukemia. *Blood*, **2001**, 97, 1892-4 2.2 112

2110 CD38 expression and Ig VH gene mutation in B-cell chronic lymphocytic leukemia. *Blood*, **2001**, 97, 1902-3.2 70

2109 Clonotypic polymerase chain reaction confirms minimal residual disease in CLL nodular PR: results from a sequential treatment CLL protocol. *Blood*, **2001**, 97, 1929-36 2.2 19

2108 Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. *Blood*, **2001**, 97, 2777-83 2.2 280

2107 Survival of leukemic B cells promoted by engagement of the antigen receptor. *Blood*, **2001**, 98, 3050-7 2.2 162

2106 Nodal marginal zone B-cell lymphomas may arise from different subsets of marginal zone B lymphocytes. *Blood*, **2001**, 98, 781-6 2.2 50

2105 Tumor cells of hairy cell leukemia express multiple clonally related immunoglobulin isotypes via RNA splicing. *Blood*, **2001**, 98, 1174-81 2.2 70

2104 Clinical significance of CD38 expression in chronic lymphocytic leukemia. *Blood*, **2001**, 98, 2633-9 2.2 216

2103 New approaches to lymphoma diagnosis. **2001**, 2001, 194-220 60

2102 The occurrence and significance of V gene mutations in B cell-derived human malignancy. **2001**, 83, 81-116 82

2101 Leukaemias and Lymphomas. **2001**,

2100 Chronic lymphocytic leukaemia. **2001**, 1, 350-3

2099 Absence of clonal chromosomal relationship between concomitant B-CLL and multiple myeloma--a report on two cases. **2001**, 80, 474-8 30

2098 Gene expression profiling of lymphomas. **2001**, 3, 243-9 9

2097 Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. *British Journal of Haematology*, **2001**, 115, 854-61 4.5 163

2096 Molecular abnormalities in B-cell chronic lymphocytic leukaemia. **2001**, 23, 139-48 4

2095 Pathology of lymphoma progression. **2001**, 38, 285-306 43

2094	Peripheral blood CD38 expression predicts survival in B-cell chronic lymphocytic leukemia. 2001 , 25, 927-32		45
2093	Lack of allelic exclusion and isotype switching in B cell chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2001 , 68, 295-7	7.1	4
2092	New aspects on the pathogenesis, diagnostic procedures, and therapeutic management of chronic lymphocytic leukemia. 2001 , 73, 32-8		13
2091	Immunoglobulin variable region structure and B-cell malignancies. 2001 , 73, 47-53		5
2090	Molecular single-cell analysis of Hodgkin- and Reed-Sternberg cells harboring unmutated immunoglobulin variable region genes. 2001 , 81, 289-95		24
2089	Analysis of the immunoglobulin heavy chain gene variable region of CD5-positive and -negative diffuse large B cell lymphoma. <i>Leukemia</i> , 2001 , 15, 452-7	10.7	21
2088	Molecular heterogeneity of splenic marginal zone lymphomas: analysis of mutations in the 5' non-coding region of the bcl-6 gene. <i>Leukemia</i> , 2001 , 15, 628-34	10.7	24
2087	Differential expression of chemokine receptors in B cell malignancies. <i>Leukemia</i> , 2001 , 15, 752-6	10.7	117
2086	A phase II study of sequential combination chemotherapy with cyclophosphamide, prednisone, and 2-chlorodeoxyadenosine in previously untreated patients with chronic lymphocytic leukemia. <i>Leukemia</i> , 2001 , 15, 1171-5	10.7	9
2085	Allogeneic and autologous transplantation for chronic lymphocytic leukemia. <i>Leukemia</i> , 2001 , 15, 1317-25	10.7	33
2084	Human CD38: a (r)evolutionary story of enzymes and receptors. 2001 , 25, 1-12		212
2083	Telomerase regulation and telomere dynamics in germinal centers. 2001 , 67, 309-17		40
2082	Laboratory, morphologic, and immunophenotypic correlates of surface immunoglobulin heavy chain isotype expression in B-cell chronic lymphocytic leukemia. 2001 , 116, 905-12		8
2081	Large cell lymphoma transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma. A flow cytometric analysis of seven cases. 2001 , 115, 385-95		37
2080	Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. 2001 , 194, 1639-47		882
2079	Somatic hypermutation and B-cell lymphoma. 2001 , 356, 73-82		26
2078	Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. 2001 , 194, 1625-38		731
2077	Typical and atypical chronic lymphocytic leukemia differ clinically and immunophenotypically. 2001 , 116, 655-64		54

2076	Immunoglobulin heavy chain variable region (VH) genes of B cell chronic lymphocytic leukemia cells from lymph nodes show somatic mutations and intraclonal diversity irrespective of follicular dendritic cell network. <i>Leukemia and Lymphoma</i> , 2001 , 42, 499-506	1.9	7
2075	CD148 and CD27 are expressed in B cell lymphomas derived from both memory and naïve B cells. <i>Leukemia and Lymphoma</i> , 2002 , 43, 1855-8	1.9	34
2074	Clinicoprognostic implications of increased serum levels of vascular endothelial growth factor and basic fibroblastic growth factor in early B-cell chronic lymphocytic leukaemia. 2002 , 86, 31-5		37
2073	Chronic lymphocytic leukemia B cells can undergo somatic hypermutation and intraclonal immunoglobulin V(H)DJ(H) gene diversification. 2002 , 196, 629-39		78
2072	The configuration of the immunoglobulin genes in B cell chronic lymphocytic leukemia. <i>Leukemia</i> , 2002 , 16, 973-84	10.7	39
2071	Comparison of immunophenotypes of small B-cell neoplasms in primary lymph node and concurrent blood or marrow samples. 2002 , 118, 758-64		18
2070	Chronic lymphocytic leukemia. 2002 , 2002, 193-213		54
2069	B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules. <i>Leukemia</i> , 2002 , 16, 911-9	10.7	109
2068	Lack of somatic hypermutation of IG V(H) genes in lymphoid malignancies with t(2;14)(p13;q32) translocation involving the BCL11A gene. <i>Leukemia</i> , 2002 , 16, 937-9	10.7	26
2067	Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia. <i>Leukemia</i> , 2002 , 16, 985-92	10.7	87
2066	Allogeneic related donor hematopoietic stem cell transplantation for treatment of chronic lymphocytic leukemia. 2002 , 29, 817-23		80
2065	CD5-induced apoptosis of B cells in some patients with chronic lymphocytic leukemia. <i>Leukemia</i> , 2002 , 16, 44-52	10.7	30
2064	CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia. <i>Leukemia</i> , 2002 , 16, 30-5	10.7	181
2063	Surface antigen expression in chronic lymphocytic leukemia: clustering analysis, interrelationships and effects of chromosomal abnormalities. <i>Leukemia</i> , 2002 , 16, 178-85	10.7	46
2062	Immunoglobulin diversification in B cell malignancies: internal splicing of heavy chain variable region as a by-product of somatic hypermutation. <i>Leukemia</i> , 2002 , 16, 636-44	10.7	7
2061	Ongoing in vivo immunoglobulin class switch DNA recombination in chronic lymphocytic leukemia B cells. 2002 , 169, 6594-603		58
2060	The role of soluble CD23 in distinguishing stable and progressive forms of B-chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2002 , 43, 549-54	1.9	22
2059	ATM mutations in sporadic lymphoid tumours. <i>Leukemia and Lymphoma</i> , 2002 , 43, 1563-71	1.9	66

2058	Immunophenotype does not correlate with lymph node histology in chronic lymphocytic leukemia/small lymphocytic lymphoma. 2002 , 26, 624-9		28
2057	Molecular diagnosis of lymphoid malignancies by gene expression profiling. 2002 , 9, 333-8		51
2056	Monoclonal B lymphocytes with the characteristics of "indolent" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts. <i>Blood</i> , 2002 , 100, 635-9	2.2	263
2055	Chronic lymphocytic leukemia preceded by cold agglutinin disease: intraclonal immunoglobulin light-chain diversity in V(H)4-34 expressing single leukemic B cells. <i>Blood</i> , 2002 , 100, 3419-22	2.2	37
2054	Ataxia telangiectasia mutated-deficient B-cell chronic lymphocytic leukemia occurs in pregerminal center cells and results in defective damage response and unrepaired chromosome damage. <i>Blood</i> , 2002 , 99, 300-9	2.2	121
2053	B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. <i>Blood</i> , 2002 , 99, 4087-93	2.2	259
2052	P2X7 receptor expression in evolutive and indolent forms of chronic B lymphocytic leukemia. <i>Blood</i> , 2002 , 99, 706-8	2.2	161
2051	CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. <i>Blood</i> , 2002 , 99, 1023-9	2.2	512
2050	Analysis of the IgV(H) somatic mutations in splenic marginal zone lymphoma defines a group of unmutated cases with frequent 7q deletion and adverse clinical course. <i>Blood</i> , 2002 , 99, 1299-304	2.2	138
2049	Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia. <i>Blood</i> , 2002 , 99, 2262-4	2.2	263
2048	The chemokine receptor CCR7 and alpha4 integrin are important for migration of chronic lymphocytic leukemia cells into lymph nodes. <i>Blood</i> , 2002 , 99, 2977-84	2.2	168
2047	Expression of MUM1/IRF4 correlates with clinical outcome in patients with B-cell chronic lymphocytic leukemia. <i>Blood</i> , 2002 , 100, 4671-5	2.2	47
2046	Activating Ras mutations in patients with plasma-cell disorders: a reappraisal. <i>Blood</i> , 2002 , 100, 1101-2; author reply 1103	2.2	9
2045	Do B-cell chronic lymphocytic leukemia patients with Ig VH3-21 genes constitute a new subset of chronic lymphocytic leukemia?. <i>Blood</i> , 2002 , 100, 1097-8; author reply 1098-9	2.2	11
2044	Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion. <i>Blood</i> , 2002 , 100, 2289-90	2.2	184
2043	CXCR4 expression is associated with survival in familial chronic lymphocytic leukemia, but CD38 expression is not. <i>Blood</i> , 2002 , 100, 1100-1	2.2	40
2042	Conversion of CD38 and/or myeloid-associated marker expression status during the course of B-CLL: association with a change to an aggressive clinical course. <i>Blood</i> , 2002 , 100, 1106	2.2	15
2041	Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. <i>Blood</i> , 2002 , 100, 4609-14	2.2	407

2040	The nosology of myelodysplastic syndromes. <i>Blood</i> , 2002 , 100, 3053; author reply3054	2.2	2
2039	CD38 expression does not change in B-cell chronic lymphocytic leukemia. <i>Blood</i> , 2002 , 100, 3052-3	2.2	18
2038	Erratum for vol. 100, p. 1404. <i>Blood</i> , 2002 , 100, 2291-2291	2.2	
2037	Genetics of chronic lymphocytic leukemia: genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course. <i>Leukemia</i> , 2002 , 16, 993-1007	10.7	197
2036	Chronic lymphocytic leukaemia--the haematologic basis for diagnosis and treatment. 2002 , 7, 33-41		1
2035	Gene expression profiling of lymphoid malignancies. 2002 , 53, 303-18		101
2034	Splenic marginal zone lymphomas appear to originate from different B cell types. 2002 , 161, 81-8		49
2033	Monitoring disease in lymphoma and CLL patients using molecular techniques. 2002 , 15, 179-95		11
2032	Chronic lymphocytic leukaemia: a model for investigating potential new targets for the therapy of indolent lymphomas. 2002 , 15, 563-75		5
2031	Chronic Lymphocytic Leukemia. 2002 , 1, 127-143		
2030	Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia. <i>Blood</i> , 2002 , 100, 1404-9	2.2	197
2029	Chronic lymphocytic leukaemia: one cell, two diseases?. 2002 , 360, 184-6		3
2028	Polymorphism in the P2X7 receptor gene and survival in chronic lymphocytic leukaemia. 2002 , 360, 1935-9		82
2027	The P2X7 receptor of CLL lymphocytes-a molecule with a split personality. 2002 , 360, 1898-9		17
2026	Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. <i>Blood</i> , 2002 , 100, 3115-20	2.2	182
2025	Practical evaluation and management of cutaneous lymphoma. 2002 , 46, 325-57; quiz, 358-60		71
2024	Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. <i>Blood</i> , 2002 , 100, 1177-1184	2.2	424
2023	The clinical significance of tumor necrosis factor- β plasma level in patients having chronic lymphocytic leukemia. <i>Blood</i> , 2002 , 100, 1215-1219	2.2	140

2022	V H mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. <i>Blood</i> , 2002 , 100, 1410-1416	2.2	633
2021	Advances in classification and therapy of indolent B-cell malignancies. 2002 , 29, 98-104		17
2020	Clinical translation of gene expression profiling in lymphomas and leukemias. 2002 , 29, 258-63		39
2019	The clinical significance of CD8+ T cell subset abnormalities in common human malignancies. 2002 , 2, 141-154		
2018	Cell surface expression of CD25, CD54, and CD95 on B- and T-cells in chronic lymphocytic leukaemia in relation to trisomy 12, atypical morphology and clinical course. 2002 , 68, 127-34		22
2017	Somatic hypermutation and V(H) gene usage in mantle cell lymphoma. 2002 , 68, 217-24		72
2016	The FAB/MIC/WHO proposals for the classification of the chronic lymphoid leukemias. 2002 , 6, 330-4		4
2015	B-chronic lymphocytic leukemia: practical aspects. 2002 , 20, 103-46		37
2014	Significance of phosphotyrosine proteins, Bcl-2 and p53 for apoptosis in resting B-chronic lymphocytic leukemia (CLL) cells. 2002 , 97, 344-8		7
2013	Mutation analysis of IgVH gene in B-cell chronic lymphocytic leukemia. 2002 , 22, 177-9, 182		
2012	Cytogenetic and FISH studies in myelodysplasia, acute myeloid leukemia, chronic lymphocytic leukemia and lymphoma. 2002 , 76 Suppl 2, 65-74		9
2011	Diagnostik und Therapie der chronisch-lymphatischen Leukämie. 2002 , 8, 708-720		
2010	CD38 expression and secondary 17p deletion are important prognostic factors in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2002 , 116, 142-50	4.5	92
2009	Symposium 6B: Unusual features of the bone marrow. 2002 , 41, 93-112		1
2008	Spontaneous clinical regression in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2002 , 116, 341-345	4.5	28
2007	Quantification improves the prognostic value of CD38 expression in B-cell chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2002 , 118, 755-61	4.5	28
2006	Spontaneous remission of b-chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2002 , 119, 874-5	4.5	4
2005	Revised guideline on immunophenotyping in acute leukaemias and chronic lymphoproliferative disorders. 2002 , 24, 1-13		73

2004	CD80 antigen expression as a predictor of ex vivo chemosensitivity in chronic lymphocytic leukemia. 2002 , 26, 443-6	7
2003	Telomere length and heavy-chain mutation status in familial chronic lymphocytic leukemia. 2002 , 26, 791-4	18
2002	MUM1/IRF4 expression is an unfavorable prognostic factor in B-cell chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). 2002 , 93, 685-94	24
2001	Surface membrane antigen expression changes induced in vitro by exogenous growth factors in chronic lymphocytic leukemia cells. <i>Leukemia</i> , 2002 , 16, 1691-8	10.7 8
2000	Do CLL B cells correspond to naive or memory B-lymphocytes? Evidence for an active Ig switch unrelated to phenotype expression and Ig mutational pattern in B-CLL cells. <i>Leukemia</i> , 2002 , 16, 2438-46 ^{10.7}	34
1999	Lymphoid malignancies: the dark side of B-cell differentiation. 2002 , 2, 920-32	310
1998	Quantitative analysis of Cyclin D1 and CD23 expression in mantle cell lymphoma and B-chronic lymphocytic leukemia. 2002 , 26, 809-15	13
1997	What are we learning from familial chronic lymphocytic leukemia?. 2002 , 26, 779-80	5
1996	CD38 is a marker of human lacteals. 2002 , 441, 605-13	7
1995	DNA microarray analysis in malignant lymphomas. 2003 , 82, 323-32	20
1994	The classification of lymphomas: a new beginning or the end of an era?. 2003 , 30 Suppl 1, S13-8	2
1993	Increased serum levels of matrix metalloproteinase-9 predict clinical outcome of patients with early B-cell chronic lymphocytic leukaemia. 2003 , 70, 373-8	37
1992	Surface antigen expression and correlation with variable heavy-chain gene mutation status in chronic lymphocytic leukemia. 2003 , 70, 53-9	20
1991	More extensive genetic alterations in unmutated than in hypermutated cases of chronic lymphocytic leukemia. 2003 , 37, 417-20	14
1990	Thymic function and immunoglobulin mutation genotype in B-cell chronic lymphocytic leukemia patients. 2003 , 107, 958-61	8
1989	Pan B-cell markers are not redundant in analysis of chronic lymphocytic leukemia (CLL). 2003 , 56, 30-42	18
1988	Ex vivo drug and irradiation sensitivities in hypermutated and unmutated forms of chronic lymphocytic leukemia cells. 2003 , 27, 337-41	8
1987	Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2003 , 120, 452-6	4.5 57

1986	Prognostic significance of CD38 and CD20 expression as assessed by quantitative flow cytometry in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2003 , 120, 1017-25	4.5	38
1985	Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2003 , 121, 287-95	4.5	176
1984	Mechanism of action of purine analogues in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2003 , 121, 692-702	4.5	61
1983	The P2X7 receptor gene polymorphism 1513 A-->C has no effect on clinical prognostic markers, in vitro sensitivity to fludarabine, Bcl-2 family protein expression or survival in B-cell chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2003 , 123, 66-71	4.5	36
1982	Role of the microenvironment in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2003 , 123, 380-8	4.5	143
1981	Anti-idiotypic vaccines. <i>British Journal of Haematology</i> , 2003 , 123, 770-81	4.5	25
1980	Prolegomenon for chronic lymphocytic leukaemia. 2003 , 58, 588-600		7
1979	A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211. <i>Leukemia</i> , 2003 , 17, 323-7	10.7	44
1978	Predictive value of serum thymidine kinase level for Ig-V mutational status in B-CLL. <i>Leukemia</i> , 2003 , 17, 133-7	10.7	46
1977	IL-4 and interferon gamma regulate expression of inducible nitric oxide synthase in chronic lymphocytic leukemia cells. <i>Leukemia</i> , 2003 , 17, 442-50	10.7	34
1976	Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning. <i>Leukemia</i> , 2003 , 17, 841-8	10.7	165
1975	P2X7 polymorphism and chronic lymphocytic leukaemia: lack of correlation with incidence, survival and abnormalities of chromosome 12. <i>Leukemia</i> , 2003 , 17, 2097-100	10.7	40
1974	Unsolved issues in CLL biology and management. <i>Leukemia</i> , 2003 , 17, 2385-91	10.7	33
1973	B Cell Chronic Lymphocytic Leukemia. 2003 , 987, 302-304		
1972	Chronic lymphocytic leukemia (B-CLL) occurring with human immunodeficiency virus (HIV) infection: implications. 2003 , 27, 853-7		6
1971	The distinct gene expression profiles of chronic lymphocytic leukemia and multiple myeloma suggest different anti-apoptotic mechanisms but predict only some differences in phenotype. 2003 , 27, 765-74		21
1970	Innate immunity is regulated by CD38, an ecto-enzyme with ADP-ribosyl cyclase activity. 2003 , 5, 49-58		73
1969	Flow cytometry in lymphoma diagnosis and prognosis: useful?. 2003 , 16, 583-97		19

1968	Classification systems for acute and chronic leukaemias. 2003 , 16, 561-82		29
1967	Variations in ATM protein expression during normal lymphoid differentiation and among B-cell-derived neoplasias. 2003 , 163, 423-32		31
1966	Splenic marginal zone lymphoma with villous lymphocytes shows on-going immunoglobulin gene mutations. 2003 , 162, 681-9		34
1965	ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. 2003 , 348, 1764-75		1093
1964	B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor. 2003 , 21, 841-94		294
1963	ZAP-70 expression is a prognostic factor in chronic lymphocytic leukemia. <i>Leukemia</i> , 2003 , 17, 2426-34	10.7	179
1962	Towards molecular diagnosis and targeted therapy of lymphoid malignancies. 2003 , 40, 296-307		21
1961	Evolution of classic Hodgkin lymphoma in correlation to changes in the lymphoid organ structure of vertebrates. 2003 , 27, 43-53		4
1960	[Genetic changes in chronic lymphocytic leukemia]. 2003 , 51, 366-74		2
1959	Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). <i>Blood</i> , 2003 , 101, 6-14	2.2	486
1958	Hodgkin and non-Hodgkin lymphoma involving bone marrow. 2003 , 20, 196-210		17
1957	Update in the pathologic features of mature B-cell and T/NK-cell leukemias. 2003 , 20, 180-95		2
1956	B-cell chronic lymphocytic leukaemia: a polymorphic family unified by genomic features. 2003 , 4, 505-14		25
1955	Molecular diagnosis of the hematologic cancers. 2003 , 348, 1777-85		162
1954	Cell cycle deregulation in B-cell lymphomas. <i>Blood</i> , 2003 , 101, 1220-35	2.2	288
1953	Chronic lymphocytic leukemia patients with highly stable and indolent disease show distinctive phenotypic and genotypic features. <i>Blood</i> , 2003 , 102, 1035-41	2.2	70
1952	Correlation between cell size and CD38 expression in chronic lymphocytic leukaemia. <i>Leukemia and Lymphoma</i> , 2003 , 44, 797-800	1.9	18
1951	Monocyte-derived dendritic cells in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2003 , 44, 1267-73	1.9	5

1950	Biological and clinical heterogeneity of B-cell chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2003 , 44, 223-8	1.9	25
1949	Phenotypic Heterogeneity of B Cells in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. 2003 , 119, 824-832		31
1948	Binet's staging system and VH genes are independent but complementary prognostic indicators in chronic lymphocytic leukemia. 2003 , 21, 3928-32		69
1947	Proteomic analysis of chronic lymphocytic leukemia subtypes with mutated or unmutated Ig V(H) genes. 2003 , 2, 1331-41		28
1946	Relative importance of CD38 expression over myeloid-associated markers expression in predicting the clinical course of B-CLL patients. <i>Leukemia and Lymphoma</i> , 2003 , 44, 977-82	1.9	11
1945	Association between telomere length and V(H) gene mutation status in chronic lymphocytic leukaemia: clinical and biological implications. 2003 , 88, 593-8		44
1944	Monoclonal antibody therapy of chronic lymphocytic leukemia. 2003 , 21, 1874-81		59
1943	Phenotypic heterogeneity of B cells in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. 2003 , 119, 824-32		6
1942	Flow Cytometry in Hematopathology. 2003 ,		8
1941	Determining the clinical course and outcome in chronic lymphocytic leukemia. 2003 , 348, 1797-9		37
1940	Biology and treatment of chronic lymphocytic leukemia. 2003 , 2003, 153-75		85
1939	Chronic lymphocytic leukemia: advances in biology and therapeutics. 2003 , 15, 16-22		4
1938	Immunobiology of chronic lymphocytic leukemia. 2003 , 10, 312-8		16
1937	Role of autologous stem cell transplantation in chronic lymphocytic leukemia. 2003 , 10, 306-11		1
1936	Somatic hypermutation patterns in germinal center B cell malignancies. 2003 , 8, 319-28		7
1935	CD100/Plexin-B1 interactions sustain proliferation and survival of normal and leukemic CD5+ B lymphocytes. <i>Blood</i> , 2003 , 101, 1962-9	2.2	113
1934	The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. <i>Blood</i> , 2003 , 101, 1262-9	2.2	204
1933	Differential signaling via surface IgM is associated with VH gene mutational status and CD38 expression in chronic lymphocytic leukemia. <i>Blood</i> , 2003 , 101, 1087-93	2.2	253

1932	Features of the overexpressed V1-69 genes in the unmutated subset of chronic lymphocytic leukemia are distinct from those in the healthy elderly repertoire. <i>Blood</i> , 2003 , 101, 3082-4	2.2	60
1931	Expression of ribosomal and translation-associated genes is correlated with a favorable clinical course in chronic lymphocytic leukemia. <i>Blood</i> , 2003 , 101, 2748-55	2.2	68
1930	Chronic lymphocytic leukemia B cells expressing AID display dissociation between class switch recombination and somatic hypermutation. <i>Blood</i> , 2003 , 101, 4029-32	2.2	95
1929	ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. <i>Blood</i> , 2003 , 101, 4944-51	2.2	650
1928	Mutated VH genes and preferential VH3-21 use define new subsets of mantle cell lymphoma. <i>Blood</i> , 2003 , 101, 4047-54	2.2	93
1927	Chronic lymphocytic leukemias utilizing the VH3-21 gene display highly restricted Vlambda2-14 gene use and homologous CDR3s: implicating recognition of a common antigen epitope. <i>Blood</i> , 2003 , 101, 4952-7	2.2	258
1926	CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells. <i>Blood</i> , 2003 , 102, 2146-55	2.2	145
1925	Activation-induced cytidine deaminase in chronic lymphocytic leukemia B cells: expression as multiple forms in a dynamic, variably sized fraction of the clone. <i>Blood</i> , 2003 , 102, 3333-9	2.2	111
1924	Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia. <i>Blood</i> , 2003 , 101, 2049-53	2.2	102
1923	Tetrcarcin-A--induced ER stress mediates apoptosis in B-CLL cells via a Bcl-2--independent pathway. <i>Blood</i> , 2003 , 101, 4561-8	2.2	43
1922	VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome. <i>Blood</i> , 2003 , 102, 3003-9	2.2	122
1921	Divergence from the germ-line sequence in unmutated chronic lymphocytic leukemia is due to somatic mutation rather than polymorphisms. <i>Blood</i> , 2003 , 102, 3075	2.2	20
1920	A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. <i>Blood</i> , 2003 , 101, 4975-81	2.2	241
1919	High expression of activation-induced cytidine deaminase (AID) and splice variants is a distinctive feature of poor-prognosis chronic lymphocytic leukemia. <i>Blood</i> , 2003 , 101, 4903-8	2.2	121
1918	Molecular detection of the G(-248)A BAX promoter nucleotide change in B cell chronic lymphocytic leukaemia. 2003 , 56, 205-9		17
1917	The North Shore-Long Island Jewish Research Institute. 2003 , 9, 63-64		
1916	Immunoglobulin heavy- and light-chain repertoire in splenic marginal zone lymphoma. 2004 , 10, 89-95		37
1915	Dendritic cells from chronic lymphocytic leukemia patients are normal regardless of Ig V gene mutation status. 2004 , 10, 96-103		5

1914	Variability in the degree of expression of phosphorylated IkappaBalpha in chronic lymphocytic leukemia cases with nodal involvement. 2004 , 10, 6796-806		35
1913	Allelotyping in B-cell chronic lymphocytic leukemia (B-CLL). <i>Leukemia and Lymphoma</i> , 2004 , 45, 887-96	1.9	1
1912	Similar humoral immunity parameters in chronic lymphocytic leukemia patients independent of VH gene mutation status. <i>Leukemia and Lymphoma</i> , 2004 , 45, 2451-4	1.9	19
1911	Bendamustine/Mitoxantrone/Rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study. <i>Leukemia and Lymphoma</i> , 2004 , 45, 2445-9	1.9	57
1910	Activation of the Wnt signaling pathway in chronic lymphocytic leukemia. 2004 , 101, 3118-23		339
1909	Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia. 2004 , 200, 519-25		331
1908	Differences in gene expression between B-cell chronic lymphocytic leukemia and normal B cells: a meta-analysis of three microarray studies. 2004 , 20, 3166-78		99
1907	Microarray gene expression profiling of B-cell chronic lymphocytic leukemia subgroups defined by genomic aberrations and VH mutation status. 2004 , 22, 3937-49		177
1906	Chemokine receptors that mediate B cell homing to secondary lymphoid tissues are highly expressed in B cell chronic lymphocytic leukemia and non-Hodgkin lymphomas with widespread nodular dissemination. 2004 , 76, 462-71		126
1905	Vdelta1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid. 2004 , 64, 9172-9		144
1904	Human B lymphocyte malignancies: exploitation of BlyS and APRIL and their receptors. 2005 , 8, 266-88		32
1903	A set of commercially available fluorescent in-situ hybridization probes efficiently detects cytogenetic abnormalities in patients with chronic lymphocytic leukemia. 2004 , 6, 48-53		26
1902	Abstracts. 2004 , 22, 1-111		
1901	Chronic lymphocytic leukemia. 2004 , 2004, 163-83		116
1900	Heterogeneous expression of interleukin-18 and its receptor in B-cell lymphoproliferative disorders deriving from naive, germinal center, and memory B lymphocytes. 2004 , 10, 144-54		28
1899	Characterization of Incidentally Identified Minute Clonal B-Lymphocyte Populations in Peripheral Blood and Bone Marrow. 2004 , 122, 588-595		17
1898	Automated array-based genomic profiling in chronic lymphocytic leukemia: development of a clinical tool and discovery of recurrent genomic alterations. 2004 , 101, 1039-44		206
1897	Expression of ZAP-70 protein correlates with disease stage in chronic lymphocytic leukemia and is associated with, but not generally restricted to, non-mutated Ig VH status. <i>Leukemia and Lymphoma</i> , 2004 , 45, 2037-45	1.9	33

1896	Assessing prognosis in patients with chronic lymphocytic leukemia a quarter of a century after Rai and Binet staging systems. 2004 , 15, 1450-1		7
1895	The Natural History of CLL. 2004 , 3-54		1
1894	Chronic lymphocytic leukaemia: new biological markers for assessing prognosis. 2004 , 5, 197-201		5
1893	Treatment options in chronic lymphocytic leukemia. 2004 , 5 Suppl 1, S2-9		9
1892	CD38 expression as a prognostic indicator in chronic lymphocytic leukaemia. 2004 , 5, 145-51		43
1891	Guidelines on the diagnosis and management of chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2004 , 125, 294-317	4.5	112
1890	Phenotypic and functional characterization of monocyte-derived dendritic cells in chronic lymphocytic leukaemia patients: influence of neoplastic CD19 cells in vivo and in vitro. <i>British Journal of Haematology</i> , 2004 , 125, 720-8	4.5	25
1889	Analysis of IgV gene mutations in B cell chronic lymphocytic leukaemia according to antigen-driven selection identifies subgroups with different prognosis and usage of the canonical somatic hypermutation machinery. <i>British Journal of Haematology</i> , 2004 , 126, 29-42	4.5	51
1888	Effect of IL-2R beta-binding cytokines on costimulatory properties of chronic lymphocytic leukaemia cells: implications for immunotherapy. <i>British Journal of Haematology</i> , 2004 , 127, 531-42	4.5	11
1887	IgV gene intraclonal diversification and clonal evolution in B-cell chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2006 , 133, 50-8	4.5	16
1886	Novel molecular diagnostic and therapeutic targets in chronic lymphocytic leukaemia. 2004 , 34 Suppl 2, 25-30		7
1885	Stem cell transplantation for chronic lymphocytic leukemia: should not more patients get a transplant?. 2004 , 34, 289-97		13
1884	Tools for molecular risk-stratification for clinical purposes: CLL as a prototype. 2004 , 12, 423		4
1883	CLL B cells with a bimodal CD38 expression pattern: persistence of bimodal populations despite effective therapy for B-CLL. <i>Leukemia</i> , 2004 , 18, 180-2	10.7	5
1882	Relationship between the mutational status of VH genes and pathogenesis of diffuse large B-cell lymphoma in Richter's syndrome. <i>Leukemia</i> , 2004 , 18, 326-30	10.7	45
1881	CD38 expression on B-cell chronic lymphocytic leukemic cells is strongly correlated with vascular endothelial growth factor expression. <i>Leukemia</i> , 2004 , 18, 649-50	10.7	10
1880	High expression of activation-induced cytidine deaminase (AID) mRNA is associated with unmutated IGHV gene status and unfavourable cytogenetic aberrations in patients with chronic lymphocytic leukaemia. <i>Leukemia</i> , 2004 , 18, 756-62	10.7	69
1879	Bcl-6 mutation status provides clinically valuable information in early-stage B-cell chronic lymphocytic leukemia. <i>Leukemia</i> , 2004 , 18, 743-6	10.7	14

1878	Variant t(2;11)(p11;q13) associated with the IgK-CCND1 rearrangement is a recurrent translocation in leukemic small-cell B-non-Hodgkin lymphoma. <i>Leukemia</i> , 2004 , 18, 1705-10	10.7	42
1877	Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation. <i>Leukemia</i> , 2004 , 18, 1637-45	10.7	77
1876	CD38 modifications in chronic lymphocytic leukemia: are they relevant?. <i>Leukemia</i> , 2004 , 18, 1733-5	10.7	18
1875	Evidence of biased immunoglobulin variable gene usage in highly stable B-cell chronic lymphocytic leukemia. <i>Leukemia</i> , 2004 , 18, 1941-7	10.7	34
1874	VH gene mutation status and cellular drug resistance in chronic lymphocytic leukaemia. 2004 , 73, 407-11		10
1873	Characterization and phylogenetic epitope mapping of CD38 ADPR cyclase in the cynomolgus macaque. 2004 , 5, 21		5
1872	Different gene expression in immunoglobulin-mutated and immunoglobulin-unmutated forms of chronic lymphocytic leukemia. 2004 , 153, 69-72		30
1871	Treatment of indolent non-Hodgkin's lymphoma with cladribine as single-agent therapy and in combination with mitoxantrone. 2004 , 79, 311-21		10
1870	Advances in the understanding of biology and prognosis in chronic lymphocytic leukemia. 2004 , 6, 348-54		8
1869	Oral fludarabine has significant activity in patients with previously untreated chronic lymphocytic leukemia, and leads to increased STAT1 levels in vivo. 2004 , 28, 139-47		16
1868	Immunoglobulin heavy chain genes somatic hypermutations and chromosome 11q22-23 deletion in classic mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research. <i>British Journal of Haematology</i> , 2004 , 124, 289-98	4.5	23
1867	Quantitative analysis of DNA methylation in chronic lymphocytic leukemia patients. 2004 , 25, 1530-5		46
1866	CD1d is expressed on B-chronic lymphocytic leukemia cells and mediates alpha-galactosylceramide presentation to natural killer T lymphocytes. 2004 , 109, 402-11		69
1865	Biallelic IgH rearrangements in patients with indolent lymphoproliferative disorders: molecular and practical implications. 2004 , 199, 217-26		7
1864	Angiogenesis in acute and chronic lymphocytic leukemia. 2004 , 28, 321-4		29
1863	Treatment of human chronic lymphocytic leukemia cells with the proteasome inhibitor bortezomib promotes apoptosis. 2004 , 28, 845-50		24
1862	Relationship between cell surface expression of CD38 and of vascular endothelial growth factor in B-cell chronic lymphocytic leukemia. 2004 , 28, 1239-40		3
1861	Role of myeloid cell factor-1 (Mcl-1) in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2004 , 45, 2017-27	1.9	29

1860	V(H)3-21 gene usage in chronic lymphocytic leukemia--characterization of a new subgroup with distinct molecular features and poor survival. <i>Leukemia and Lymphoma</i> , 2004 , 45, 221-8	1.9	32
1859	The prognostic value of CD38 expression and its quantification in B cell chronic lymphocytic leukemia (B-CLL). <i>Leukemia and Lymphoma</i> , 2004 , 45, 455-62	1.9	33
1858	Quantification of CD38 expression in B-cell chronic lymphocytic leukemia (B-CLL): a comparison between antibody binding capacity (ABC) and relative median fluorescence (RMF). <i>Leukemia and Lymphoma</i> , 2004 , 45, 1167-73	1.9	3
1857	Chronic lymphocytic leukemia: revelations from the B-cell receptor. <i>Blood</i> , 2004 , 103, 4389-95	2.2	322
1856	Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins. <i>Blood</i> , 2004 , 104, 2499-504	2.2	200
1855	hTERT expression and prognosis in B-chronic lymphocytic leukemia. 2004 , 15, 1476-80		35
1854	Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. <i>Blood</i> , 2004 , 103, 1202-10	2.2	195
1853	CD38 autoimmunity: recent advances and relevance to human diabetes. 2004 , 27, 695-707		17
1852	Histopathology of B-cell chronic lymphocytic leukemia. 2004 , 18, 807-26, viii		6
1851	Current guidelines in defining therapeutic strategies. 2004 , 18, 881-93, ix		3
1850	Molecular genetics and its clinical relevance. 2004 , 18, 827-48, viii		16
1849	Perspectives in chronic lymphocytic leukemia biology and management. 2004 , 18, 927-43, x		3
1848	Role of auto- and allotransplantation in B-cell chronic lymphocytic leukemia. 2004 , 18, 915-26, x		11
1847	Expression of the chemokine receptors CXCR4 and CCR7 and disease progression in B-cell chronic lymphocytic leukemia/ small lymphocytic lymphoma. 2004 , 79, 318-25		69
1846	Current approach to diagnosis and management of chronic lymphocytic leukemia. 2004 , 79, 388-98		24
1845	45th Annual Meeting of the American Society of Hematology December 6-9, 2003. 2004 , 4, 206-12		2
1844	Routine analysis of IgVH mutational status in CLL patients using BIOMED-2 standardized primers and protocols. <i>Leukemia and Lymphoma</i> , 2004 , 45, 1899-904	1.9	45
1843	Mutational status of IgVH genes consistent with antigen-driven selection but not percent of mutations has prognostic impact in B-cell chronic lymphocytic leukemia. 2004 , 5, 123-6		8

1842	Epigenetic profiling in chronic lymphocytic leukemia reveals novel methylation targets. 2004 , 64, 2424-33	120
1841	The nature and origin of the B-chronic lymphocytic leukemia cell: a tentative model. 2004 , 18, 849-62, viii	11
1840	Recent advances in understanding small B-cell leukaemias and lymphomas. 2004 , 10, 374-384	3
1839	Microenvironmental interactions and survival of CLL B-cells. <i>Leukemia and Lymphoma</i> , 2004 , 45, 2365-72.9	109
1838	Clinical staging and prognostic markers in chronic lymphocytic leukemia. 2004 , 18, 795-805, vii	19
1837	ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. 2004 , 351, 893-901	754
1836	Novel therapies for chronic lymphocytic leukemia. 2004 , 18, 137-48	26
1835	Clonal lymphocytes in persons without known chronic lymphocytic leukemia (CLL): implications of recent findings in family members of CLL patients. 2004 , 41, 192-200	15
1834	Recent advances in the molecular biology and immunobiology of chronic lymphocytic leukemia. 2004 , 41, 207-23	28
1833	The role of stem cell transplantation in chronic lymphocytic leukemia. 2004 , 41, 246-53	9
1832	ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. 2004 , 363, 105-11	465
1831	Molecular cytogenetic studies for hematological malignancies. 2004 , 121, 69-112	7
1830	Small Lymphocytic Lymphoma. 2004 , 9, 214-220	
1829	Aberrant morphology, proliferation, and apoptosis of B-cell chronic lymphocytic leukemia cells. 2004 , 9, 279-86	20
1828	Prognostic factors in B-CLL. 2004 , 11, 172-173	
1827	A National Data Base for Prostate Cancer. 2004 , 11, 172	
1826	EpsteinBarr Virus may have a role in progression of thyroid carcinoma. 2004 , 11, 173	
1825	The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational status. <i>Blood</i> , 2004 , 103, 2850-8	2.2 93

1824	Microarray analysis reveals that TP53- and ATM-mutant B-CLLs share a defect in activating proapoptotic responses after DNA damage but are distinguished by major differences in activating prosurvival responses. <i>Blood</i> , 2004 , 103, 291-300	2.2	88
1823	Telomere length and telomerase activity delineate distinctive replicative features of the B-CLL subgroups defined by immunoglobulin V gene mutations. <i>Blood</i> , 2004 , 103, 375-82	2.2	152
1822	Geldanamycin and herbimycin A induce apoptotic killing of B chronic lymphocytic leukemia cells and augment the cells' sensitivity to cytotoxic drugs. <i>Blood</i> , 2004 , 103, 1855-61	2.2	38
1821	Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response. <i>Blood</i> , 2004 , 104, 1428-34	2.2	115
1820	The pattern and distribution of immunoglobulin VH gene mutations in chronic lymphocytic leukemia B cells are consistent with the canonical somatic hypermutation process. <i>Blood</i> , 2004 , 103, 3490-5	2.2	63
1819	The cycling history of CLL. <i>Blood</i> , 2004 , 103, 367-367	2.2	2
1818	Utilization of Ig heavy chain variable, diversity, and joining gene segments in children with B-lineage acute lymphoblastic leukemia: implications for the mechanisms of VDJ recombination and for pathogenesis. <i>Blood</i> , 2004 , 103, 4602-9	2.2	34
1817	CD38 on B-cell chronic lymphocytic leukemia cells has higher expression in lymph nodes than in peripheral blood or bone marrow. <i>Blood</i> , 2004 , 103, 1968-9	2.2	44
1816	Efficacy of alemtuzumab treatment for refractory T-cell large granular lymphocytic leukemia. <i>Blood</i> , 2004 , 103, 1969-71	2.2	42
1815	Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR. <i>Blood</i> , 2004 , 104, 2600-2	2.2	139
1814	Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia. <i>Blood</i> , 2004 , 104, 2879-85	2.2	216
1813	CLL: to mend it or be rid of it. <i>Blood</i> , 2004 , 104, 2210-2210	2.2	
1812	Stem cell expansion: success and complexities. <i>Blood</i> , 2004 , 104, 2210-2211	2.2	5
1811	Advances in the diagnosis and classification of chronic lymphoproliferative disorders. 2004 , 121, 145-65		5
1810	Clinical Flow Cytometry. 2004 , 239-257		1
1809	New developments in the diagnosis, prognosis and treatment of chronic lymphocytic leukemia. 2005 , 17, 597-604		17
1808	Leukaemias and Lymphomas. 2005 ,		
1807	Unmutated and mutated chronic lymphocytic leukemias derive from self-reactive B cell precursors despite expressing different antibody reactivity. 2005 , 115, 1636-43		248

1806	Immunophenotyping of lymphoproliferative disorders: state of the art. 2005 , 37, 457-78		11
1805	CD38 as a prognostic marker in CLL. 2005 , 10, 39-46		45
1804	Recent advances in immunotherapy of B-CLL using ex vivo modified dendritic cells. 2005 , 10, 189-203		2
1803	CD38 and CD100 lead a network of surface receptors relaying positive signals for B-CLL growth and survival. <i>Blood</i> , 2005 , 105, 3042-50	2.2	161
1802	Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. <i>Blood</i> , 2005 , 105, 49-53	2.2	349
1801	Adaphostin-induced apoptosis in CLL B cells is associated with induction of oxidative stress and exhibits synergy with fludarabine. <i>Blood</i> , 2005 , 105, 2099-106	2.2	38
1800	Deregulated expression of the Myc cellular oncogene drives development of mouse "Burkitt-like" lymphomas from naive B cells. <i>Blood</i> , 2005 , 105, 2135-7	2.2	33
1799	Geographic patterns and pathogenetic implications of IGHV gene usage in chronic lymphocytic leukemia: the lesson of the IGHV3-21 gene. <i>Blood</i> , 2005 , 105, 1678-85	2.2	168
1798	Sustained signaling through the B-cell receptor induces Mcl-1 and promotes survival of chronic lymphocytic leukemia B cells. <i>Blood</i> , 2005 , 105, 4820-7	2.2	208
1797	The LPL/ADAM29 expression ratio is a novel prognosis indicator in chronic lymphocytic leukemia. <i>Blood</i> , 2005 , 106, 650-7	2.2	113
1796	Lower levels of surface B-cell-receptor expression in chronic lymphocytic leukemia are associated with glycosylation and folding defects of the mu and CD79a chains. <i>Blood</i> , 2005 , 105, 2933-40	2.2	53
1795	Different isoforms of BSAP regulate expression of AID in normal and chronic lymphocytic leukemia B cells. <i>Blood</i> , 2005 , 105, 2495-503	2.2	30
1794	Splenic marginal zone lymphoma: proposal of new diagnostic and prognostic markers identified after tissue and cDNA microarray analysis. <i>Blood</i> , 2005 , 106, 1831-8	2.2	123
1793	Distinctive gene expression pattern in VH3-21 utilizing B-cell chronic lymphocytic leukemia. <i>Blood</i> , 2005 , 106, 681-9	2.2	38
1792	Telomere length as a prognostic parameter in chronic lymphocytic leukemia with special reference to VH gene mutation status. <i>Blood</i> , 2005 , 105, 4807-12	2.2	110
1791	Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL. <i>Blood</i> , 2005 , 106, 3175-82	2.2	189
1790	Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. <i>Blood</i> , 2005 , 106, 4389-96	2.2	182
1789	ZAP-70 staining in chronic lymphocytic leukemia. 2005 , Chapter 6, Unit 6.19		2

1788	Heterogeneous somatic hypermutation status confounds the cell of origin in hairy cell leukemia. 2005 , 29, 153-8		35
1787	Protein expression profiling of CLL B cells using replicate off-line strong cation exchange chromatography and LC-MS/MS. 2005 , 819, 33-9		13
1786	Microarray-based gene expression profiling of hematologic malignancies: basic concepts and clinical applications. 2005 , 19, 223-34		39
1785	B-cell chronic lymphocytic leukemia, a clonal disease of B lymphocytes with receptors that vary in specificity for (auto)antigens. 2005 , 1062, 1-12		47
1784	Prognostic usage of V(H) gene mutation status and its surrogate markers and the role of antigen selection in chronic lymphocytic leukemia. 2005 , 22, 217-28		21
1783	Immunoglobulin gene analysis of mature B-cell malignancies: reconsideration of cellular origin and potential antigen involvement in pathogenesis. 2005 , 22, 327-41		25
1782	CD5+ diffuse large B-cell lymphoma consists of germline cases and hypermutated cases in the immunoglobulin heavy chain gene variable region. 2005 , 81, 58-61		4
1781	Bodyguards and assassins: Bcl-2 family proteins and apoptosis control in chronic lymphocytic leukaemia. 2005 , 114, 441-9		122
1780	Stem cell transplantation for chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2005 , 128, 145-52	4.5	25
1779	Unique gene expression and clinical characteristics are associated with the 11q23 deletion in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2005 , 128, 460-71	4.5	19
1778	Differential control of G0 programme in chronic lymphocytic leukaemia: a novel prognostic factor. <i>British Journal of Haematology</i> , 2005 , 128, 472-81	4.5	18
1777	p53 Aberrations do not predict individual response to fludarabine in patients with B-cell chronic lymphocytic leukaemia in advanced stages Rai III/IV. <i>British Journal of Haematology</i> , 2005 , 129, 53-9	4.5	30
1776	Immunoglobulin gene segment usage, location and immunogenicity in mutated and unmutated chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2005 , 129, 499-510	4.5	41
1775	The prognostic value of CD38 expression in chronic lymphocytic leukaemia patients studied prospectively at diagnosis: a single institute experience. <i>British Journal of Haematology</i> , 2005 , 130, 549-575	4.5	45
1774	Differential expression of CD 180 and IgM by B-cell chronic lymphocytic leukaemia cells using mutated and unmutated immunoglobulin VH genes. <i>British Journal of Haematology</i> , 2005 , 131, 313-9	4.5	26
1773	Comparison of flow cytometric methods for the measurement of ZAP-70 expression in a routine diagnostic laboratory. 2005 , 27, 258-66		44
1772	Myeloablative allografting for chronic lymphocytic leukemia: evidence for a potent graft-versus-leukemia effect associated with graft-versus-host disease. 2005 , 36, 825-30		67
1771	Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1. 2005 , 12, 773-82		128

1770	Translocation t(1;6)(p35.3;p25.2): a new recurrent aberration in "unmutated" B-CLL. <i>Leukemia</i> , 2005 , 19, 77-82	10.7	22
1769	Chronic lymphocytic leukemia cells display p53-dependent drug-induced Puma upregulation. <i>Leukemia</i> , 2005 , 19, 427-34	10.7	77
1768	Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia. <i>Leukemia</i> , 2005 , 19, 750-8	10.7	175
1767	Mcl-1 gene promoter insertions do not correlate with disease outcome, stage or VH gene mutation status in chronic lymphocytic leukaemia. <i>Leukemia</i> , 2005 , 19, 871-3	10.7	18
1766	Analysis of VH gene sequences using two web-based immunogenetics resources gives different results, but the affinity maturation status of chronic lymphocytic leukaemia clones as assessed from either of the resulting data sets has no prognostic significance. <i>Leukemia</i> , 2005 , 19, 741-9	10.7	7
1765	ZAP-70 is expressed by a subset of normal human B-lymphocytes displaying an activated phenotype. <i>Leukemia</i> , 2005 , 19, 1018-24	10.7	69
1764	Reduced-intensity conditioning lowers treatment-related mortality of allogeneic stem cell transplantation for chronic lymphocytic leukemia: a population-matched analysis. <i>Leukemia</i> , 2005 , 19, 1029-33	10.7	135
1763	High expression of lipoprotein lipase in poor risk B-cell chronic lymphocytic leukemia. <i>Leukemia</i> , 2005 , 19, 1216-23	10.7	118
1762	CD38 expression levels in chronic lymphocytic leukemia B cells are associated with activation marker expression and differential responses to interferon stimulation. <i>Leukemia</i> , 2005 , 19, 2264-72	10.7	43
1761	Incidence of chromosomal anomalies detected with FISH and their clinical correlations in B-chronic lymphocytic leukemia. 2005 , 160, 27-34		28
1760	Mitogen induced activation, proliferation and surface antigen expression patterns in unmutated and hypermutated chronic lymphocytic leukemia cells. 2005 , 75, 34-40		3
1759	Surface-antigen expression profiling (SEP) in B-cell chronic lymphocytic leukemia (B-CLL): Identification of markers with prognostic relevance. 2005 , 305, 20-32		14
1758	Signature of B-CLL with different prognosis by Shrunken centroids of surface antigen expression profiling. 2005 , 204, 113-23		28
1757	Advances in the diagnosis and treatment of chronic lymphocytic leukemia. 2005 , 23, 34-40		4
1756	High expression of bfl-1 contributes to the apoptosis resistant phenotype in B-cell chronic lymphocytic leukemia. 2005 , 113, 730-7		63
1755	Zeta-chain associated protein 70 and CD38 combined predict the time to first treatment in patients with chronic lymphocytic leukemia. 2005 , 104, 2124-32		58
1754	The addition of rituximab to fludarabine improves clinical outcome in untreated patients with ZAP-70-negative chronic lymphocytic leukemia. 2005 , 104, 2743-52		43
1753	Bcl-2 regulatory pathway is functional in chronic lymphocytic leukemia. 2005 , 63, 36-46		12

1752	Xanthohumol kills B-chronic lymphocytic leukemia cells by an apoptotic mechanism. 2005 , 49, 844-50	59
1751	Excellent response of chemotherapy-resistant B-cell-type chronic lymphocytic leukemia with meningeal involvement to rituximab. 2005 , 10, 357-61	20
1750	Genetics and molecular biology of chronic lymphocytic leukemia. 2005 , 6, 215-25	12
1749	A population-based assessment of the prognostic value of the CD19 positive lymphocyte count in B-cell chronic lymphocytic leukemia using Cox and Markov models. 2005 , 20, 993-1001	2
1748	Immunohistochemical analysis of ZAP-70 expression in B-cell lymphoid neoplasms. 2005 , 205, 507-13	62
1747	SAIVGeM: spreadsheet analysis of immunoglobulin VH gene mutations. 2005 , 39, 353-8	3
1746	Cytogenetics of Hematologic Neoplasms. 2005 , 365-420	1
1745	Biology and treatment of chronic lymphocytic leukemia. 2005 , 16 Suppl 2, ii113-23	10
1744	B-cell receptor translocation to lipid rafts and associated signaling differ between prognostically important subgroups of chronic lymphocytic leukemia. 2005 , 65, 7328-37	52
1743	Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. 2005 , 23, 3433-8	116
1742	Evidence for distinct pathomechanisms in genetic subgroups of chronic lymphocytic leukemia revealed by quantitative expression analysis of cell cycle, activation, and apoptosis-associated genes. 2005 , 23, 3780-92	60
1741	The immunoglobulin genes and chronic lymphocytic leukemia (CLL). 2005 , 110, 97-113	8
1740	Revisiting the role of hematopoietic stem cell transplantation in chronic lymphocytic leukemia. 2005 , 5, 875-91	
1739	Identification and assembly of V genes as idiotype-specific DNA fusion vaccines in multiple myeloma. 2005 , 113, 105-19	3
1738	The Principles of Clinical Cytogenetics. 2005 ,	25
1737	A gender-based score system predicts the clinical outcome of patients with early B-cell chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2005 , 46, 553-60	1.9 19
1736	Bimodal Cell Populations Are Common in Chronic Lymphocytic Leukemia but Do Not Impact Overall Survival. 2005 , 123, 818-825	7
1735	TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia. 2005 , 23, 3877-85	78

1734	Determining mutational status of immunoglobulin v genes in chronic lymphocytic leukemia: a useful prognostic indicator. 2005 , 115, 129-44		3
1733	B cell response to surface IgM cross-linking identifies different prognostic groups of B-chronic lymphocytic leukemia patients. 2005 , 174, 3749-56		49
1732	Genotypic prognostic markers. 2005 , 294, 147-64		8
1731	Immunoglobulin light chain repertoire in chronic lymphocytic leukemia. <i>Blood</i> , 2005 , 106, 3575-83	2.2	78
1730	Chronic lymphocytic leukemia: to transplant or not to transplant... that is the question?. 2005 , 23, 8126-7; author reply 8127		
1729	Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses. <i>Blood</i> , 2005 , 105, 397-404	2.2	94
1728	Activation-induced cytidine deaminase and CD38 expression in B-cell chronic lymphocytic leukemia. 2005 , 6, 251-2		3
1727	Biological validation of differentially expressed genes in chronic lymphocytic leukemia identified by applying multiple statistical methods to oligonucleotide microarrays. 2005 , 7, 337-45		13
1726	Immunoglobulin mutational status detected through single-round amplification of partial V(H) region represents a good prognostic marker for clinical outcome in chronic lymphocytic leukemia. 2005 , 7, 566-74		11
1725	Lymphoma. 2005 ,		
1724	Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. <i>Blood</i> , 2006 , 107, 859-61	2.2	115
1723	Economic assessment on the management of chronic lymphocytic leukaemia. 2005 , 6, 1179-89		5
1722	Touch-down reverse transcriptase-PCR detection of IgV(H) rearrangement and Sybr-Green-based real-time RT-PCR quantitation of minimal residual disease in patients with chronic lymphocytic leukemia. 2005 , 9, 23-34		14
1721	Common polymorphism G(-248)A in the promoter region of the bax gene results in significantly shorter survival in patients with chronic lymphocytic Leukemia once treatment is initiated. 2005 , 23, 1514-21		65
1720	CLL biology and prognosis. 2005 , 2005, 278-84		44
1719	Quantitative protein expression analysis of CLL B cells from mutated and unmutated IgV(H) subgroups using acid-cleavable isotope-coded affinity tag reagents. 2005 , 4, 1310-7		14
1718	Chronic lymphocytic leukemia: a review of some new aspects of the biology, factors influencing prognosis and therapeutic options. 2005 , 32, 85-97		16
1717	The emerging role of alemtuzumab in chronic lymphocytic leukemia. 2005 , 6, 115-21		9

1716	A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. 2005 , 353, 1793-801		2041
1715	Multiple Myeloma. 2005 ,		1
1714	Chronic lymphocytic leukemia. 2005 , 352, 804-15		1261
1713	Immunophenotyping. 2006 , 335-355		3
1712	Lipoprotein lipase expression is a novel prognostic factor in B-cell chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2006 , 47, 1053-61	1.9	46
1711	Recent advances in chronic lymphocytic leukemia. 2006 , 24, 302-9		5
1710	CD38 expression level and pattern of expression remains a reliable and robust marker of progressive disease in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2006 , 47, 2371-9	1.9	26
1709	ZAP-70 immunoreactivity is a prognostic marker of disease progression in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2006 , 47, 245-51	1.9	14
1708	New molecular markers in resistant B-CLL. <i>Leukemia and Lymphoma</i> , 2006 , 47, 791-801	1.9	12
1707	Urinary bladder infiltration with chronic B-lymphocytic leukemia: two cases with unusual presentation. <i>Leukemia and Lymphoma</i> , 2006 , 47, 1184-7	1.9	4
1706	Serum levels of syndecan-1 in B-cell chronic lymphocytic leukemia: correlation with the extent of angiogenesis and disease-progression risk in early disease. <i>Leukemia and Lymphoma</i> , 2006 , 47, 1034-40	1.9	11
1705	Prognostic factors in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2006 , 47, 2261-2	1.9	6
1704	Update on risk-stratified management for chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2006 , 47, 1738-46	1.9	19
1703	Evaluation of clinical staging in chronic lymphocytic leukemia- population-based study. <i>Leukemia and Lymphoma</i> , 2006 , 47, 2505-16	1.9	13
1702	Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. <i>Blood</i> , 2006 , 108, 853-61	2.2	155
1701	Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. 2006 , 24, 4634-41		208
1700	Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: justification for risk-adapted therapy. 2006 , 24, 437-43		212
1699	Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational status. <i>Blood</i> , 2006 , 107, 2889-94	2.2	149

1698	Fludarabine in chronic lymphocytic leukaemia. 2006 , 7, 1641-51		32
1697	Chronic lymphocytic leukemia: diagnosis and treatment. 2006 , 81, 1105-29		49
1696	Surface-antigen expression profiling of B cell chronic lymphocytic leukemia: from the signature of specific disease subsets to the identification of markers with prognostic relevance. 2006 , 4, 11		7
1695	Pathology of B-cell non-Hodgkin's lymphomas and multiple myeloma. 2006 , 131, 1-48		1
1694	Monoclonal antibody combinations in CLL: evolving strategies. 2006 , 19, 781-93		6
1693	Concomitant chronic lymphocytic leukemia and acute myeloid leukemia: evidence of simultaneous expansion of two independent clones. <i>Leukemia and Lymphoma</i> , 2006 , 47, 885-9	1.9	14
1692	The proliferation center microenvironment and prognostic markers in chronic lymphocytic leukemia/small lymphocytic lymphoma. 2006 , 37, 152-9		65
1691	Bone marrow infiltration pattern in B-cell chronic lymphocytic leukemia is related to immunoglobulin heavy-chain variable region mutation status and expression of 70-kd zeta-associated protein (ZAP-70). 2006 , 37, 1153-61		17
1690	Classification and Histopathology of the Lymphomas. 2006 , 2-38		4
1689	The CD38 ectoenzyme family: advances in basic science and clinical practice. 2006 , 12, 342-4		25
1688	Similarities and differences between the light and heavy chain Ig variable region gene repertoires in chronic lymphocytic leukemia. 2006 , 12, 300-8		18
1687	A novel gene for an old disease. <i>Blood</i> , 2006 , 107, 2594-2594	2.2	2
1686	Distinct gene expression patterns in chronic lymphocytic leukemia defined by usage of specific VH genes. <i>Blood</i> , 2006 , 107, 2090-3	2.2	46
1685	ZAP-70 expression is associated with enhanced ability to respond to migratory and survival signals in B-cell chronic lymphocytic leukemia (B-CLL). <i>Blood</i> , 2006 , 107, 3584-92	2.2	154
1684	ZAP-70 expression in acute lymphoblastic leukemia: association with the E2A/PBX1 rearrangement and the pre-B stage of differentiation and prognostic implications. <i>Blood</i> , 2006 , 107, 197-204	2.2	25
1683	Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. <i>Blood</i> , 2006 , 107, 742-51	2.2	230
1682	Plasma thrombopoietin compared with immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukemia. <i>Blood</i> , 2006 , 108, 1001-6	2.2	19
1681	Identification of a gene on chromosome 12q22 uniquely overexpressed in chronic lymphocytic leukemia. <i>Blood</i> , 2006 , 107, 2904-11	2.2	47

1680	Interleukin-21 receptor (IL-21R) is up-regulated by CD40 triggering and mediates proapoptotic signals in chronic lymphocytic leukemia B cells. <i>Blood</i> , 2006 , 107, 3708-15	2.2	89
1679	In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia. <i>Blood</i> , 2006 , 108, 1135-44	2.2	120
1678	FIXing hemophilia B with gene therapy. <i>Blood</i> , 2006 , 107, 2593-2594	2.2	
1677	Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: A study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression. <i>Blood</i> , 2006 , 108, 3152-60	2.2	181
1676	Expression levels of CD38 in T cells predict course of disease in male patients with B-chronic lymphocytic leukemia. <i>Blood</i> , 2006 , 108, 2950-6	2.2	27
1675	Chronic lymphoproliferative disorders and malignant lymphoma. 93-109		
1674	Chronic Lymphocytic Leukemia (CLL). 2006 ,		
1673	Leucmie lymphoïde chronique. 2006 , 1, 1-12		
1672	Genetics, gene expression, and targeted therapies in chronic lymphocytic leukemia. 2006 , 7, 1313-27		7
1671	Role of allogeneic transplantation in low-grade lymphoma and chronic lymphocytic leukemia. 2006 , 13, 273-9		4
1670	Purine antagonists for chronic lymphocytic leukaemia. 2006 , CD004270		21
1669	Use of prognostic factors in risk stratification at diagnosis and time of treatment of patients with chronic lymphocytic leukemia. 2006 , 13, 266-72		13
1668	Pattern and distribution of immunoglobulin VH gene usage in a cohort of B-CLL patients from a Northeastern region of Italy. 2006 , 15, 206-15		13
1667	Immunophenotyping of Leukemia and Lymphoma by Flow Cytometry. 2006 , 171-186		
1666	Immunoglobulin VH genes in thymic MALT lymphoma are biased toward a restricted repertoire and are frequently unmutated. 2006 , 208, 415-22		21
1665	Leucmie lymphoïde chronique: Biologie et pronostic. 2006 , 2006, 37-43		0
1664	Chronic lymphocytic leukaemia profiled for prognosis using a fluorescence in situ hybridisation panel. <i>British Journal of Haematology</i> , 2006 , 132, 705-22	4.5	54
1663	Somatic hypermutation and VH gene usage in hairy cell leukaemia. <i>British Journal of Haematology</i> , 2006 , 133, 504-12	4.5	34

1662	Plasma as a source of mRNA for determining IgV(H) mutation status in patients with chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2006 , 133, 690-2	4.5	7
1661	Prognostic importance of soluble CD23 in B-cell chronic lymphocytic leukemia. 2006 , 28, 30-5		20
1660	Immunoglobulin VH somatic hypermutation in mantle cell lymphoma: mutated genotype correlates with better clinical outcome. 2006 , 19, 1498-505		26
1659	The G(-248)A polymorphism in the promoter region of the Bax gene does not correlate with prognostic markers or overall survival in chronic lymphocytic leukemia. <i>Leukemia</i> , 2006 , 20, 77-81	10.7	29
1658	CD49d in B-cell chronic lymphocytic leukemia: correlated expression with CD38 and prognostic relevance. <i>Leukemia</i> , 2006 , 20, 523-5; author reply 528-9	10.7	43
1657	Reply to Pittner et al.. <i>Leukemia</i> , 2006 , 20, 528-529	10.7	10
1656	CD38+ chronic lymphocytic leukaemia cells co-express high levels of ZAP-70 and are functionally distinct from their CD38- counter-parts. <i>Leukemia</i> , 2006 , 20, 743-4	10.7	15
1655	Richter's and prolymphocytic transformation of chronic lymphocytic leukemia are associated with high mRNA expression of activation-induced cytidine deaminase and aberrant somatic hypermutation. <i>Leukemia</i> , 2006 , 20, 1089-95	10.7	51
1654	Deregulated expression of fat and muscle genes in B-cell chronic lymphocytic leukemia with high lipoprotein lipase expression. <i>Leukemia</i> , 2006 , 20, 1080-8	10.7	53
1653	IgVH genes mutation and usage, ZAP-70 and CD38 expression provide new insights on B-cell prolymphocytic leukemia (B-PLL). <i>Leukemia</i> , 2006 , 20, 1231-7	10.7	48
1652	Gene expression signatures separate B-cell chronic lymphocytic leukaemia prognostic subgroups defined by ZAP-70 and CD38 expression status. <i>Leukemia</i> , 2006 , 20, 1774-82	10.7	64
1651	The role of microRNAs in normal hematopoiesis and hematopoietic malignancies. <i>Leukemia</i> , 2006 , 20, 1931-6	10.7	86
1650	Chronic lymphocytic leukemia cell CD38 expression and inducible nitric oxide synthase expression are associated with serum IL-4 levels. 2006 , 30, 24-8		11
1649	Distinctive immunoglobulin VH gene usage in Japanese patients with chronic lymphocytic leukemia. 2006 , 30, 272-6		21
1648	Nocodazole, a microtubule de-polymerising agent, induces apoptosis of chronic lymphocytic leukaemia cells associated with changes in Bcl-2 phosphorylation and expression. 2006 , 30, 427-36		41
1647	Is chronic lymphocytic leukemia a response to infectious agents?. 2006 , 30, 1063-4		12
1646	The CD38/CD157 mammalian gene family: An evolutionary paradigm for other leukocyte surface enzymes. 2006 , 2, 431-41		22
1645	Leucémie lymphoïde chronique: progrès récents. 2006 , 8, 350-355		

1644	Cyclin E but not bcl-2, bax or mcl-1 is differentially expressed in ZAP 70-positive and ZAP 70-negative B-CLL cells. 2006 , 85, 458-62	10
1643	Feasibility of an easily applicable method of ZAP-70 measurement in chronic lymphocytic leukemia in the routine flow cytometry setting: A methodological approach. 2006 , 85, 795-805	7
1642	Bortezomib induces different apoptotic rates in B-CLL cells according to IgVH and BCL-6 mutations. 2006 , 8, 805-11	4
1641	New agents in chronic lymphocytic leukemia. 2006 , 7, 200-12	10
1640	New aspects of the treatment of chronic lymphocytic leukemia. 2006 , 1, 251-7	
1639	Serum insulin-like growth factor is not elevated in patients with early B-cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression. 2006 , 76, 51-7	9
1638	Serum TK levels in CLL identify Binet stage A patients within biologically defined prognostic subgroups most likely to undergo disease progression. 2006 , 77, 309-17	25
1637	Lack of association between the TNF-alpha promoter gene polymorphism and susceptibility to B-cell chronic lymphocytic leukaemia. 2006 , 33, 21-4	23
1636	Clinical, immunophenotypic, and molecular profiling of trisomy 12 in chronic lymphocytic leukemia and comparison with other karyotypic subgroups defined by cytogenetic analysis. 2006 , 168, 109-19	38
1635	Genetic abnormalities and clinical outcome in chronic lymphocytic leukemia. 2006 , 171, 57-64	50
1634	Constitutive and activation-inducible cyclooxygenase-2 expression enhances survival of chronic lymphocytic leukemia B cells. 2006 , 120, 76-90	23
1633	The origin of B-cell chronic lymphocytic leukemia. 2006 , 33, 150-6	30
1632	Initial therapy for patients with chronic lymphocytic leukemia. 2006 , 33, 202-9	16
1631	Risk stratification in chronic lymphocytic leukemia. 2006 , 33, 186-94	62
1630	CLLU1 expression levels predict time to initiation of therapy and overall survival in chronic lymphocytic leukemia. 2006 , 76, 455-64	29
1629	CD38 as a prognostic factor in B cell chronic lymphocytic leukaemia (B-CLL): comparison of three approaches to analyze its expression. 2006 , 70, 136-41	35
1628	ZAP-70 by flow cytometry: a comparison of different antibodies, anticoagulants, and methods of analysis. 2006 , 70, 235-41	26
1627	Kolmogorov-Smirnov statistical test for analysis of ZAP-70 expression in B-CLL, compared with quantitative PCR and IgV(H) mutation status. 2006 , 70, 302-8	14

1626	Use of a blocking antibody method for the flow cytometric measurement of ZAP-70 in B-CLL. 2006 , 70, 251-8	8
1625	Flow cytometry for ZAP-70: New colors for chronic lymphocytic leukemia. 2006 , 70, 201-3	6
1624	ZAP-70 expression in B-cell chronic lymphocytic leukemia: evaluation by external (isotypic) or internal (T/NK cells) controls and correlation with IgV(H) mutations. 2006 , 70, 284-92	31
1623	Clinical utility of assessing ZAP-70 and CD38 in chronic lymphocytic leukemia. 2006 , 70, 209-13	22
1622	Clinical implications of ZAP-70 expression in chronic lymphocytic leukemia. 2006 , 70, 214-7	22
1621	Evaluation of ZAP-70 expression by flow cytometry in chronic lymphocytic leukemia: A multicentric international harmonization process. 2006 , 70, 309-14	58
1620	Comparison of methods for determining zeta-chain associated protein - 70 (ZAP-70) expression in patients with B-cell chronic lymphocytic leukemia (B-CLL). 2006 , 70, 293-301	12
1619	Variations in the detection of ZAP-70 in chronic lymphocytic leukemia: Comparison with IgV(H) mutation analysis. 2006 , 70, 270-5	18
1618	B lymphocytes in humans express ZAP-70 when activated in vivo. 2006 , 36, 558-69	55
1617	IGHV gene insertions and deletions in chronic lymphocytic leukemia: "CLL-biased" deletions in a subset of cases with stereotyped receptors. 2006 , 36, 1963-74	33
1616	A scoring system based on the expression of six surface molecules allows the identification of three prognostic risk groups in B-cell chronic lymphocytic leukemia. 2006 , 207, 354-63	40
1615	The effect of immunoglobulin VH gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia. 2006 , 107, 1023-33	71
1614	What is the current evidence for antigen involvement in the development of chronic lymphocytic leukemia?. 2006 , 24, 7-13	11
1613	D Cyclins in CD5+ B-Cell Lymphoproliferative Disorders. 2006 , 125, 241-250	23
1612	Retrospective analysis of CD38 expression in 102 patients with B-CLL with a maximum follow-up of 18 years: incidence and prognostic significance. 2006 , 29, 437-41	1
1611	New prognostic markers in CLL. 2006 , 2006, 279-84	53
1610	Molecular Genetic Abnormalities in Acute and Chronic Leukemias. 2006 , 415-436	1
1609	Structural and functional features of the B-cell receptor in IgG-positive chronic lymphocytic leukemia. 2006 , 12, 1672-9	32

1608	Evolving view of the in-vivo kinetics of chronic lymphocytic leukemia B cells. 2006 , 2006, 273-8, 512		18
1607	Chronic lymphocytic leukemia: recent advances in diagnosis and treatment. 2006 , 11, 21-30		45
1606	Molecular pathogenesis of chronic lymphocytic leukemia. 2006 , 6, 665-75		33
1605	The clinical significance of ZAP-70 and CD38 expression in B-cell chronic lymphocytic leukaemia. 2006 , 17, 683-90		53
1604	Immunoglobulin V(H) genes and CD38 expression analysis in B-cell chronic lymphocytic leukemia. 2006 , 116, 72-4		1
1603	The biology and treatment of chronic lymphocytic leukemia. 2006 , 17 Suppl 10, x144-54		20
1602	Role of immunochemotherapy in the treatment of chronic lymphocytic leukemia. 2006 , 6, 1787-800		3
1601	Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. 2006 , 24, 969-75		157
1600	CD38 induces apoptosis of a murine pro-B leukemic cell line by a tyrosine kinase-dependent but ADP-ribosyl cyclase- and NAD glycohydrolase-independent mechanism. 2006 , 18, 1029-42		26
1599	B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia. 2006 , 103, 11713-8		139
1598	Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. <i>Blood</i> , 2007 , 109, 4679-85	2.2	264
1597	The prognostic evaluation of CLLU1 expression levels in 50 Chinese patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2007 , 48, 1785-92	1.9	12
1596	B cell chronic lymphocytic leukaemia/small lymphocytic lymphoma: role of ZAP70 determination on bone marrow biopsy specimens. 2007 , 60, 627-32		6
1595	Abdominal computed tomography predicts progression in patients with Rai stage 0 chronic lymphocytic leukemia. 2007 , 25, 1576-80		43
1594	Upregulation of bfl-1 is a potential mechanism of chemoresistance in B-cell chronic lymphocytic leukaemia. 2007 , 97, 769-77		43
1593	iHMMune-align: hidden Markov model-based alignment and identification of germline genes in rearranged immunoglobulin gene sequences. 2007 , 23, 1580-7		105
1592	Emerging therapeutic options for B-cell disorders: idiopathic thrombocytopenic purpura and chronic lymphocytic leukemia. 2007 , 11, 23-36		
1591	Molecular diagnostics of non-Hodgkin lymphoma. 2007 , 1, 47-63		2

1590	The immunoglobulin genes: structure and specificity in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2007 , 48, 1081-6	1.9	8
1589	Multi-drug resistance mediated by P-glycoprotein overexpression is not correlated with ZAP-70/CD38 expression in B-cell chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2007 , 48, 1556-60	1.9	10
1588	Biomarkers and the design of clinical trials in cancer. 2007 , 1, 387-97		6
1587	A novel nonobese diabetic/severe combined immunodeficient xenograft model for chronic lymphocytic leukemia reflects important clinical characteristics of the disease. 2007 , 67, 8653-61		54
1586	Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. 2007 , 25, 1114-20		268
1585	Chronic Lymphocytic Leukemia. 2007 , 1-5		
1584	Quantification of ZAP70 mRNA in B cells by real-time PCR is a powerful prognostic factor in chronic lymphocytic leukemia. 2007 , 53, 1757-66		35
1583	Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival. 2007 , 92, 1242-5		179
1582	ATM, CTLA4, MND1, and HEM1 in high versus low CD38 expressing B-cell chronic lymphocytic leukemia. 2007 , 13, 5295-304		53
1581	Comparative analysis of flow cytometric techniques in assessment of ZAP-70 expression in relation to IgVH mutational status in chronic lymphocytic leukemia. 2007 , 127, 182-91		26
1580	Familial B-cell chronic lymphocytic leukemia: analysis of cytogenetic abnormalities, immunophenotypic profiles, and immunoglobulin heavy chain gene usage. 2007 , 127, 31-8		10
1579	17p Deletion is associated with resistance of B-cell chronic lymphocytic leukemia cells to in vitro fludarabine-induced apoptosis. <i>Leukemia and Lymphoma</i> , 2007 , 48, 311-20	1.9	32
1578	High-resolution oligonucleotide array-CGH pinpoints genes involved in cryptic losses in chronic lymphocytic leukemia. 2007 , 118, 8-12		49
1577	Microarray expression technology in clinical research of non-Hodgkin lymphoma. 2007 , 15, 28-35		1
1576	Murine models for chronic lymphocytic leukaemia. 2007 , 35, 1009-12		3
1575	ZAP-70 enhances B-cell-receptor signaling despite absent or inefficient tyrosine kinase activation in chronic lymphocytic leukemia and lymphoma B cells. <i>Blood</i> , 2007 , 109, 2032-9	2.2	141
1574	Over 20% of patients with chronic lymphocytic leukemia carry stereotyped receptors: Pathogenetic implications and clinical correlations. <i>Blood</i> , 2007 , 109, 259-70	2.2	402
1573	Progressive immunoglobulin gene mutations in chronic lymphocytic leukemia: evidence for antigen-driven intracлонаl diversification. <i>Blood</i> , 2007 , 109, 1559-67	2.2	29

1572	Expansion of Vdelta1 T lymphocytes producing IL-4 in low-grade non-Hodgkin lymphomas expressing UL-16-binding proteins. <i>Blood</i> , 2007 , 109, 2078-85	2.2	48
1571	Temporal genetic program following B-cell receptor cross-linking: altered balance between proliferation and death in healthy and malignant B cells. <i>Blood</i> , 2007 , 109, 3989-97	2.2	44
1570	Comprehensive characterization of IGHV3-21-expressing B-cell chronic lymphocytic leukemia: an Italian multicenter study. <i>Blood</i> , 2007 , 109, 2989-98	2.2	57
1569	CLLU1 expression analysis adds prognostic information to risk prediction in chronic lymphocytic leukemia. <i>Blood</i> , 2007 , 109, 4973-9	2.2	45
1568	Reversible anergy of sIgM-mediated signaling in the two subsets of CLL defined by VH-gene mutational status. <i>Blood</i> , 2007 , 109, 4424-31	2.2	184
1567	IgVH mutational status and clonality analysis of Richter's transformation: diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution. 2007 , 31, 1605-14		176
1566	ZAP70 expression assessed by immunohistochemistry on peripheral blood: a simple prognostic assay for patients with chronic lymphocytic leukemia. 2007 , 15, 471-6		5
1565	Regulation of CD38 in proliferating chronic lymphocytic leukemia cells stimulated with CD154 and interleukin-4. 2007 , 92, 1359-66		20
1564	Pathology of chronic lymphocytic leukemia: an update. 2007 , 11, 363-89		44
1563	Recent progress in the management of chronic lymphocytic leukemia. 2007 , 33, 710-28		30
1562	Laminin-332 (Laminin-5) is the major motility ligand for B cell chronic lymphocytic leukemia. 2007 , 26, 473-84		8
1561	Diagnostic, pronostic et traitement chez les patients avec une leucémie lymphoïde chronique. 2007 , 22, 313-318		0
1560	Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. 2007 , 370, 230-239		610
1559	Prognostic markers in chronic lymphocytic leukaemia. 2007 , 20, 455-68		44
1558	p53 as a predictor for chemotherapy response in CLL cells. <i>Leukemia and Lymphoma</i> , 2007 , 48, 219-20	1.9	5
1557	CD38 expression labels an activated subset within chronic lymphocytic leukemia clones enriched in proliferating B cells. <i>Blood</i> , 2007 , 110, 3352-9	2.2	133
1556	Flow Cytometry in Hematopathology. 2007 ,		1
1555	Role of AID in tumorigenesis. 2007 , 94, 245-73		112

1554	Expression level of lipoprotein lipase and dystrophin genes predict survival in B-cell chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2007 , 48, 912-22	1.9	25
1553	Microarray Technology and Cancer Gene Profiling. 2007 ,		4
1552	Lipoprotein lipase mRNA expression in whole blood is a prognostic marker in B cell chronic lymphocytic leukemia. 2007 , 53, 204-12		47
1551	Using smudge cells on routine blood smears to predict clinical outcome in chronic lymphocytic leukemia: a universally available prognostic test. 2007 , 82, 449-53		47
1550	The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy. <i>Leukemia and Lymphoma</i> , 2007 , 48, 1931-9	1.9	85
1549	Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. 2007 , 25, 799-804		296
1548	CD5 does not regulate the signaling triggered through BCR in B cells from a subset of B-CLL patients. <i>Leukemia and Lymphoma</i> , 2007 , 48, 147-57	1.9	3
1547	Hematopoietic stem cell transplantation for chronic lymphocytic leukemia: potential cure for an incurable disease. 2007 , 7, 1789-97		7
1546	The changing face of chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2007 , 48, 2283-4	1.9	2
1545	Identification and validation of biomarkers of IgV(H) mutation status in chronic lymphocytic leukemia using microfluidics quantitative real-time polymerase chain reaction technology. 2007 , 9, 546-55		20
1544	Revision of the guidelines for diagnosis and therapy of chronic lymphocytic leukemia (CLL). 2007 , 20, 469-77		14
1543	A Highly Sensitive Method for Detecting Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia: Interphase Fluorescence In Situ Hybridization on Flow-Sorted Cells. 2007 , 1, 304-308		
1542	Update on Genomic Profiling in Chronic Lymphocytic Leukemia. 2007 , 1, 217-222		
1541	The Role of MicroRNAs in Chronic Lymphocytic Leukemia. 2007 , 1, 287-291		
1540	Chronic Lymphocytic Leukemia: How to Assess Prognosis in 2007. 2007 , 1, 162-167		1
1539	Genetic alteration associated with chronic lymphocytic leukemia. 2007 , 118, 310-9		12
1538	The normal counterpart to the chronic lymphocytic leukemia B cell. 2007 , 20, 385-97		26
1537	Genetics and risk-stratified approach to therapy in chronic lymphocytic leukemia. 2007 , 20, 439-53		58

1536	Differential diagnosis in chronic lymphocytic leukaemia. 2007 , 20, 367-84		23
1535	Stem-cell transplantation in chronic lymphocytic leukaemia. 2007 , 20, 513-27		8
1534	Novel agents and strategies for treatment of p53-defective chronic lymphocytic leukemia. 2007 , 20, 545-56		25
1533	Cell proliferation and death: forgotten features of chronic lymphocytic leukemia B cells. 2007 , 20, 399-413		86
1532	Introduction: Chronic lymphocytic leukemia in perspective. 2007 , 20, 363-5		1
1531	The B-cell receptor and ZAP-70 in chronic lymphocytic leukemia. 2007 , 20, 415-24		32
1530	[Chronic lymphocytic leukaemia: an autoimmune disorder? Prognostic factors and the current view of pathogenesis]. 2007 , 148, 867-78		0
1529	The prognostic role of CXCR3 expression by chronic lymphocytic leukemia B cells. 2007 , 92, 349-56		34
1528	Management of Haematological Malignancies. 2007 ,		1
1527	Igbeta(CD79b) mRNA expression in chronic lymphocytic leukaemia cells correlates with immunoglobulin heavy chain gene mutational status but does not serve as an independent predictor of clinical severity. <i>American Journal of Hematology</i> , 2007 , 82, 712-20	7.1	4
1526	Prognostic significance of combined analysis of ZAP-70 and CD38 in chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2007 , 82, 787-91	7.1	33
1525	Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2007 , 82, 1063-70	7.1	41
1524	IgVH gene mutation status and genomic imbalances in chronic lymphocytic leukaemia with increased prolymphocytes (CLL/PL). 2007 , 25, 90-5		1
1523	High rate of centrosome aberrations and correlation with proliferative activity in patients with untreated B-cell chronic lymphocytic leukemia. 2007 , 121, 978-83		11
1522	Overexpression of the paternally expressed gene 10 (PEG10) from the imprinted locus on chromosome 7q21 in high-risk B-cell chronic lymphocytic leukemia. 2007 , 121, 1984-93		50
1521	Animal models for chronic lymphocytic leukemia. 2007 , 100, 1109-18		39
1520	Expression of inhibitory receptor ILT3 on neoplastic B cells is associated with lymphoid tissue involvement in chronic lymphocytic leukemia. 2007 , 72, 354-62		37
1519	Prevalence and natural history of monoclonal and polyclonal B-cell lymphocytosis in a residential adult population. 2007 , 72, 344-53		58

1518	CD5 provides viability signals to B cells from a subset of B-CLL patients by a mechanism that involves PKC. 2007 , 31, 183-93		20
1517	V(H)3-48 and V(H)3-53, as well as V(H)3-21, gene rearrangements define unique subgroups in CLL and are associated with biased lambda light chain restriction, homologous Lcdr3 sequences and poor prognosis. 2007 , 31, 231-4		14
1516	Chronic lymphocytic leukemia patients with a V1-69 gene rearrangement do not have inferior survival with respect to patients that express other unmutated V(H) genes. 2007 , 31, 245-8		8
1515	Is "leukemia" an appropriate label for all patients who meet the diagnostic criteria of chronic lymphocytic leukemia?. 2007 , 31, 273-5		14
1514	Progressive disease in chronic lymphocytic leukemia is correlated with the DNA methylation index. 2007 , 31, 773-7		10
1513	Use of IGHJ and IGHD gene mutations in analysis of immunoglobulin sequences for the prognosis of chronic lymphocytic leukemia. 2007 , 31, 1247-52		10
1512	Pharmacological inhibitors of NF-kappaB accelerate apoptosis in chronic lymphocytic leukaemia cells. 2007 , 26, 1166-77		66
1511	Fetal B-cell lymphopoiesis and the emergence of B-1-cell potential. 2007 , 7, 213-9		113
1510	The Akt signaling pathway determines the different proliferative capacity of chronic lymphocytic leukemia B-cells from patients with progressive and stable disease. <i>Leukemia</i> , 2007 , 21, 110-20	10.7	125
1509	Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. <i>Leukemia</i> , 2007 , 21, 12-7	10.7	297
1508	ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia. <i>Leukemia</i> , 2007 , 21, 1-3	10.7	181
1507	ZAP-70 expression, as detected by immunohistochemistry on bone marrow biopsies from early-phase CLL patients, is a strong adverse prognostic factor. <i>Leukemia</i> , 2007 , 21, 102-9	10.7	31
1506	Telomere length identifies two different prognostic subgroups among VH-unmutated B-cell chronic lymphocytic leukemia patients. <i>Leukemia</i> , 2007 , 21, 697-705	10.7	40
1505	Highly purified CD38+ and CD38- sub-clones derived from the same chronic lymphocytic leukemia patient have distinct gene expression signatures despite their monoclonal origin. <i>Leukemia</i> , 2007 , 21, 687-96	10.7	46
1504	Telomerase expression in B-cell chronic lymphocytic leukemia predicts survival and delineates subgroups of patients with the same igVH mutation status and different outcome. <i>Leukemia</i> , 2007 , 21, 965-72	10.7	53
1503	Chromosomal translocations independently predict treatment failure, treatment-free survival and overall survival in B-cell chronic lymphocytic leukemia patients treated with cladribine. <i>Leukemia</i> , 2007 , 21, 1715-22	10.7	76
1502	The role of prognostic factors in assessing 'high-risk' subgroups of patients with chronic lymphocytic leukemia. <i>Leukemia</i> , 2007 , 21, 1885-91	10.7	83
1501	Molecular heterogeneity in chronic lymphocytic leukemia is dependent on BCR signaling: clinical correlation. <i>Leukemia</i> , 2007 , 21, 1984-91	10.7	47

1500	Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping. <i>Leukemia</i> , 2007 , 21, 2442-51	10.7	281
1499	Molecular genetic analysis of haematological malignancies II: Mature lymphoid neoplasms. 2007 , 29, 229-60		21
1498	Minimal residual disease in chronic lymphocytic leukaemia: is it ready for primetime?. <i>British Journal of Haematology</i> , 2007 , 136, 379-92	4.5	21
1497	Cytogenetic abnormalities additional to t(11;14) correlate with clinical features in leukaemic presentation of mantle cell lymphoma, and may influence prognosis: a study of 60 cases by FISH. <i>British Journal of Haematology</i> , 2007 , 137, 117-24	4.5	41
1496	Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2007 , 137, 355-63	4.5	84
1495	CD154 induces a switch in pro-survival Bcl-2 family members in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2007 , 138, 721-32	4.5	54
1494	Chronic lymphocytic leukaemia: an overview of aetiology in light of recent developments in classification and pathogenesis. <i>British Journal of Haematology</i> , 2007 , 139, 672-86	4.5	63
1493	Molecular profiling of chronic lymphocytic leukaemia: genetics meets epigenetics to identify predisposing genes. <i>British Journal of Haematology</i> , 2007 , 139, 744-52	4.5	20
1492	Discordance of ZAP-70 in patients with chronic lymphocytic leukemia. 2008 , 30, 36-40		2
1491	From normal to clonal B cells: Chronic lymphocytic leukemia (CLL) at the crossroad between neoplasia and autoimmunity. 2007 , 7, 127-31		39
1490	Signaling pathways activated by antigen-receptor engagement in chronic lymphocytic leukemia B-cells. 2007 , 7, 102-8		61
1489	Bulky lymphadenopathy with poor clinical outcome is associated with ATM downregulation in B-cell chronic lymphocytic leukemia patients irrespective of 11q23 deletion. 2007 , 172, 120-6		7
1488	Translocations as a mechanism for homozygous deletion of 13q14 and loss of the ATM gene in a patient with B-cell chronic lymphocytic leukemia. 2007 , 174, 57-60		14
1487	p53 pathway gene single nucleotide polymorphisms and chronic lymphocytic leukemia. 2007 , 179, 36-44		15
1486	Pathophysiologic mechanisms of chronic lymphocytic leukemia and their application to therapy. 2007 , 35, 134-6		7
1485	Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response. 2007 , 35, 1527-37		55
1484	Zap-70 and CD38 as predictors of IgVH mutation in CLL. 2007 , 83, 459-61		6
1483	Expression of soluble CD27 and interleukins-8 and -10 in B-cell chronic lymphocytic leukemia: correlation with disease stage and prognosis. <i>Advances in Therapy</i> , 2007 , 24, 29-40	4.1	23

1482	Correlation of ZAP-70 expression in B cell leukemias to the ex vivo response to a combination of fludarabine/genistein. 2007 , 56, 501-14	13
1481	Prognostic factors in chronic lymphocytic leukemia. 2007 , 2, 49-55	10
1480	Chronic lymphocytic leukemia: biology and current treatment. 2007 , 9, 345-52	8
1479	Chronic lymphocytic leukemia. 2007 , 64, 234-46	73
1478	Oral fludarabine and cyclophosphamide as front-line chemotherapy in patients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration. 2008 , 87, 891-8	12
1477	Chronisch lymphatische Leukämie (CLL). 2008 , 3, 81-91	
1476	miRNA analysis in B-cell chronic lymphocytic leukaemia: proliferation centres characterized by low miR-150 and high BIC/miR-155 expression. 2008 , 215, 13-20	100
1475	Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. 2008 , 112, 119-28	78
1474	Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years. 2008 , 113, 1933-52	74
1473	Clinical and therapeutic implications of the mutational status of IgVH in patients with chronic lymphocytic leukemia. 2008 , 113, 897-906	29
1472	Early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. 2008 , 113, 2110-8	62
1471	Impact of trisomy 12, del(13q), del(17p), and del(11q) on the immunophenotype, DNA ploidy status, and proliferative rate of leukemic B-cells in chronic lymphocytic leukemia. 2008 , 74, 139-49	49
1470	Immunophenotypic features distinguishing familial chronic lymphocytic leukemia from sporadic chronic lymphocytic leukemia. 2008 , 74, 221-6	10
1469	Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy. 2008 , 123, 1190-5	138
1468	Fc receptor-like 1-5 molecules are similarly expressed in progressive and indolent clinical subtypes of B-cell chronic lymphocytic leukemia. 2008 , 123, 2113-9	29
1467	Molecular and transcriptional characterization of 17p loss in B-cell chronic lymphocytic leukemia. 2008 , 47, 781-93	54
1466	Redundant role for Zap70 in B cell development and activation. 2008 , 38, 1721-33	17
1465	Peripheral blood and bone marrow TNF and TNF receptors in early and advanced stages of B-CLL in correlation with ZAP-70 protein and CD38 antigen. 2008 , 32, 225-33	18

1464	Chronic lymphocytic leukemia patients exposed to ionizing radiation due to the Chernobyl NPP accident--with focus on immunoglobulin heavy chain gene analysis. 2008 , 32, 535-45		21
1463	Controversies in the front-line management of chronic lymphocytic leukemia. 2008 , 32, 679-88		8
1462	The significance of soluble HLA-G plasma levels as well as messenger HLA-G for B-cell chronic lymphocytic leukemia (B-CLL). 2008 , 32, 1815-9		15
1461	New prognostic markers in chronic lymphocytic leukemia. 2008 , 22, 211-9		107
1460	Doubling time of soluble CD23: a powerful prognostic factor for newly diagnosed and untreated stage A chronic lymphocytic leukemia patients. <i>Leukemia</i> , 2008 , 22, 1882-90	10.7	23
1459	Apolipoprotein E genotype as a determinant of survival in chronic lymphocytic leukemia. <i>Leukemia</i> , 2008 , 22, 2184-92	10.7	8
1458	Hsp90 inhibition has opposing effects on wild-type and mutant p53 and induces p21 expression and cytotoxicity irrespective of p53/ATM status in chronic lymphocytic leukaemia cells. 2008 , 27, 2445-55		56
1457	A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia. 2008 , 40, 1204-10		294
1456	Many human immunoglobulin heavy-chain IGHV gene polymorphisms have been reported in error. 2008 , 86, 111-5		50
1455	Efficient gene transfer in CLL by mRNA electroporation. <i>Leukemia</i> , 2008 , 22, 323-9	10.7	19
1454	Small RNAs analysis in CLL reveals a deregulation of miRNA expression and novel miRNA candidates of putative relevance in CLL pathogenesis. <i>Leukemia</i> , 2008 , 22, 330-8	10.7	158
1453	The BCL-2 promoter (-938C>A) polymorphism does not predict clinical outcome in chronic lymphocytic leukemia. <i>Leukemia</i> , 2008 , 22, 339-43	10.7	6
1452	Targeting lipid metabolism by the lipoprotein lipase inhibitor orlistat results in apoptosis of B-cell chronic lymphocytic leukemia cells. <i>Leukemia</i> , 2008 , 22, 585-92	10.7	78
1451	Determination of how many immunoglobulin variable region heavy chain mutations are allowable in unmutated chronic lymphocytic leukaemia - long-term follow up of patients with different percentages of mutations. <i>British Journal of Haematology</i> , 2008 , 140, 320-3	4.5	34
1450	The prognostic significance of cytopenia in chronic lymphocytic leukaemia/small lymphocytic lymphoma. <i>British Journal of Haematology</i> , 2008 , 141, 615-21	4.5	84
1449	Analysis of a large multi-generational family provides insight into the genetics of chronic lymphocytic leukemia. <i>British Journal of Haematology</i> , 2008 , 142, 238-45	4.5	24
1448	Highly purified CD38 sub-populations show no evidence of preferential clonal evolution despite having increased proliferative activity when compared with CD38 sub-populations derived from the same chronic lymphocytic leukaemia patient. <i>British Journal of Haematology</i> , 2008 , 142, 595-605	4.5	12
1447	Microenvironmental influences in chronic lymphocytic leukaemia: the role of antigen stimulation. 2008 , 264, 549-62		131

1446	Stem cell transplantation in poor-risk chronic lymphocytic leukemia: assessment of post-transplant minimal residual disease using four- and six-color flow cytometry and allele-specific RQ-PCR. 2008 , 81, 100-6		4
1445	Human B cell subsets. 2008 , 98, 151-224		62
1444	Molecular genetic characterization reveals new subsets of mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , 2008 , 49, 1042-9	1.9	28
1443	Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. 2008 , 359, 575-83		447
1442	Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2008 , 49, 49-56	1.9	146
1441	Targeted Cancer Therapy. 2008 ,		6
1440	Human leukocyte antigen class II allele association to disease progression in Iranian patients with chronic lymphocytic leukemia. 2008 , 69, 666-74		8
1439	CD38 at the junction between prognostic marker and therapeutic target. 2008 , 14, 210-8		59
1438	Alteration of enzymatic properties of cell-surface antigen CD38 by agonistic anti-CD38 antibodies that prolong B cell survival and induce activation. 2008 , 8, 59-70		7
1437	[Chronic lymphocytic leukaemia: current management]. 2008 , 29, 424-35		2
1436	Predominantly post-transcriptional regulation of activation molecules in chronic lymphocytic leukemia: the case of transferrin receptors. 2008 , 41, 203-9		4
1435	Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis. <i>Blood</i> , 2008 , 111, 1524-33	2.2	263
1434	Lack of the leukocyte-associated Ig-like receptor-1 expression in high-risk chronic lymphocytic leukaemia results in the absence of a negative signal regulating kinase activation and cell division. <i>Leukemia</i> , 2008 , 22, 980-8	10.7	38
1433	Molecular diagnostics in chronic lymphocytic leukemia - pathogenetic and clinical implications. <i>Leukemia and Lymphoma</i> , 2008 , 49, 864-73	1.9	36
1432	Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. <i>Blood</i> , 2008 , 111, 5446-56	2.2	2531
1431	Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. <i>Blood</i> , 2008 , 112, 975-80	2.2	568
1430	Chronic lymphocytic leukaemia. 2008 , 371, 1017-29		235
1429	Novel insights in chronic lymphocytic leukemia: are we getting closer to understanding the pathogenesis of the disease?. 2008 , 26, 4497-503		161

1428	Usefulness of Risk Stratification in the Treatment of Patients with Chronic Lymphocytic Leukemia. 2008 , 2, 46-54		
1427	Indolent lymphomas other than follicular and marginal zone lymphomas. 2008 , 22, 903-40, viii		5
1426	Current Treatment for Chronic Lymphocytic Leukemia. 2008 , 2, 230-236		0
1425	Chronic Lymphocytic Leukemia: An Amazing Time Given the Development of New Combination Therapies and New Agents, but Still No Cure, and a Need to Focus on Patient-Specific Treatment Options. 2008 , 2, 221-222		
1424	Clinical application of array-based comparative genomic hybridization for the identification of prognostically important genetic alterations in chronic lymphocytic leukemia. 2008 , 12, 271-80		18
1423	First-Line Treatment in Chronic Lymphocytic Leukemia: A Risk-Stratified Approach. 2008 , 2, 121-127		
1422	MUM1/IRF4 expression in the circulating compartment of chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2008 , 49, 273-80	1.9	6
1421	Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. <i>Blood</i> , 2008 , 111, 1584-93	2.2	103
1420	Combinations of ZAP-70, CD38 and IGHV mutational status as predictors of time to first treatment in CLL. <i>Leukemia and Lymphoma</i> , 2008 , 49, 2108-15	1.9	43
1419	Characterising the TP53-deleted subgroup of chronic lymphocytic leukemia: an analysis of additional cytogenetic abnormalities detected by interphase fluorescence in situ hybridisation and array-based comparative genomic hybridisation. <i>Leukemia and Lymphoma</i> , 2008 , 49, 1879-86	1.9	12
1418	Humoral immune responses against the immature laminin receptor protein show prognostic significance in patients with chronic lymphocytic leukemia. 2008 , 180, 6374-84		14
1417	ZAP-70 mRNA expression provides clinically valuable information in early-stage chronic lymphocytic leukemia. 2008 , 93, 1422-4		5
1416	Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia. 2008 , 14, 396-404		173
1415	Mutated IgHV1-69 gene usage represents a distinct subgroup associated with indolent disease in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2008 , 49, 763-8	1.9	6
1414	Is assessment of surface CD38 expression worthwhile as a prognostic factor in chronic lymphocytic leukemia patients?. 2008 , 13, 24-7		
1413	In vivo dynamics of stable chronic lymphocytic leukemia inversely correlate with somatic hypermutation levels and suggest no major leukemic turnover in bone marrow. 2008 , 68, 10137-44		44
1412	Hedgehog-induced survival of B-cell chronic lymphocytic leukemia cells in a stromal cell microenvironment: a potential new therapeutic target. 2008 , 6, 1928-36		88
1411	Prognostic factors in chronic lymphocytic leukemia. 2008 , 19 Suppl 4, iv51-3		18

1410	Purine-rich box-1-mediated reduced expression of CD20 alters rituximab-induced lysis of chronic lymphocytic leukemia B cells. 2008 , 68, 7512-9		25
1409	Chronic lymphocytic leukaemia: a short overview. 2008 , 19 Suppl 7, vii320-5		26
1408	Serum thrombopoietin compared with ZAP-70 and immunoglobulin heavy-chain gene mutation status as a predictor of time to first treatment in early chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2008 , 49, 62-7	1.9	3
1407	Chronic lymphocytic leukemia with mutated IgVH1-69 usage: a distinct CLL subgroup with more indolent behavior?. <i>Leukemia and Lymphoma</i> , 2008 , 49, 648-9	1.9	1
1406	Peripheral blood lymphocytosis--what is the threshold for further investigation?. <i>Leukemia and Lymphoma</i> , 2008 , 49, 1659-61	1.9	2
1405	Monoclonal B-cell lymphocytosis--a frequent premalignant condition. 2008 , 359, 638-40		5
1404	Protein expression profiling of cytokines and cytokine receptors on purified chronic lymphocytic leukemia cells from patients with favourable prognostic indicators. <i>Leukemia and Lymphoma</i> , 2008 , 49, 751-6	1.9	8
1403	Molecular profiling in CLL. 2008 , 444-9		21
1402	Biologic prognostic markers and their application in clinical trials and management of chronic lymphocytic leukaemia patients. 2008 , 2, 101-12		1
1401	Multicenter study of ZAP-70 expression in patients with B-cell chronic lymphocytic leukemia using an optimized flow cytometry method. 2008 , 93, 215-23		30
1400	CD49d expression is an independent risk factor of progressive disease in early stage chronic lymphocytic leukemia. 2008 , 93, 1575-9		66
1399	The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. <i>Blood</i> , 2008 , 111, 846-55	2.2	254
1398	Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. <i>Blood</i> , 2008 , 111, 865-73	2.2	197
1397	Short telomeres are associated with genetic complexity, high-risk genomic aberrations, and short survival in chronic lymphocytic leukemia. <i>Blood</i> , 2008 , 111, 2246-52	2.2	117
1396	Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. <i>Blood</i> , 2008 , 112, 1923-30	2.2	254
1395	Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia. <i>Blood</i> , 2008 , 112, 1993-2003	2.2	83
1394	CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment. <i>Blood</i> , 2008 , 111, 5173-81	2.2	173
1393	Constitutive activation of distinct BCR-signaling pathways in a subset of CLL patients: a molecular signature of energy. <i>Blood</i> , 2008 , 112, 188-95	2.2	180

1392	Increased proteasomal degradation of Bax is a common feature of poor prognosis chronic lymphocytic leukemia. <i>Blood</i> , 2008 , 111, 2790-6	2.2	25
1391	SAGE analysis demonstrates increased expression of TOSO contributing to Fas-mediated resistance in CLL. <i>Blood</i> , 2008 , 112, 394-7	2.2	37
1390	The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. <i>Blood</i> , 2008 , 111, 4681-9	2.2	128
1389	A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies. <i>Blood</i> , 2008 , 111, 3838-48	2.2	210
1388	BCR ligation induced by IgM stimulation results in gene expression and functional changes only in IgV H unmutated chronic lymphocytic leukemia (CLL) cells. <i>Blood</i> , 2008 , 112, 782-92	2.2	108
1387	Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection. <i>Blood</i> , 2008 , 111, 5101-8	2.2	62
1386	CD38 gene polymorphism and chronic lymphocytic leukemia: a role in transformation to Richter syndrome?. <i>Blood</i> , 2008 , 111, 5646-53	2.2	63
1385	FCRL2 expression predicts IGHV mutation status and clinical progression in chronic lymphocytic leukemia. <i>Blood</i> , 2008 , 112, 179-87	2.2	44
1384	Geldanamycin-induced Lyn dissociation from aberrant Hsp90-stabilized cytosolic complex is an early event in apoptotic mechanisms in B-chronic lymphocytic leukemia. <i>Blood</i> , 2008 , 112, 4665-74	2.2	50
1383	Insight into the pathogenesis of chronic lymphocytic leukemia (CLL) through analysis of IgVH gene usage and mutation status in familial CLL. <i>Blood</i> , 2008 , 111, 5691-3	2.2	25
1382	EnABLING the immune synapse. <i>Blood</i> , 2008 , 112, 3	2.2	
1381	Ligandless receptors find a role. <i>Blood</i> , 2008 , 112, 2-3	2.2	1
1380	No convincing evidence for a role of CD31-CD38 interactions in the pathogenesis of chronic lymphocytic leukemia. <i>Blood</i> , 2008 , 112, 840-3	2.2	16
1379	Overexpression of TOSO in CLL is triggered by B-cell receptor signaling and associated with progressive disease. <i>Blood</i> , 2008 , 112, 4213-9	2.2	43
1378	Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA. <i>Blood</i> , 2008 , 112, 5122-9	2.2	127
1377	Impact of cytogenetic and molecular prognostic markers on the clinical management of chronic lymphocytic leukemia. 2008 , 93, 14-9		15
1376	Autoimmune conditions and chronic infections in chronic lymphocytic leukemia patients at diagnosis are associated with unmutated IgVH genes. 2008 , 93, 1912-6		20
1375	Clonal heterogeneity in chronic lymphocytic leukemia cells: superior response to surface IgM cross-linking in CD38, ZAP-70-positive cells. 2008 , 93, 413-22		39

1374	Chronic lymphocytic leukemia cells recognize conserved epitopes associated with apoptosis and oxidation. 2008 , 14, 665-74	153
1373	Chronic lymphocytic leukemia: "Cinderella" is becoming a star. 2009 , 15, 67-9	9
1372	Gene Expression and Serum Cytokine Profiling of Low Stage CLL Identify WNT/PCP, Flt-3L/Flt-3 and CXCL9/CXCR3 as Regulators of Cell Proliferation, Survival and Migration. 2009 , 2009, 453634	17
1371	CD38 gene polymorphisms contribute to genetic susceptibility to B-cell chronic lymphocytic leukemia: evidence from two case-control studies in Polish Caucasians. 2009 , 18, 945-53	26
1370	Rel a is an independent biomarker of clinical outcome in chronic lymphocytic leukemia. 2009 , 27, 763-9	45
1369	Bone Marrow. 2009 , 1536-1593	
1368	HLA-G expression in B chronic lymphocytic leukemia: a new prognostic marker?. 2009 , 14, 101-5	35
1367	Apoptosis of B-cell chronic lymphocytic leukemia cells induced by a novel BH3 peptidomimetic. 2009 , 8, 263-71	17
1366	NF-kappaB as a prognostic marker and therapeutic target in chronic lymphocytic leukemia. 2009 , 5, 1027-37	26
1365	Chronic lymphocytic leukemia microenvironment: shifting the balance from apoptosis to proliferation. 2009 , 94, 752-6	35
1364	A novel type of p53 pathway dysfunction in chronic lymphocytic leukemia resulting from two interacting single nucleotide polymorphisms within the p21 gene. 2009 , 69, 5210-7	37
1363	Lymph Nodes. 2009 , 1431-1511	
1362	Chronic lymphocytic leukemia. 2009 , 105-112	
1361	Bendamustine therapy in chronic lymphocytic leukemia. 2009 , 10, 1687-98	1
1360	Large-scale analysis of DNA methylation in chronic lymphocytic leukemia. 2009 , 1, 39-61	49
1359	Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia. 2009 , 69, 5424-32	141
1358	Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome. 2009 , 15, 4415-22	155
1357	A genomic approach to improve prognosis and predict therapeutic response in chronic lymphocytic leukemia. 2009 , 15, 6947-55	31

1356	CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival. 2009 , 69, 4001-9	134
1355	Information Preserving Component Analysis: Data Projections for Flow Cytometry Analysis. 2009 , 3, 148-158	9
1354	In vitro activity of 20 agents in different prognostic subgroups of chronic lymphocytic leukemia--rolipram and prednisolone active in cells from patients with poor prognosis. 2009 , 83, 22-34	4
1353	High CD49d protein and mRNA expression predicts poor outcome in chronic lymphocytic leukemia. 2009 , 131, 472-80	27
1352	T-cell CD38 expression in B-chronic lymphocytic leukaemia. 2009 , 27, 82-9	6
1351	The role of stem cell transplantation in the management of chronic lymphocytic leukaemia. 2009 , 27, 53-60	8
1350	CD26 expression in mature B-cell neoplasia: its possible role as a new prognostic marker in B-CLL. 2009 , 27, 140-7	41
1349	Validation of a new prognostic index for patients with chronic lymphocytic leukemia. 2009 , 115, 363-72	64
1348	Treatment of fludarabine-refractory chronic lymphocytic leukemia. 2009 , 115, 2824-36	51
1347	Chronic lymphocytic leukemia: treatment options for patients with refractory disease. 2009 , 115, 3830-41	10
1346	Correlation of flow cytometrically determined expression of ZAP-70 using the SBZAP antibody with IgVH mutation status and cytogenetics in 1,229 patients with chronic lymphocytic leukemia. 2009 , 76, 385-93	27
1345	Immunohistochemical analysis of ZAP-70 expression in chronic lymphocytic leukemia. 2009 , 40, 81-6	3
1344	Chronic lymphocytic leukemia: new concepts and emerging therapies. 2009 , 10, 16-32	7
1343	Prognostic factors in low-grade non-Hodgkin lymphomas. 2009 , 4, 202-10	11
1342	Incorporating prognostic information into treatment decisions in chronic lymphocytic leukemia. 2009 , 11, 353-9	1
1341	IGHV gene mutational status and LPL/ADAM29 gene expression as clinical outcome predictors in CLL patients in remission following treatment with oral fludarabine plus cyclophosphamide. 2009 , 88, 1215-21	23
1340	La leucémie lymphoïde chronique en 2009: quelles avancées clinico-biologiques?. 2009 , 2009, 12-15	1
1339	Validation of an LC-MS based approach for profiling histones in chronic lymphocytic leukemia. 2009 , 9, 1197-206	19

1338	Characterization of immunoglobulin heavy and light chain gene expression in chronic lymphocytic leukemia and related disorders. 2009 , 100, 671-7		11
1337	Immunoglobulin heavy chain variable region gene usage and mutational status of the leukemic B cells in Iranian patients with chronic lymphocytic leukemia. 2009 , 100, 2346-53		24
1336	Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study. <i>British Journal of Haematology</i> , 2009 , 144, 492-506	4.5	100
1335	Definition of progression risk based on combinations of cellular and molecular markers in patients with Binet stage A chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2009 , 146, 44-53	4.5	46
1334	Gene expression signature of chronic lymphocytic leukaemia with Trisomy 12. 2009 , 39, 568-75		28
1333	Expression level of lipoprotein lipase in Chinese patients with chronic lymphocytic leukemia and its correlation with other prognostic factors. 2009 , 31, 552-9		8
1332	The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. <i>Leukemia</i> , 2009 , 23, 117-24	10.7	167
1331	Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells. <i>Leukemia</i> , 2009 , 23, 686-97	10.7	154
1330	Telomere length is an independent predictor of survival, treatment requirement and Richter's syndrome transformation in chronic lymphocytic leukemia. <i>Leukemia</i> , 2009 , 23, 1062-72	10.7	85
1329	Hypermutation in mantle cell lymphoma does not indicate a clinical or biological subentity. 2009 , 22, 416-25		26
1328	Prognostic irrelevance of HLA-G in B-cell chronic lymphocytic leukemia. 2009 , 31, 327-37		19
1327	Computational identification of CDR3 sequence archetypes among immunoglobulin sequences in chronic lymphocytic leukemia. 2009 , 33, 368-76		19
1326	CD38 as a prognostic factor in Chinese patients with chronic lymphocytic leukaemia. 2009 , 33, 237-43		25
1325	Expression levels of CD38 on leukemic B cells but not on non-leukemic T cells are comparably stable over time and predict the course of disease in patients with chronic lymphocytic leukemia. 2009 , 33, 775-8		9
1324	Further evidence that antigen selection shapes the Ig repertoire in CLL. 2009 , 33, 363-5		
1323	Characterization of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in Shanghai, China: molecular and cytogenetic characteristics, IgV gene restriction and hypermutation patterns. 2009 , 33, 1599-603		11
1322	BAFF and APRIL expression in B-cell chronic lymphocytic leukemia: correlation with biological and clinical features. 2009 , 33, 1319-27		40
1321	Prognostic markers in chronic lymphocytic leukemia: a comprehensive review. 2009 , 23, 25-47		92

1320	Customized oligonucleotide array-based comparative genomic hybridization as a clinical assay for genomic profiling of chronic lymphocytic leukemia. 2009 , 11, 25-34		39
1319	Gene expression profiling in chronic lymphocytic leukaemia. 2009 , 22, 211-22		18
1318	Stem cell transplantation in chronic lymphocytic leukemia. 2009 , 15, 53-8		37
1317	Facteurs pronostiques utiles dans l'évaluation personnalisée d'un patient avec une leucémie lymphoïde chronique (LLC). 2009 , 24, 1-8		
1316	[B-chronic lymphocytic leukemia: epidemiological study and comparison of MDACC and GIMENA prognostic indexes]. 2009 , 133, 161-6		8
1315	La tomographie par émission de positons au 2-[18F]fluoro-2-désoxy-d-glucose (TEP-FDG) permet d'identifier les stades A et B des leucémies lymphoïdes chroniques (LLC). 2009 , 33, 539-546		
1314	Analysis of chronic lymphocytic leukemia transcriptomic profile: differences between molecular subgroups. <i>Leukemia and Lymphoma</i> , 2009 , 50, 68-79	1.9	17
1313	Current and emerging treatments for chronic lymphocytic leukaemia. 2009 , 69, 2415-49		33
1312	Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance. 2009 , 7, 76		31
1311	BCL6: somatic mutations and expression in early-stage chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2009 , 50, 773-80	1.9	12
1310	B-cell clones as early markers for chronic lymphocytic leukemia. 2009 , 360, 659-67		265
1309	A high number of losses in 13q14 chromosome band is associated with a worse outcome and biological differences in patients with B-cell chronic lymphoid leukemia. 2009 , 94, 364-71		50
1308	Transcriptional profiling of chronic lymphocytic leukemia: is there still more to learn?. <i>Leukemia and Lymphoma</i> , 2009 , 50, 10-1	1.9	
1307	CpG island methylation patterns in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2009 , 50, 419-26	1.9	22
1306	Autoimmune cytopenia in chronic lymphocytic leukemia/small lymphocytic lymphoma: changes in clinical presentation and prognosis. <i>Leukemia and Lymphoma</i> , 2009 , 50, 1261-8	1.9	60
1305	How and why minimal residual disease studies are necessary in leukemia: a review from WP10 and WP12 of the European LeukaemiaNet. 2009 , 94, 1135-50		36
1304	Molecular and cellular mechanisms of CLL: novel therapeutic approaches. 2009 , 6, 405-18		122
1303	Management of chronic lymphocytic leukemia: an update. 2009 , 6, 271-278		

1302	Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital Clinic of Barcelona experience. <i>Blood</i> , 2009 , 114, 2044-50	2.2	120
1301	Novel genomic alterations and clonal evolution in chronic lymphocytic leukemia revealed by representational oligonucleotide microarray analysis (ROMA). <i>Blood</i> , 2009 , 113, 1294-303	2.2	86
1300	Predicting clinical outcome in CLL: how and why. 2009 , 421-9		47
1299	Molecular diagnosis of hematopoietic and lymphoid neoplasms. 2009 , 23, 903-33		8
1298	The leukemias of mature lymphocytes. 2009 , 23, 843-71		7
1297	Activated T-cell-mediated immunotherapy with a chimeric receptor against CD38 in B-cell non-Hodgkin lymphoma. 2009 , 32, 737-43		37
1296	Cryptochrome-1 expression: a new prognostic marker in B-cell chronic lymphocytic leukemia. 2009 , 94, 280-4		15
1295	Evidence for the significant role of immunoglobulin light chains in antigen recognition and selection in chronic lymphocytic leukemia. <i>Blood</i> , 2009 , 113, 403-11	2.2	61
1294	B-cell count and survival: differentiating chronic lymphocytic leukemia from monoclonal B-cell lymphocytosis based on clinical outcome. <i>Blood</i> , 2009 , 113, 4188-96	2.2	91
1293	The immunoglobulin gene repertoire of low-count chronic lymphocytic leukemia (CLL)-like monoclonal B lymphocytosis is different from CLL: diagnostic implications for clinical monitoring. <i>Blood</i> , 2009 , 114, 26-32	2.2	107
1292	Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens. <i>Blood</i> , 2009 , 113, 3168-71	2.2	73
1291	Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. <i>Blood</i> , 2009 , 113, 4637-45	2.2	132
1290	Characterization of structurally defined epitopes recognized by monoclonal antibodies produced by chronic lymphocytic leukemia B cells. <i>Blood</i> , 2009 , 114, 3615-24	2.2	35
1289	In vivo intraclonal and interclonal kinetic heterogeneity in B-cell chronic lymphocytic leukemia. <i>Blood</i> , 2009 , 114, 4832-42	2.2	111
1288	Extensive intraclonal diversification in a subgroup of chronic lymphocytic leukemia patients with stereotyped IGHV4-34 receptors: implications for ongoing interactions with antigen. <i>Blood</i> , 2009 , 114, 4460-8	2.2	58
1287	Karyotype-specific microRNA signature in chronic lymphocytic leukemia. <i>Blood</i> , 2009 , 114, 3872-9	2.2	159
1286	B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. <i>Blood</i> , 2009 , 114, 1029-37 ^{2.2}		196
1285	Chronic Lymphocytic Leukemia. 119-130		

1284	Gene expression profiling reveals differences in microenvironment interaction between patients with chronic lymphocytic leukemia expressing high versus low ZAP70 mRNA. 2009 , 94, 790-9		27
1283	The basis and rational use of molecular genetic testing in mature B-cell lymphomas. 2010 , 17, 333-58		7
1282	Most morphologic features in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) do not reliably predict underlying FISH genetics or immunoglobulin heavy chain variable region somatic mutational status. 2010 , 18, 119-27		4
1281	Gene expression factors as predictors of genetic risk and survival in chronic lymphocytic leukemia. 2010 , 95, 102-9		24
1280	High-density screening reveals a different spectrum of genomic aberrations in chronic lymphocytic leukemia patients with 'stereotyped' IGHV3-21 and IGHV4-34 B-cell receptors. 2010 , 95, 1519-25		40
1279	Distinct gene expression profiles in subsets of chronic lymphocytic leukemia expressing stereotyped IGHV4-34 B-cell receptors. 2010 , 95, 2072-9		29
1278	Genetic lesions in chronic lymphocytic leukemia: what's ready for prime time use?. 2010 , 95, 12-5		13
1277	Natural killer-like T CD3+/CD16+CD56+ cells in chronic lymphocytic leukemia: intracellular cytokine expression and relationship with clinical outcome. 2010 , 24, 803-10		26
1276	The normal IGHV1-69-derived B-cell repertoire contains stereotypic patterns characteristic of unmutated CLL. <i>Blood</i> , 2010 , 115, 71-7	2.2	74
1275	Differential genome-wide array-based methylation profiles in prognostic subsets of chronic lymphocytic leukemia. <i>Blood</i> , 2010 , 115, 296-305	2.2	112
1274	Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia. <i>Blood</i> , 2010 , 115, 4497-506	2.2	152
1273	Phase 1/2 study of lumiliximab combined with fludarabine, cyclophosphamide, and rituximab in patients with relapsed or refractory chronic lymphocytic leukemia. <i>Blood</i> , 2010 , 115, 489-95	2.2	75
1272	Many chronic lymphocytic leukemia antibodies recognize apoptotic cells with exposed nonmuscle myosin heavy chain IIA: implications for patient outcome and cell of origin. <i>Blood</i> , 2010 , 115, 3907-15	2.2	143
1271	Surface IgM of CLL cells displays unusual glycans indicative of engagement of antigen in vivo. <i>Blood</i> , 2010 , 115, 4198-205	2.2	47
1270	High expression of AID and active class switch recombination might account for a more aggressive disease in unmutated CLL patients: link with an activated microenvironment in CLL disease. <i>Blood</i> , 2010 , 115, 4488-96	2.2	69
1269	Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group. <i>Blood</i> , 2010 , 116, 1479-88	2.2	145
1268	The Syk inhibitor fostamatinib disodium (R788) inhibits tumor growth in the EBTCL1 transgenic mouse model of CLL by blocking antigen-dependent B-cell receptor signaling. <i>Blood</i> , 2010 , 116, 4894-905 ²	2.2	113
1267	Genetic modification of primary chronic lymphocytic leukemia cells with a lentivirus expressing CD38. 2010 , 95, 514-7		8

1266	The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis, down-regulates the CXCR4 chemokine receptor and impairs migration of chronic lymphocytic leukemia cells. 2010 , 95, 1136-43		25
1265	Immunoregulatory roles for fc receptor-like molecules. 2011 , 350, 89-104		29
1264	Molecular and clinical features of chronic lymphocytic leukemia with stereotyped B-cell receptors in a Ukrainian cohort. <i>Leukemia and Lymphoma</i> , 2010 , 51, 822-38	1.9	8
1263	Angiopoietin-2 plasma dosage predicts time to first treatment and overall survival in chronic lymphocytic leukemia. <i>Blood</i> , 2010 , 116, 584-92	2.2	46
1262	p53 protein overexpression in bone marrow biopsies from chronic lymphocytic leukaemia is associated with TP53 deletion and resistance to fludarabine. 2010 , 3, 61-68		3
1261	Challenges in the frontline treatment of patients with chronic lymphocytic leukemia. 2010 , 5, 45-51		3
1260	CD38 as a molecular compass guiding topographical decisions of chronic lymphocytic leukemia cells. 2010 , 20, 416-23		26
1259	The role of the B-cell receptor in the pathogenesis of chronic lymphocytic leukaemia. 2010 , 20, 391-9		37
1258	CLL-like monoclonal B-cell lymphocytosis: are we all bound to have it?. 2010 , 20, 384-90		44
1257	Antigens in chronic lymphocytic leukemia--implications for cell origin and leukemogenesis. 2010 , 20, 400-9		59
1256	Where is the biology of CLL leading us?. 2010 , 20, 361-2		4
1255	Using gene co-expression network analysis to predict biomarkers for chronic lymphocytic leukemia. 2010 , 11 Suppl 9, S5		51
1254	Cytogenetic investigations of chronic lymphocytic leukemia. 2010 , 198, 155-61		8
1253	The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. 2010 , 17, 28-40		662
1252	CD154 expression triggered by purine analogues in vitro: Correlation with treatment response and autoimmune events in chronic lymphocytic leukemia. 2010 , 38, 165-73		2
1251	Dipeptidyl peptidase 2 apoptosis assay determines the B-cell activation stage and predicts prognosis in chronic lymphocytic leukemia. 2010 , 38, 1167-77		12
1250	IGHV3-21 gene usage is associated with high TCL1 expression in chronic lymphocytic leukemia. 2010 , 84, 109-16		7
1249	The clinical and biological features of a series of immunophenotypic variant of B-CLL. 2010 , 85, 120-9		11

1248	Toward a comprehensive prognostic scoring system in chronic lymphocytic leukemia based on a combination of genetic parameters. 2010 , 49, 851-9		40
1247	Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia. 2010 , 116, 4777-87		91
1246	Telomeres and telomerase in normal and malignant B-cells. 2010 , 28, 157-67		10
1245	Toll-like receptors on B-CLL cells: expression and functional consequences of their stimulation. 2010 , 126, 1132-43		44
1244	Different biology and clinical outcome according to the absolute numbers of clonal B-cells in monoclonal B-cell lymphocytosis (MBL). 2010 , 78 Suppl 1, S19-23		71
1243	Chronic lymphocytic leukaemia (CLL) and CLL-type monoclonal B-cell lymphocytosis (MBL) show differential expression of molecules involved in lymphoid tissue homing. 2010 , 78 Suppl 1, S42-6		22
1242	Identical IGHV-D-J gene rearrangement may precede the clinical onset of chronic lymphocytic leukemia by several years. <i>American Journal of Hematology</i> , 2010 , 85, 868-71	7.1	4
1241	Lack of association between the MDM2 promoter polymorphism SNP309 and clinical outcome in chronic lymphocytic leukemia. 2010 , 34, 335-9		9
1240	Lipoprotein lipase is differentially expressed in prognostic subsets of chronic lymphocytic leukemia but displays invariably low catalytical activity. 2010 , 34, 301-6		27
1239	Increased trisomy 12 frequency and a biased IgVH 3-21 gene usage characterize small lymphocytic lymphoma. 2010 , 34, 580-4		11
1238	Erufosine, a novel alkylphosphocholine, induces apoptosis in CLL through a caspase-dependent pathway. 2010 , 34, 1064-9		21
1237	The proliferative response to CpG-ODN stimulation predicts PFS, TTT and OS in patients with chronic lymphocytic leukemia. 2010 , 34, 1189-94		23
1236	Percentage of smudge cells determined on routine blood smears is a novel prognostic factor in chronic lymphocytic leukemia. 2010 , 34, 892-8		26
1235	Biologic and clinical significance of molecular profiling in Chronic Lymphocytic Leukemia. 2010 , 24, 135-41		11
1234	Concomitant heterochromatinisation and down-regulation of gene expression unveils epigenetic silencing of RELB in an aggressive subset of chronic lymphocytic leukemia in males. 2010 , 3, 53		10
1233	Dic(17;18)(p11.2;p11.2) is a recurring abnormality in chronic lymphocytic leukaemia associated with aggressive disease. <i>British Journal of Haematology</i> , 2010 , 148, 754-9	4.5	14
1232	NOTCH2 links protein kinase C delta to the expression of CD23 in chronic lymphocytic leukaemia (CLL) cells. <i>British Journal of Haematology</i> , 2010 , 148, 868-78	4.5	21
1231	SYK carries no activating point mutations in patients with chronic lymphocytic leukaemia (CLL). <i>British Journal of Haematology</i> , 2010 , 150, 633-6	4.5	9

1230	Engagement of CD31 delivers an activating signal that contributes to the survival of chronic lymphocytic leukaemia cells. <i>British Journal of Haematology</i> , 2010 , 151, 252-64	4.5	11
1229	Inhibition of GLI, but not Smoothed, induces apoptosis in chronic lymphocytic leukemia cells. 2010 , 29, 4885-95		56
1228	Dichotomy in NF-kappaB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40/TLR9 triggering. 2010 , 29, 5071-82		56
1227	Quercetin induced apoptosis in association with death receptors and fludarabine in cells isolated from chronic lymphocytic leukaemia patients. 2010 , 103, 642-8		38
1226	Recruitment of PKC-beta1 to lipid rafts mediates apoptosis-resistance in chronic lymphocytic leukemia expressing ZAP-70. <i>Leukemia</i> , 2010 , 24, 141-52	10.7	34
1225	Monoclonal B-cell lymphocytosis (MBL): biology, natural history and clinical management. <i>Leukemia</i> , 2010 , 24, 512-20	10.7	166
1224	Serum metabolome analysis by 1H-NMR reveals differences between chronic lymphocytic leukaemia molecular subgroups. <i>Leukemia</i> , 2010 , 24, 788-97	10.7	117
1223	Variant IRF4/MUM1 associates with CD38 status and treatment-free survival in chronic lymphocytic leukaemia. <i>Leukemia</i> , 2010 , 24, 877-81	10.7	17
1222	CD38 increases CXCL12-mediated signals and homing of chronic lymphocytic leukemia cells. <i>Leukemia</i> , 2010 , 24, 958-69	10.7	72
1221	Intraclonal diversification of immunoglobulin light chains in a subset of chronic lymphocytic leukemia alludes to antigen-driven clonal evolution. <i>Leukemia</i> , 2010 , 24, 1317-24	10.7	42
1220	Common variants at 2q37.3, 8q24.21, 15q21.3 and 16q24.1 influence chronic lymphocytic leukemia risk. 2010 , 42, 132-6		196
1219	From pathogenesis to treatment of chronic lymphocytic leukaemia. 2010 , 10, 37-50		438
1218	Management of chronic leukemia in older adults. 230-244		
1217	A molecular score by quantitative PCR as a new prognostic tool at diagnosis for chronic lymphocytic leukemia patients. 2010 , 5, e12780		24
1216	Telomere length, molecular cytogenetic findings, and immunophenotypic features in previously untreated patients with B-chronic lymphocytic leukemia. 2010 , 57, 215-21		2
1215	Molecular pathology of leukemia. 1-25		
1214	The spectrum of use of rituximab in chronic lymphocytic leukemia. 2010 , 3, 227-46		4
1213	CD38/CD31 interactions activate genetic pathways leading to proliferation and migration in chronic lymphocytic leukemia cells. 2010 , 16, 87-91		58

1212	O transplante de células-tronco hematopoiéticas na leucemia linfóide crônica, uma proposta do I Encontro de Diretrizes do Transplante de Medula Óssea da Sociedade Brasileira de Transplante de Medula Óssea, Rio de Janeiro 2009. 2010 , 32, 91-96		
1211	First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab. 2010 , 3, 53-67		14
1210	Allogeneic transplantation for chronic lymphocytic leukemia. 2010 , 2, e2010026		2
1209	Allogeneic hematopoietic cell transplantation in the treatment of chronic lymphocytic leukemia: why and when?. 2010 , 2, e2010018		1
1208	A single tube, four-color flow cytometry assay for evaluation of ZAP-70 and CD38 expression in chronic lymphocytic leukemia. 2010 , 133, 708-17		8
1207	Integrative genomics analyses reveal molecularly distinct subgroups of B-cell chronic lymphocytic leukemia patients with 13q14 deletion. 2010 , 16, 5641-53		46
1206	High serum thymidine kinase 1 level predicts poorer survival in patients with chronic lymphocytic leukemia. 2010 , 134, 472-7		30
1205	Coordinate suppression of B cell lymphoma by PTEN and SHIP phosphatases. 2010 , 207, 2407-20		74
1204	Aggressive chronic lymphocytic leukemia with elevated genomic complexity is associated with multiple gene defects in the response to DNA double-strand breaks. 2010 , 16, 835-47		63
1203	Concomitant conjunctival mucosa-associated lymphoid tissue lymphoma and small lymphocytic lymphoma associated with immunoglobulin M macroglobulinemia successfully treated with intensity modulated radiation therapy. <i>Leukemia and Lymphoma</i> , 2010 , 51, 952-5	1.9	3
1202	Modifying akt signaling in B-cell chronic lymphocytic leukemia cells. 2010 , 70, 7336-44		18
1201	Standard of care and novel treatments for chronic lymphocytic leukemia. 2010 , 67, 1813-24		2
1200	Interaction with vascular endothelium enhances survival in primary chronic lymphocytic leukemia cells via NF-kappaB activation and de novo gene transcription. 2010 , 70, 7523-33		75
1199	Transcriptional and post-transcriptional mechanisms of BAFF-receptor dysregulation in human B lineage malignancies. 2010 , 9, 4884-92		12
1198	Angiopoietin-2 mRNA expression is increased in chronic lymphocytic leukemia patients with poor prognostic features. 2010 , 15, 210-4		5
1197	Expression and prognostic assessment of dipeptidyl peptidase IV and related enzymes in B-cell chronic lymphocytic leukemia. 2010 , 10, 180-9		18
1196	Spontaneous apoptosis and proliferation detected by BCL-2 and CD71 proteins are important progression indicators within ZAP-70 negative chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2010 , 51, 95-106	1.9	13
1195	The utility of a prognostic index for predicting time to first treatment in early chronic lymphocytic leukemia: the GIMEMA experience. 2010 , 95, 464-9		31

1194	Prognostic markers and stratification of chronic lymphocytic leukemia. 2010 , 2010, 77-81	31
1193	CXCL12-induced chemotaxis is impaired in T cells from patients with ZAP-70-negative chronic lymphocytic leukemia. 2010 , 95, 768-75	12
1192	Biological diversity and risk-adapted treatment of chronic lymphocytic leukemia. 2010 , 95, 1441-3	9
1191	Clinical consequences of defects in B-cell development. 2010 , 125, 778-87	50
1190	Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation. 2010 , 95, 1705-12	102
1189	Prognostic impact of ZAP-70 expression in chronic lymphocytic leukemia: mean fluorescence intensity T/B ratio versus percentage of positive cells. 2010 , 8, 23	15
1188	High expression of lymphocyte-activation gene 3 (LAG3) in chronic lymphocytic leukemia cells is associated with unmutated immunoglobulin variable heavy chain region (IGHV) gene and reduced treatment-free survival. 2010 , 12, 328-34	31
1187	Clinical laboratory analysis of immunoglobulin heavy chain variable region genes for chronic lymphocytic leukemia prognosis. 2010 , 12, 244-9	5
1186	Multiplex ligation-dependent probe amplification versus multiprobe fluorescence in situ hybridization to detect genomic aberrations in chronic lymphocytic leukemia: a tertiary center experience. 2010 , 12, 197-203	22
1185	Activities of SYK and PLCgamma2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinib. 2010 , 16, 587-99	47
1184	Molecular Diagnostics and Cytogenetic Testing. 2010 , 61-95	
1183	Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma. 2010 , 251-261	
1182	[Chronic lymphocytic leukemia]. 2010 , 135, 172-8	4
1181	Moving from prognostic to predictive factors in chronic lymphocytic leukaemia (CLL). 2010 , 23, 71-84	51
1180	Diagnostic issues in chronic lymphocytic leukaemia (CLL). 2010 , 23, 3-20	33
1179	Chronic lymphocytic leukaemia: a disease of activated monoclonal B cells. 2010 , 23, 33-45	43
1178	Activation-induced cytidine deaminase splicing patterns in chronic lymphocytic leukemia. 2010 , 44, 262-7	15
1177	TP53 mutation and survival in chronic lymphocytic leukemia. 2010 , 28, 4473-9	430

1176	Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. <i>Blood</i> , 2010 , 116, 2438-47	2.2	240
1175	Immunoglobulin heavy chain V-D-J gene rearrangement and mutational status in Uruguayan patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2010 , 51, 2070-8	1.9	8
1174	Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. 2010 , 376, 1164-74		1471
1173	Rituximab in chronic lymphocytic leukemia. 2010 , 47, 156-69		29
1172	How I treat CLL up front. <i>Blood</i> , 2010 , 115, 187-97	2.2	154
1171	Chronic lymphocytic leukemia in a Japanese population: varied immunophenotypic profile, distinctive usage of frequently mutated IGH gene, and indolent clinical behavior. <i>Leukemia and Lymphoma</i> , 2010 , 51, 2230-9	1.9	17
1170	Prognostic significance of CD8 and CD4 T cells in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2010 , 51, 1829-36	1.9	55
1169	Molecular insight into the biology and clinical course of hairy cell leukemia utilizing immunoglobulin gene analysis. <i>Leukemia and Lymphoma</i> , 2011 , 52, 15-23	1.9	8
1168	Immunoglobulin class switch recombination in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2011 , 52, 1398-400	1.9	3
1167	Allogeneic hematopoietic cell transplant with fludarabine-based reduced-intensity conditioning as treatment for advanced chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2011 , 52, 719-23	1.9	5
1166	Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. 2011 , 29, 2223-9		207
1165	B-cell receptor signaling in chronic lymphocytic leukemia. <i>Blood</i> , 2011 , 118, 4313-20	2.2	281
1164	Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. 2011 , 475, 101-5		1206
1163	Histone deacetylase in chronic lymphocytic leukemia. 2011 , 81, 325-9		71
1162	Information-Geometric Dimensionality Reduction. 2011 , 28, 89-99		15
1161	IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells. <i>Leukemia</i> , 2011 , 25, 828-37	10.7	53
1160	Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. 2011 , 208, 1389-401		483
1159	Hematopathology. 2011 ,		

1158	Enhanced detection of chromosomal abnormalities in chronic lymphocytic leukemia by conventional cytogenetics using CpG oligonucleotide in combination with pokeweed mitogen and phorbol myristate acetate. 2011 , 204, 77-83		37
1157	Clonal diversity analysis using SNP microarray: a new prognostic tool for chronic lymphocytic leukemia. 2011 , 204, 654-65		26
1156	Human B1 cells in umbilical cord and adult peripheral blood express the novel phenotype CD20+ CD27+ CD43+ CD70-. 2011 , 208, 67-80		467
1155	Dynamic conformations of the CD38-mediated NAD cyclization captured in a single crystal. 2011 , 405, 1070-8		20
1154	The Syk kinase as a therapeutic target in leukemia and lymphoma. 2011 , 20, 623-36		38
1153	Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. 2011 , 29, 3559-66		315
1152	Advances in the clinical staging of chronic lymphocytic leukemia. 2011 , 57, 1771-2		7
1151	MFI ratio estimation of ZAP-70 in B-CLL by flow cytometry can be improved by considering the isotype-matched antibody signal. 2011 , 33, 194-200		6
1150	Phase précoce de la leucémie lymphoïde chronique (LLC) et concept de lymphocytose B monoclonale (MBL). 2011 , 2011, 47-53		
1149	Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacy. <i>Blood</i> , 2011 , 118, 2530-40	2.2	175
1148	Missense mutations located in structural p53 DNA-binding motifs are associated with extremely poor survival in chronic lymphocytic leukemia. 2011 , 29, 2703-8		76
1147	Genetics of chronic lymphocytic leukemia. 2011 , 31, 649-58, ix		6
1146	Torque teno virus 10 isolated by genome amplification techniques from a patient with concomitant chronic lymphocytic leukemia and polycythemia vera. 2011 , 17, 1338-48		10
1145	Mutation pattern of paired immunoglobulin heavy and light variable domains in chronic lymphocytic leukemia B cells. 2011 , 17, 1188-95		9
1144	Intraclonal complexity in chronic lymphocytic leukemia: fractions enriched in recently born/divided and older/quiescent cells. 2011 , 17, 1374-82		100
1143	Proliferative index and expression of CD38, Zap-70, and CD25 in different lymphoid compartments of chronic lymphocytic leukemia patients. 2011 , 7		
1142	The chronic lymphoid leukemias. 2011 , 407-418		1
1141	CD38 expression as response of hematopoietic system to cancer. 2011 , 2, 659-664		3

1140	Analysis of CD38 and ZAP70 mRNA expression among cytogenetic subgroups of Iranian chronic-lymphocytic-leukemia patients. 2011 , 10, 2415-23		2
1139	Sequential development of histiocytic sarcoma and diffuse large b-cell lymphoma in a patient with a remote history of follicular lymphoma with genotypic evidence of a clonal relationship: a divergent (bilineal) neoplastic transformation of an indolent B-cell lymphoma in a single individual. 2011 , 35, 457-63		49
1138	Association of reactive oxygen species-mediated signal transduction with in vitro apoptosis sensitivity in chronic lymphocytic leukemia B cells. 2011 , 6, e24592		13
1137	CD38 in chronic lymphocytic leukemia: from bench to bedside?. 2011 , 11, 503-7		10
1136	Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis. <i>Blood</i> , 2011 , 117, 1817-21	2.2	32
1135	Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities. <i>Blood</i> , 2011 , 117, 1781-91	2.2	190
1134	LDOC1 mRNA is differentially expressed in chronic lymphocytic leukemia and predicts overall survival in untreated patients. <i>Blood</i> , 2011 , 117, 4076-84	2.2	28
1133	CCL3 (MIP-1 β) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. <i>Blood</i> , 2011 , 117, 1662-9	2.2	98
1132	Autologous stem cell transplantation as a first-line treatment strategy for chronic lymphocytic leukemia: a multicenter, randomized, controlled trial from the SFGM-TC and GFLLC. <i>Blood</i> , 2011 , 117, 6109-19	2.2	56
1131	A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the disease. <i>Blood</i> , 2011 , 117, 5463-72	2.2	156
1130	Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia. <i>Blood</i> , 2011 , 118, 3051-61	2.2	102
1129	A unique proteomic profile on surface IgM ligation in unmutated chronic lymphocytic leukemia. <i>Blood</i> , 2011 , 118, e1-15	2.2	20
1128	Identification of outcome-correlated cytokine clusters in chronic lymphocytic leukemia. <i>Blood</i> , 2011 , 118, 5201-10	2.2	78
1127	Enhanced levels of both the membrane-bound and soluble forms of IgM Fc receptor (Fc β) in patients with chronic lymphocytic leukemia. <i>Blood</i> , 2011 , 118, 4902-9	2.2	24
1126	CD38 and chronic lymphocytic leukemia: a decade later. <i>Blood</i> , 2011 , 118, 3470-8	2.2	153
1125	Inflammation, the microenvironment and chronic lymphocytic leukemia. 2011 , 96, 353-5		18
1124	LPL is the strongest prognostic factor in a comparative analysis of RNA-based markers in early chronic lymphocytic leukemia. 2011 , 96, 1153-60		39
1123	Non-Hodgkin's lymphomas. 2011 , 9, 484-560		47

1122	Small cell variant of mantle cell lymphoma is an indolent lymphoma characterized by bone marrow involvement, splenomegaly, and a low Ki-67 index. 2011 , 102, 1734-41		16
1121	B-cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: the growing saga of the IGHV3 subgroup gene usage. <i>British Journal of Haematology</i> , 2011 , 153, 3-14	4.5	21
1120	CD180 functions in activation, survival and cycling of B chronic lymphocytic leukaemia cells. <i>British Journal of Haematology</i> , 2011 , 153, 486-98	4.5	16
1119	Evidence for a macromolecular complex in poor prognosis CLL that contains CD38, CD49d, CD44 and MMP-9. <i>British Journal of Haematology</i> , 2011 , 154, 216-22	4.5	60
1118	Immunophenotypic and gene expression analysis of monoclonal B-cell lymphocytosis shows biologic characteristics associated with good prognosis CLL. <i>Leukemia</i> , 2011 , 25, 1459-66	10.7	29
1117	Immunoglobulin sequence analysis and prognostication in CLL: guidelines from the ERIC review board for reliable interpretation of problematic cases. <i>Leukemia</i> , 2011 , 25, 979-84	10.7	59
1116	A novel role of the CX3CR1/CX3CL1 system in the cross-talk between chronic lymphocytic leukemia cells and tumor microenvironment. <i>Leukemia</i> , 2011 , 25, 1268-77	10.7	39
1115	CCR4 expression in a case of cutaneous Richter's transformation of chronic lymphocytic leukemia (CLL) to diffuse large B-cell lymphoma (DLBCL) and in CLL patients with no skin manifestations. 2011 , 87, 80-6		3
1114	Modern and conventional prognostic markers of chronic lymphocytic leukaemia in the everyday haematological practice. 2011 , 87, 130-7		14
1113	Unlocking the secrets of immunoglobulin receptors in mantle cell lymphoma: implications for the origin and selection of the malignant cells. 2011 , 21, 299-307		13
1112	Searching for surrogates for IGHV mutations in chronic lymphocytic leukemia. 2011 , 35, 1432-5		8
1111	MicroRNAs in chronic lymphocytic leukemia. 2011 , 90, 173-8		9
1110	NAD ⁺ -metabolizing ecto-enzymes shape tumor-host interactions: the chronic lymphocytic leukemia model. 2011 , 585, 1514-20		16
1109	Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia. 2011 , 20, 246-59		203
1108	Prognostic factors in chronic lymphocytic leukemia-what do we need to know?. 2011 , 8, 38-47		128
1107	Comparison between oral and intravenous fludarabine plus cyclophosphamide regime as front-line therapy in patients affected by chronic lymphocytic leukaemia: influence of biological parameters on the clinical outcome. 2011 , 90, 59-65		13
1106	Cluster analysis of immunophenotypic data: the example of chronic lymphocytic leukemia. 2011 , 134, 137-44		17
1105	The autocrine motility factor receptor is overexpressed on the surface of B cells in Binet C chronic lymphocytic leukemia. 2011 , 28, 1542-8		2

1104	Telomeres and prognosis in patients with chronic lymphocytic leukaemia. 2011 , 93, 74-82	21
1103	New insights into the pathobiology of chronic lymphocytic leukemia. 2011 , 4, 149-163	0
1102	High prevalence of adverse prognostic genetic aberrations and unmutated IGHV genes in small lymphocytic lymphoma as compared to chronic lymphocytic leukemia. 2011 , 4, 189-197	1
1101	Evaluation of chronic lymphocytic leukemia by oligonucleotide-based microarray analysis uncovers novel aberrations not detected by FISH or cytogenetic analysis. 2011 , 4, 25	14
1100	Evaluation of TP53 mutations with the AmpliChip p53 research test in chronic lymphocytic leukemia: correlation with clinical outcome and gene expression profiling. 2011 , 50, 263-74	22
1099	13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia. 2011 , 50, 633-43	57
1098	Multiplex ligation-dependent probe amplification and fluorescence in situ hybridization to detect chromosomal abnormalities in chronic lymphocytic leukemia: a comparative study. 2011 , 50, 726-34	16
1097	Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemia. 2011 , 117, 2163-9	42
1096	A novel scoring system combining expression of CD23, CD20, and CD38 with platelet count predicts for the presence of the t(11;14) translocation of mantle cell lymphoma. 2011 , 80, 230-7	11
1095	Methodological comparison of two anti-ZAP-70 antibodies. 2011 , 80, 300-8	8
1094	Improved ZAP-70 assay using two clones, multiple methods of analysis and clinical correlation. 2011 , 80, 309-17	8
1093	Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia. 2011 , 29, 91-9	24
1092	Hairy cell leukaemia: biological and clinical overview from immunogenetic insights. 2011 , 29, 55-66	30
1091	Mutation analysis of the TNFAIP3 (A20) tumor suppressor gene in CLL. 2011 , 128, 1747-50	15
1090	High expression of the immature laminin receptor protein correlates with mutated IGVH status and predicts a favorable prognosis in chronic lymphocytic leukemia. 2011 , 35, 721-9	9
1089	CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL. 2011 , 35, 750-6	53
1088	Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2011 , 22 Suppl 6, vi50-4	109
1087	Lenalidomide in the treatment of chronic lymphocytic leukemia. 2011 , 20, 273-86	7

1086	Importance of immunoglobulin heavy chain variable region mutational status in del(13q) chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2011 , 52, 1873-81	1.9	12
1085	Array-based genomic screening at diagnosis and during follow-up in chronic lymphocytic leukemia. 2011 , 96, 1161-9		74
1084	Biologic agent activity in chronic lymphocytic leukemia: a framework for future therapies. <i>Leukemia and Lymphoma</i> , 2011 , 52, 374-86	1.9	1
1083	Prospective study of clinical and biological prognostic factors at diagnosis in patients with early stage B-cell chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2011 , 52, 429-35	1.9	6
1082	Multi-parameter prognostication in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2011 , 52, 1823-4	1.9	
1081	Biological and clinical relevance of quantitative global methylation of repetitive DNA sequences in chronic lymphocytic leukemia. 2011 , 6, 188-94		50
1080	Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia. 2011 , 29, 4088-95		105
1079	Chronic lymphocytic leukemia with t(14;19)(q32;q13) is characterized by atypical morphologic and immunophenotypic features and distinctive genetic features. 2011 , 135, 686-96		30
1078	Molecular Pathology of Chronic Lymphocytic Leukemia. 2011 , 255-291		
1077	Unraveling the molecular pathogenesis of chronic lymphocytic leukemia: dissecting a microRNA regulatory network. 2011 , 305, 95-7		4
1076	Relevance of IgVH gene somatic hypermutation and interphase cytogenetics in lymphomatous presentation of chronic lymphocytic leukemia/small lymphocytic lymphoma. 2011 , 19, 563-9		2
1075	The emerging role of ofatumumab in the treatment of chronic lymphocytic leukemia. 2011 , 5, 45-53		7
1074	A pathobiological role of the insulin receptor in chronic lymphocytic leukemia. 2011 , 17, 2679-92		27
1073	The novel member of the BCL2 gene family, BCL2L12, is substantially elevated in chronic lymphocytic leukemia patients, supporting its value as a significant biomarker. 2011 , 16, 1280-91		34
1072	Management of patients with chronic lymphocytic leukemia with a high risk of adverse outcome: the Mayo Clinic approach. <i>Leukemia and Lymphoma</i> , 2011 , 52, 1425-34	1.9	11
1071	Choosing first-line therapy for chronic lymphocytic leukemia. 2011 , 11, 1379-90		13
1070	Antigens. 2011 , 1-157		0
1069	The diagnostic value of CD1d expression in a large cohort of patients with B-cell chronic lymphoproliferative disorders. 2011 , 136, 400-8		20

1068	Update on therapy of chronic lymphocytic leukemia. 2011 , 29, 544-50		88
1067	Current strategies for the diagnosis and management of chronic lymphocytic leukemia (CLL), with a focus on poor-risk CLL: A review. 2011 , 28, 86-96		
1066	Lymphomas: its gene expression profiling. 2011 , 7, 393-8		2
1065	A review of pharmacologic options for previously untreated chronic lymphocytic leukemia. 2011 , 17, 91-103		3
1064	Immunoglobulin gene repertoire in chronic lymphocytic leukemia: insight into antigen selection and microenvironmental interactions. 2012 , 4, e2012052		14
1063	Recent advances in chronic lymphocytic leukemia. 2012 , 49, 137-43		7
1062	Autologous transplantation in CLL patients with B and C Binet stages: final results of the prospective randomized GOELAMS LLC 98 trial. 2012 , 47, 542-8		31
1061	Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. 2012 , 72, 5307-16		195
1060	Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2012 , 53, 2136-42	1.9	90
1059	Small lymphocytic lymphoma and chronic lymphocytic leukemia: are they the same disease?. 2012 , 18, 396-403		36
1058	Phase II study of cenersen, an antisense inhibitor of p53, in combination with fludarabine, cyclophosphamide and rituximab for high-risk chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2012 , 53, 218-24	1.9	10
1057	Distinct transcriptional control in major immunogenetic subsets of chronic lymphocytic leukemia exhibiting subset-biased global DNA methylation profiles. 2012 , 7, 1435-42		29
1056	Prognostic factors in CLL. 2012 , 1, S29-30		4
1055	The times they are a-changin': prognostic markers in the new era of BCR-targeting therapies for CLL. 2012 , 6, 49-57		3
1054	The CD49d/CD29 complex is physically and functionally associated with CD38 in B-cell chronic lymphocytic leukemia cells. <i>Leukemia</i> , 2012 , 26, 1301-12	10.7	63
1053	Chronic lymphocytic leukemia: treatment of relapse. 2012 , 1, S31-2		1
1052	Stromal endothelial cells establish a bidirectional crosstalk with chronic lymphocytic leukemia cells through the TNF-related factors BAFF, APRIL, and CD40L. 2012 , 188, 6071-83		60
1051	Chronic Lymphocytic Leukemia. 2012 , 85-101		

1050	The role of B cell receptor stimulation in CLL pathogenesis. 2012 , 18, 3335-55		12
1049	Microenvironmental interactions in chronic lymphocytic leukemia: hints for pathogenesis and identification of targets for rational therapy. 2012 , 18, 3323-34		11
1048	Clinical and laboratory prognostic indicators in chronic lymphocytic leukemia. 2012 , 19, 18-25		28
1047	Prognostic markers in chronic lymphocytic leukemia. 2012 , 76-86		
1046	The initial approach to patients with chronic lymphocytic leukemia diagnosed in day-to-day practice. 2012 , 1, 47-55		
1045	Dysfunctional V β V δ T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells. <i>Blood</i> , 2012 , 120, 3271-9	2.2	40
1044	Trisomy 12 and elevated GLI1 and PTCH1 transcript levels are biomarkers for Hedgehog-inhibitor responsiveness in CLL. <i>Blood</i> , 2012 , 119, 997-1007	2.2	34
1043	Mechanisms and clinical significance of BIM phosphorylation in chronic lymphocytic leukemia. <i>Blood</i> , 2012 , 119, 1726-36	2.2	49
1042	Surface IgM stimulation induces MEK1/2-dependent MYC expression in chronic lymphocytic leukemia cells. <i>Blood</i> , 2012 , 119, 170-9	2.2	77
1041	Enhanced outgrowth of EBV-transformed chronic lymphocytic leukemia B cells mediated by coculture with macrophage feeder cells. <i>Blood</i> , 2012 , 119, e35-44	2.2	11
1040	Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. <i>Blood</i> , 2012 , 119, 2854-62	2.2	236
1039	Overexpression of the autoimmunity-associated phosphatase PTPN22 promotes survival of antigen-stimulated CLL cells by selectively activating AKT. <i>Blood</i> , 2012 , 119, 6278-87	2.2	66
1038	T-cell independent, B-cell receptor-mediated induction of telomerase activity differs among IGHV mutation-based subgroups of chronic lymphocytic leukemia patients. <i>Blood</i> , 2012 , 120, 2438-49	2.2	13
1037	Subnetwork-based analysis of chronic lymphocytic leukemia identifies pathways that associate with disease progression. <i>Blood</i> , 2012 , 120, 2639-49	2.2	51
1036	CD69 is independently prognostic in chronic lymphocytic leukemia: a comprehensive clinical and biological profiling study. 2012 , 97, 279-87		21
1035	Molecular pathogenesis of chronic lymphocytic leukemia. 2012 , 122, 3432-8		124
1034	Molecular characterization of chronic lymphocytic leukemia patients with a high number of losses in 13q14. 2012 , 7, e48485		29
1033	Identification of a novel recurrent gain on 20q13 in chronic lymphocytic leukemia by array CGH and gene expression profiling. 2012 , 23, 2138-2146		12

1032	Mimicking the tumour microenvironment: three different co-culture systems induce a similar phenotype but distinct proliferative signals in primary chronic lymphocytic leukaemia cells. <i>British Journal of Haematology</i> , 2012 , 158, 589-99	4.5	36
1031	IGHV-unmutated and IGHV-mutated chronic lymphocytic leukemia cells produce activation-induced deaminase protein with a full range of biologic functions. <i>Blood</i> , 2012 , 120, 4802-11	2.2	42
1030	Predicting survival in chronic lymphocytic leukemia. 2012 , 12, 393-403		15
1029	Studies of Rearrangements and Somatic Hypermutation of IGHV Genes in Chronic Lymphocytic Leukemia. 2012 , 429-442		
1028	[Bone marrow histology from the clinical point of view]. 2012 , 33, 490-5		1
1027	Nowe markery prognostyczne przewlekłej białaczki limfocytowej badane metodą immunofenotypizacji. 2012 , 43, 271-276		
1026	Surface profiles for subclassification of chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2012 , 53, 1046-56	1.9	10
1025	KIBRA gene methylation is associated with unfavorable biological prognostic parameters in chronic lymphocytic leukemia. 2012 , 7, 211-5		27
1024	Association of interleukin-6 and interleukin-8 with poor prognosis in elderly patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2012 , 53, 1735-42	1.9	34
1023	Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies. <i>Blood</i> , 2012 , 119, 4467-75	2.2	289
1022	Cellular origin and pathophysiology of chronic lymphocytic leukemia. 2012 , 209, 2183-98		178
1021	Signaling pathways activated by the B-cell receptor in chronic lymphocytic leukemia. 2012 , 5, 341-8		20
1020	Phenotypic complexity of T regulatory subsets in patients with B-chronic lymphocytic leukemia. 2012 , 25, 246-59		26
1019	Genetics in chronic lymphocytic leukemia. 2012 , 16-24		
1018	The importance of IGHV mutational status in del(11q) and del(17p) chronic lymphocytic leukemia. 2012 , 12, 132-7		15
1017	IGHV3-21 gene frequency in a Swedish cohort of patients with newly diagnosed chronic lymphocytic leukemia. 2012 , 12, 201-6		10
1016	Mutational status and gene repertoire of IGHV-IGHD-IGHJ rearrangements in Serbian patients with chronic lymphocytic leukemia. 2012 , 12, 252-60		10
1015	Changes in the apoptotic gene expression profile in CLL patients treated with rituximab combined with cladribine and cyclophosphamide-preliminary results. 2012 , 36, 1134-40		

1014	CD38 gene polymorphism and risk of chronic lymphocytic leukemia. 2012 , 36, 1237-40		5
1013	Variants of CD38 gene and lipid metabolism: a link in chronic lymphocytic leukemia?. 2012 , 36, 1227-8		1
1012	Molecular Profiling Methods in the Diagnosis of Hematologic Disorders. 2012 , 244-266		
1011	Comprehensive assessment of prognostic factors predicting outcome in Chinese patients with chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide. 2012 , 29, 2102-10		3
1010	Exploiting biological diversity and genomic aberrations in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2012 , 53, 1023-31	1.9	28
1009	Myeloma and Leukemia. 2012 , 509-529		
1008	Bone Marrow Lymphoid Infiltrates. 2012 ,		1
1007	Heat shock protein-90 inhibitor, NVP-AUY922, is effective in combination with fludarabine against chronic lymphocytic leukemia cells cultured on CD40L-stromal layer and inhibits their activated/proliferative phenotype. <i>Leukemia and Lymphoma</i> , 2012 , 53, 2314-20	1.9	13
1006	Molecular Aspects of Hematologic Malignancies. 2012 ,		2
1005	Methylation of tumor suppressor microRNAs: lessons from lymphoid malignancies. 2012 , 12, 755-65		14
1004	Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study. <i>Leukemia and Lymphoma</i> , 2012 , 53, 1743-8	1.9	14
1003	Lymphoproliferative Disorders in Patients with Systemic Lupus Erythematosus. 2012 ,		
1002	Distinct innate immunity pathways to activation and tolerance in subgroups of chronic lymphocytic leukemia with distinct immunoglobulin receptors. 2012 , 18, 1281-91		56
1001	Lipoprotein lipase: a new prognostic factor in chronic lymphocytic leukaemia. 2012 , 16, 474-9		1
1000	The Biological Relevance of ZAP-70 in CLL. 2012 ,		
999	Predicting clinical outcome in B-chronic lymphocytic leukemia. 2012 , 394-8		1
998	Mouse Models of Chronic Lymphocytic Leukemia. 2012 ,		2
997	Upper respiratory tract colonization by gram-negative rods in patients with chronic lymphocytic leukemia: analysis of risk factors. 2012 , 2012, 617218		3

996	Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes. 2012 , 97, 849-53		9
995	Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. 2011 , 44, 47-52		75 ²
994	Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. <i>Blood</i> , 2012 , 119, 521-9	2.2	337
993	Diagnostic techniques and therapeutic challenges in patients with TP53 dysfunctional chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2012 , 53, 2105-15	1.9	4
992	Molecular genetic characterization of lymphoma: application to cytology diagnosis. 2012 , 40, 542-55		20
991	Next generation RNA-sequencing in prognostic subsets of chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2012 , 87, 737-40	7.1	21
990	Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia. 2012 , 30, 2483-91		100
989	Telomere length and telomerase levels delineate subgroups of B-cell chronic lymphocytic leukemia with different biological characteristics and clinical outcomes. 2012 , 97, 56-63		43
988	RNA-based markers as prognostic factors in chronic lymphocytic leukemia. 2012 , 5, 69-79		8
987	Unexpectedly high frequency of European parentage in Venezuelan patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2012 , 53, 235-41	1.9	4
986	Immune thrombocytopenia in patients with chronic lymphocytic leukemia is associated with stereotyped B-cell receptors. 2012 , 18, 1870-8		23
985	Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia with "normal" FISH: correlations with clinicobiologic parameters. <i>Blood</i> , 2012 , 119, 2310-3	2.2	57
984	Pathogenesis of human B cell lymphomas. 2012 , 30, 565-610		307
983	Overexpression of Fc mu receptor (FCMR, TOSO) gene in chronic lymphocytic leukemia patients. 2012 , 29, 1068-72		9
982	IGHV gene rearrangements as outcome predictors for CLL patients: experience of Ukrainian group. 2012 , 29, 1093-101		8
981	Immunological aspects in chronic lymphocytic leukemia (CLL) development. 2012 , 91, 981-96		32
980	Detection methods of ZAP-70 in chronic lymphocytic leukemia. 2012 , 12, 69-77		13
979	Defining the prognosis of early stage chronic lymphocytic leukaemia patients. <i>British Journal of Haematology</i> , 2012 , 156, 499-507	4.5	38

978	A subset of chronic lymphocytic leukemia patients display reduced levels of PARP1 expression coupled with a defective irradiation-induced apoptosis. 2012 , 40, 197-206.e1		14
977	Pathologic and molecular genetic features of chronic lymphocytic leukemia. 2012 , 39, 74-9		11
976	Clinical utility of molecular and flow cytometric markers in chronic lymphocytic leukaemia. 2012 , 42, 137-46		2
975	IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia. 2012 , 10, 18		18
974	Combined normal donor and CLL: Single tube ZAP-70 analysis. 2012 , 82, 67-77		4
973	Improved flow cytometric detection of ZAP-70 in chronic lymphocytic leukemia using experimentally optimized isotypic control antibodies. 2012 , 82, 78-84		9
972	Mantle cell lymphoma displays a homogenous methylation profile: a comparative analysis with chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2012 , 87, 361-7	7.1	11
971	Can prognostic factors be used to direct therapy in chronic lymphocytic leukemia?. 2012 , 7, 3-12		13
970	Novel agents for chronic lymphocytic leukemia. 2013 , 6, 36		25
969	B cell receptor signaling in chronic lymphocytic leukemia. 2013 , 34, 592-601		207
968	Antigen selection in B-cell lymphomas--tracing the evidence. 2013 , 23, 399-409		32
967	Lymphoma. 2013 ,		1
966	Cancer Genomics. 2013 ,		4
965	MBL versus CLL: how important is the distinction?. 2013 , 27, 251-65		9
964	BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies. 2013 , 32, 358-76		35
963	NOTCH1 mutations influence survival in chronic lymphocytic leukemia patients. 2013 , 13, 274		23
962	Chronic Lymphoid Leukaemias and Exfoliating Lymphoma. 2013 , 100-151		
961	Biology of chronic lymphocytic leukemia in different microenvironments: clinical and therapeutic implications. 2013 , 27, 173-206		73

960	CD38 Gene polymorphisms and susceptibility to B cell chronic lymphocytic leukemia. 2013 , 22, 573-579		
959	GS-1101: a delta-specific PI3K inhibitor in chronic lymphocytic leukemia. 2013 , 8, 22-7		35
958	Novel Molecular Acquisitions in Leukemias. 2013 , 453-493		
957	Distinctive patterns of naïve/memory subset distribution and cytokine expression in CD4 T lymphocytes in ZAP-70 B-chronic lymphocytic patients. 2013 ,		10
956	Very low levels of surface CD45 reflect CLL cell fragility, are inversely correlated with trisomy 12 and are associated with increased treatment-free survival. <i>American Journal of Hematology</i> , 2013 , 88, 747-53	7.1	13
955	Molecular bases of chronic lymphocytic leukemia in light of new treatments. 2013 , 155, 51-5		10
954	"Role of the B-cell receptor and the microenvironment in chronic lymphocytic leukemia". 2013 , 3, e149		29
953	Targeting the LYN/HS1 signaling axis in chronic lymphocytic leukemia. <i>Blood</i> , 2013 , 121, 2264-73	2.2	48
952	Insulin-like growth factor-1 receptor (IGF1R) as a novel target in chronic lymphocytic leukemia. <i>Blood</i> , 2013 , 122, 1621-33	2.2	52
951	Molecular biomarkers in chronic lymphocytic leukemia. 2013 , 792, 193-214		10
950	Nouveautés sur les hémopathies lymphoïdes chroniques B matures. 2013 , 28, 174-182		
949	Chronic lymphocytic leukaemia. 2013 , 41, 278-281		
948	Small nucleolar RNAs as new biomarkers in chronic lymphocytic leukemia. 2013 , 6, 27		54
947	Advances in Chronic Lymphocytic Leukemia. 2013 ,		2
946	Towards targeted therapy of chronic lymphocytic leukemia. 2013 , 792, 259-91		10
945	Dielectrophoretic isolation and detection of cfc-DNA nanoparticulate biomarkers and virus from blood. 2013 , 34, 1076-84		54
944	B-cell receptor signaling in chronic lymphocytic leukemia leans on Lyn. <i>Leukemia and Lymphoma</i> , 2013 , 54, 1125-6	1.9	3
943	T/B ratio does not reflect levels of ZAP70 expression in clonal CLL B-cells due to ZAP70 overexpression in patient T-cells. 2013 , 84, 125-32		6

942	6q deletion detected by fluorescence in situ hybridization using bacterial artificial chromosome in chronic lymphocytic leukemia. 2013 , 91, 10-9		7
941	Patients with chronic lymphocytic leukaemia and clonal deletion of both 17p13.1 and 11q22.3 have a very poor prognosis. <i>British Journal of Haematology</i> , 2013 , 163, 326-33	4.5	31
940	Expression of ZAP70 in chronic lymphocytic leukaemia activates NF- κ B signalling. <i>British Journal of Haematology</i> , 2013 , 163, 621-30	4.5	9
939	ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). 2013 , 24, 561-76		162
938	Flow cytometry for non-Hodgkin and classical Hodgkin lymphoma. <i>Methods in Molecular Biology</i> , 2013 , 971, 27-47	1.4	17
937	Chromosome 2p gain in monoclonal B-cell lymphocytosis and in early stage chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2013 , 88, 24-31	7.1	21
936	B-cell receptor configuration and adverse cytogenetics are associated with autoimmune hemolytic anemia in chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2013 , 88, 32-6	7.1	29
935	Lipoprotein lipase in chronic lymphocytic leukaemia - strong biomarker with lack of functional significance. 2013 , 37, 631-6		14
934	Prognostic value of ZAP-70 expression in chronic lymphocytic leukemia as assessed by quantitative polymerase chain reaction and flow cytometry. 2014 , 86, 80-90		4
933	IgD cross-linking induces gene expression profiling changes and enhances apoptosis in chronic lymphocytic leukemia cells. 2013 , 37, 455-62		7
932	Chronic lymphocytic leukemia with t(14;18)(q32;q21). 2013 , 44, 598-605		14
931	The automated monocyte count is independently predictive of overall survival from diagnosis in chronic lymphocytic leukaemia and of survival following first-line chemotherapy. 2013 , 37, 614-8		6
930	Expression of Bcl2L12 in chronic lymphocytic leukemia patients: association with clinical and molecular prognostic markers. 2013 , 30, 405		13
929	Aggressive disease defined by cytogenetics is associated with cytokine dysregulation in CLL/SLL patients. 2013 , 93, 161-70		13
928	Prognostic markers and their clinical applicability in chronic lymphocytic leukemia: where do we stand?. <i>Leukemia and Lymphoma</i> , 2013 , 54, 2351-64	1.9	48
927	Targeting pathological B cell receptor signalling in lymphoid malignancies. 2013 , 12, 229-43		286
926	Overall and cancer-specific survival of patients with breast, colon, kidney, and lung cancers with and without chronic lymphocytic leukemia: a SEER population-based study. 2013 , 31, 930-7		43
925	Histopathology, Morphology and Immunophenotyping of CLL. 2013 , 71-89		

924 Treatment of Chronic Lymphocytic Leukemia and Related Disorders. **2013**, 103-119

923 Pathology of Non-Hodgkin and Hodgkin Lymphomas. **2013**, 867-918

922 Double productive immunoglobulin sequence rearrangements in patients with chronic lymphocytic leukemia. *American Journal of Hematology*, **2013**, 88, 277-82 7.1 11

921 Chronic lymphocytic leukemia: a clinical and molecular heterogenous disease. **2013**, 206, 49-62 51

920 The role of bone marrow biopsy examination at diagnosis of chronic lymphocytic leukemia: a reappraisal. *Leukemia and Lymphoma*, **2013**, 54, 2377-84 1.9 5

919 Chronic lymphocytic leukaemia--the role of the microenvironment pathogenesis and therapy. *British Journal of Haematology*, **2013**, 162, 15-24 4.5 30

918 A protein disulfide isomerase/thioredoxin-1 complex is physically attached to exofacial membrane tumor necrosis factor receptors: overexpression in chronic lymphocytic leukemia cells. **2013**, 18, 363-75 18

917 Immunoglobulin gene rearrangements and mutational status in argentinian patients with chronic lymphocytic leukemia. **2013**, 13, 447-457.e2 13

916 Stereotyped B cell receptors in B cell leukemias and lymphomas. *Methods in Molecular Biology*, **2013**, 971, 135-48 1.4 18

915 Distinct patterns of novel gene mutations in poor-prognostic stereotyped subsets of chronic lymphocytic leukemia: the case of SF3B1 and subset #2. *Leukemia*, **2013**, 27, 2196-9 10.7 78

914 The changing paradigm of chronic lymphocytic leukemia management. **2013**, 24, 401-10 7

913 Aberrant epigenetic gene regulation in lymphoid malignancies. **2013**, 50, 38-47 16

912 Targeting the microenvironment in chronic lymphocytic leukemia offers novel therapeutic options. **2013**, 328, 27-35 14

911 CLLU1 expression has prognostic value in chronic lymphocytic leukemia after first-line therapy in younger patients and in those with mutated IGHV genes. **2013**, 98, 274-8 13

910 Genomic arrays in chronic lymphocytic leukemia routine clinical practice: are we ready to substitute conventional cytogenetics and fluorescence in situ hybridization techniques?. *Leukemia and Lymphoma*, **2013**, 54, 986-95 1.9 16

909 Structural alterations in chronic lymphocytic leukaemia. Cytogenetic and FISH analysis. **2013**, 31, 79-87 18

908 B-cell chronic lymphocytic leukemia/lymphoma. **2013**, 196-214

907 Pathologic diagnosis: molecular genetics. **2013**, 56-81

906	[Chronic lymphocytic leukemia]. 2013 , 138, 2153-66		4
905	Addition of granulocyte macrophage colony stimulating factor does not improve response to early treatment of high-risk chronic lymphocytic leukemia with alemtuzumab and rituximab. <i>Leukemia and Lymphoma</i> , 2013 , 54, 476-82	1.9	10
904	Quantitative detection of zeta-chain-associated protein 70 expression in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2013 , 54, 579-86	1.9	1
903	A mutated B cell chronic lymphocytic leukemia subset that recognizes and responds to fungi. 2013 , 210, 59-70		107
902	Clinico-pathological impact of cytogenetic subgroups in B-cell chronic lymphocytic leukemia: experience from India. 2013 , 50, 261-7		14
901	Genomic stratification for the treatment of lymphomas. 2013 , 2013, 331-4		2
900	Clonal evolution, genomic drivers, and effects of therapy in chronic lymphocytic leukemia. 2013 , 19, 2893-904		52
899	Functional analysis of sucrase-isomaltase mutations from chronic lymphocytic leukemia patients. 2013 , 22, 2273-82		21
898	CIP4 controls CCL19-driven cell steering and chemotaxis in chronic lymphocytic leukemia. 2013 , 73, 3412-24		15
897	Prognostic significance of serum free light chains in chronic lymphocytic leukemia. 2013 , 2013, 359071		5
896	Igs expressed by chronic lymphocytic leukemia B cells show limited binding-site structure variability. 2013 , 190, 5771-8		18
895	Gene expression and epigenetic deregulation. 2013 , 792, 133-50		4
894	Towards an integrated framework for clinico-biological data management and analysis: The case of Chronic Lymphocytic Leukemia. 2013 ,		
893	A method to detect differentially methylated loci with next-generation sequencing. 2013 , 37, 377-82		11
892	Identification in CLL of circulating intraclonal subgroups with varying B-cell receptor expression and function. <i>Blood</i> , 2013 , 122, 2664-72	2.2	53
891	Pathology consultation on evaluating prognosis in incidental monoclonal lymphocytosis and chronic lymphocytic leukemia. 2013 , 139, 708-12		9
890	Autoantigen can promote progression to a more aggressive TCL1 leukemia by selecting variants with enhanced B-cell receptor signaling. 2013 , 110, E1500-7		37
889	Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44. 2013 , 110, 6127-32		63

888	Lymphoma. <i>Methods in Molecular Biology</i> , 2013 ,	1.4	
887	Overexpression of uridine diphospho glucuronosyltransferase 2B17 in high-risk chronic lymphocytic leukemia. <i>Blood</i> , 2013 , 121, 1175-83	2.2	32
886	Autoantigenic targets of B-cell receptors derived from chronic lymphocytic leukemias bind to and induce proliferation of leukemic cells. <i>Blood</i> , 2013 , 121, 4708-17	2.2	33
885	Survival of the weak (signalers): anergy in CLL. <i>Blood</i> , 2013 , 121, 3781-3	2.2	10
884	Purification of NAD glycohydrolase from human serum. 2013 , 6, 227-231		
883	Differential microRNA profiles and their functional implications in different immunogenetic subsets of chronic lymphocytic leukemia. 2013 , 19, 115-23		42
882	Peptides that bind specifically to an antibody from a chronic lymphocytic leukemia clone expressing unmutated immunoglobulin variable region genes. 2013 , 19, 245-52		6
881	Anti-CD38 antibody therapy: windows of opportunity yielded by the functional characteristics of the target molecule. 2013 , 19, 99-108		51
880	Temporal dynamics of clonal evolution in chronic lymphocytic leukemia with stereotyped IGHV4-34/IGKV2-30 antigen receptors: longitudinal immunogenetic evidence. 2013 , 19, 230-6		11
879	B-cell chronic lymphocytic leukemia. 786-792		
878	TLR9 signaling defines distinct prognostic subsets in CLL. 2013 , 18, 371-86		12
877	Multidimensional single-cell analysis of BCR signaling reveals proximal activation defect as a hallmark of chronic lymphocytic leukemia B cells. 2014 , 9, e79987		8
876	Serum thymidine kinase activity: analytical performance, age-related reference ranges and validation in chronic lymphocytic leukemia. 2014 , 9, e91647		8
875	B-cell malignancies: capture-sequencing strategies for identification of gene rearrangements and translocations into immunoglobulin gene loci. 2014 , 107		
874	Prognostic relevance of angiopoietin-2, fibroblast growth factor-2 and endoglin mRNA expressions in chronic lymphocytic leukemia. 2014 , 61, 585-92		1
873	Pathology of indolent B-cell neoplasms other than follicular lymphoma. 2014 , 54, 11-22		9
872	Nucleic Acids as Molecular Diagnostics in Hematopoietic Malignancies ¶ Implications in Diagnosis, Prognosis, and Therapeutic Management. 2014 , 185-200		
871	No evidence of Polyomavirus and EBV infections in Italian patients with mixed cryoglobulinemia infected chronically with HCV. 2014 , 86, 666-71		5

870	CD49d expression identifies a chronic-lymphocytic leukemia subset with high levels of mobilized circulating CD34(+) hemopoietic progenitors cells. <i>Leukemia</i> , 2014 , 28, 705-8	10.7	5
869	Emerging roles for the FCRL family members in lymphocyte biology and disease. 2014 , 382, 29-50		29
868	The emerging role of Twist proteins in hematopoietic cells and hematological malignancies. 2014 , 4, e206		23
867	Genomic imbalance defines three prognostic groups for risk stratification of patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2014 , 55, 920-8	1.9	23
866	Prognostic factors in chronic lymphocytic leukemia: a conceptual approach. 2014 , 3, 145-152		1
865	Low tumor burden is associated with early B-cell reconstitution and is a predictor of favorable outcome after non-myeloablative stem cell transplant for chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2014 , 55, 1274-80	1.9	3
864	Clonotypic analysis of immunoglobulin heavy chain sequences in patients with Waldenström's macroglobulinemia: correlation with MYD88 L265P somatic mutation status, clinical features, and outcome. 2014 , 2014, 809103		8
863	On-target effect of FK866, a nicotinamide phosphoribosyl transferase inhibitor, by apoptosis-mediated death in chronic lymphocytic leukemia cells. 2014 , 20, 4861-72		51
862	The outcome of B-cell receptor signaling in chronic lymphocytic leukemia: proliferation or anergy. 2014 , 99, 1138-48		68
861	Residual cancer lymphocytes in patients with chronic lymphocytic leukemia after therapy show increased expression of surface antigen CD52 detected using quantitative fluorescence cytometry. 2014 , 14, 411-8		1
860	Comparison of CD38, ZAP70 and hTERT Expression with Known Prognostic Markers in Patients with Chronic Lymphocytic Leukemia During Five-Year Follow- up Period. 2014 , 24, 179-184		
859	ATRA-induced cellular differentiation and CD38 expression inhibits acquisition of BCR-ABL mutations for CML acquired resistance. 2014 , 10, e1004414		23
858	Spontaneous in vitro apoptosis of de novo chronic lymphocytic leukemia cells correlates with risk of the disease progression. 2014 , 86, 410-7		7
857	Bortezomib just for induction or also for maintenance in myeloma patients with renal impairment?. 2014 , 99, 5-6		7
856	2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography examination in patients with chronic lymphocytic leukemia may reveal Richter transformation. <i>Leukemia and Lymphoma</i> , 2014 , 55, 314-9	1.9	43
855	The prognostic impact of minimal residual disease in patients with chronic lymphocytic leukemia requiring first-line therapy. 2014 , 99, 873-80		28
854	Recent advances in the pathogenesis and treatment of chronic lymphocytic leukemia. 2014 , 35, 105-20		0
853	Clinical significance of LAIR1 (CD305) as assessed by flow cytometry in a prospective series of patients with chronic lymphocytic leukemia. 2014 , 99, 881-7		25

852	Multiple productive immunoglobulin heavy chain gene rearrangements in chronic lymphocytic leukemia are mostly derived from independent clones. 2014 , 99, 329-38		28
851	Prognostic value of ZAP-70 expression in chronic lymphocytic leukemia as assessed by quantitative polymerase chain reaction and flow cytometry. 2014 , 86, 80-90		3
850	Adult advanced chronic lymphocytic leukemia: computational analysis of whole-body CT documents a bone structure alteration. 2014 , 271, 805-13		14
849	Prospective validation of a risk score based on biological markers for predicting progression free survival in Binet stage A chronic lymphocytic leukemia patients: results of the multicenter O-CLL1-GISL study. <i>American Journal of Hematology</i> , 2014 , 89, 743-50	7.1	13
848	Cell surface phenotype profiles distinguish stable and progressive chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2014 , 55, 2085-92	1.9	25
847	Comprehensive characterization of immunoglobulin gene rearrangements in patients with chronic lymphocytic leukaemia. 2014 , 18, 979-90		3
846	Distinctive patterns of naïve/memory subset distribution and cytokine expression in CD4 T lymphocytes in ZAP-70 B-chronic lymphocytic patients. 2014 , 86, 32-43		10
845	Distinct patterns of global promoter methylation in early stage chronic lymphocytic leukemia. 2014 , 53, 264-73		9
844	Chronic lymphocytic leukaemia: could immunological tolerance mechanisms be the origin of lymphoid neoplasms?. 2014 , 142, 536-50		9
843	Telomere dysfunction accurately predicts clinical outcome in chronic lymphocytic leukaemia, even in patients with early stage disease. <i>British Journal of Haematology</i> , 2014 , 167, 214-23	4.5	67
842	Management of chronic lymphocytic leukemia. 2014 , 99, 965-72		28
841	CD38 mediates the intracellular ATP levels and cell survival of C6 glioma cells. 2014 , 25, 569-73		5
840	CD38 variation as a prognostic factor in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2014 , 55, 191-4	1.9	9
839	Mutation status and immunoglobulin gene rearrangements in patients from northwest and central region of Spain with chronic lymphocytic leukemia. 2014 , 2014, 257517		11
838	Stereotyped subset #1 chronic lymphocytic leukemia: a direct link between B-cell receptor structure, function, and patients' prognosis. <i>American Journal of Hematology</i> , 2014 , 89, 74-82	7.1	18
837	Microenvironmental interactions in chronic lymphocytic leukemia: the master role of CD49d. 2014 , 51, 168-76		27
836	Frequency analysis of HLA class I alleles in Iranian patients with progressive and non-progressive chronic lymphocytic leukemia. 2014 , 75, 170-5		3
835	Prognostic and predictive significance of smudge cell percentage on routine blood smear in chronic lymphocytic leukemia. 2014 , 14, 514-7		15

834	CD1d expression as a prognostic marker for chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2014 , 55, 320-5	1.9	14
833	The role of ATM mutations and 11q deletions in disease progression in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2014 , 55, 1227-39	1.9	48
832	B-cell receptor configuration and mutational analysis of patients with chronic lymphocytic leukaemia and trisomy 12 reveal recurrent molecular abnormalities. 2014 , 32, 22-30		19
831	The pathogenesis of chronic lymphocytic leukemia. 2014 , 9, 103-18		62
830	The pathogenic relevance of the prognostic markers CD38 and CD49d in chronic lymphocytic leukemia. 2014 , 93, 361-74		34
829	Functional impact of NOTCH1 mutations in chronic lymphocytic leukemia. <i>Leukemia</i> , 2014 , 28, 1060-70	10.7	83
828	HLA-G expression as a prognostic indicator in B-cell chronic lymphocytic leukemia. 2014 , 132, 53-8		18
827	Qualifying high-throughput immune repertoire sequencing. 2014 , 288, 31-8		8
826	Cryptic polyreactivity of IgG expressed by splenic marginal zone B-cell lymphoma. 2014 , 60, 54-61		9
825	miR-150 influences B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1. <i>Blood</i> , 2014 , 124, 84-95	2.2	106
824	Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. <i>Blood</i> , 2014 , 124, 49-62	2.2	202
823	Heterogeneous functional effects of concomitant B cell receptor and TLR stimulation in chronic lymphocytic leukemia with mutated versus unmutated Ig genes. 2014 , 192, 4518-24		19
822	TP53 Pro72 allele potentially increases the poor prognostic significance of TP53 mutation in chronic lymphocytic leukemia. 2014 , 31, 908		7
821	GALNT11 as a new molecular marker in chronic lymphocytic leukemia. 2014 , 533, 270-9		17
820	Monoclonal B cell lymphocytosis and "in situ" lymphoma. 2014 , 24, 3-14		32
819	Spontaneous in vitro apoptosis of de novo chronic lymphocytic leukemia cells correlates with risk of the disease progression. 2014 ,		5
818	Molecular pathways: targeting the microenvironment in chronic lymphocytic leukemia--focus on the B-cell receptor. 2014 , 20, 548-56		66
817	Stereotyped B-cell receptors in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2014 , 55, 2252-61		19

816	Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study. 2014 , 1, e74-84		76
815	Antibody modeling using the prediction of immunoglobulin structure (PIGS) web server [corrected]. 2014 , 9, 2771-83		46
814	Proteomics-based strategies to identify proteins relevant to chronic lymphocytic leukemia. 2014 , 13, 5051-62		22
813	Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome. <i>Blood</i> , 2014 , 123, 3790-6	2.2	82
812	Bendamustine in combination with ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA Multicenter Phase II Trial. <i>Leukemia</i> , 2014 , 28, 642-8	10.7	48
811	CD38 expression in CLL: a dynamic marker of prognosis. <i>Leukemia and Lymphoma</i> , 2014 , 55, 1-2	1.9	9
810	Rapid electrokinetic isolation of cancer-related circulating cell-free DNA directly from blood. 2014 , 60, 500-9		46
809	B-cell receptor signaling in lymphoid malignancies and autoimmunity. 2014 , 123, 1-49		28
808	AID induces intraclonal diversity and genomic damage in CD86(+) chronic lymphocytic leukemia cells. 2014 , 44, 3747-57		16
807	Italian external and multicentric validation of the MD Anderson Cancer Center nomogram and prognostic index for chronic lymphocytic leukaemia patients: analysis of 1502 cases. <i>British Journal of Haematology</i> , 2014 , 167, 224-32	4.5	22
806	Five important advances in hematopathology. 2014 , 138, 410-9		2
805	A new hope: novel therapeutic approaches to treatment of chronic lymphocytic leukaemia with defects in TP53. <i>British Journal of Haematology</i> , 2014 , 167, 149-61	4.5	22
804	Immunogenetic studies of chronic lymphocytic leukemia: revelations and speculations about ontogeny and clinical evolution. 2014 , 74, 4211-6		36
803	SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies. 2014 , 20, 4574-83		199
802	Cytokine-driven loss of plasmacytoid dendritic cell function in chronic lymphocytic leukemia. <i>Leukemia</i> , 2014 , 28, 2005-15	10.7	37
801	Prognostic and predictive factors in patients with chronic lymphocytic leukemia: relevant in the era of novel treatment approaches?. 2014 , 32, 869-72		32
800	Serum copper is a simple but valuable prognostic marker in B-cell chronic lymphocytic leukemia. 2014 , 100, 575-81		4
799	Fludarabine plus alemtuzumab (FA) front-line treatment in young patients with chronic lymphocytic leukemia (CLL) and an adverse biologic profile. 2014 , 38, 198-203		4

798	Frontline low-dose alemtuzumab with fludarabine and cyclophosphamide prolongs progression-free survival in high-risk CLL. <i>Blood</i> , 2014 , 123, 3255-62	2.2	31
797	Rekomendacje diagnostyczne i terapeutyczne dla przewlekłej białaczki limfocytowej w 2014 r. □ raport Grupy Roboczej PTHiT oraz PALG [CLL]. 2014 , 45, 221-239		3
796	Microenvironment dependency in Chronic Lymphocytic Leukemia: The basis for new targeted therapies. 2014 , 144, 338-48		43
795	CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia. 2014 , 32, 897-904		118
794	Dielectrophoretic isolation and detection of cancer-related circulating cell-free DNA biomarkers from blood and plasma. 2014 , 35, 1828-36		42
793	Evolving understanding of the CLL genome. 2014 , 51, 177-87		22
792	Relevance of telomere/telomerase system impairment in early stage chronic lymphocytic leukemia. 2014 , 53, 612-21		32
791	The meaning and relevance of B-cell receptor structure and function in chronic lymphocytic leukemia. 2014 , 51, 158-67		30
790	NOTCH1, SF3B1, BIRC3 and TP53 mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment. <i>Leukemia and Lymphoma</i> , 2014 , 55, 2785-92	1.9	40
789	Identification of B-cell lymphoma subsets by plasma protein profiling using recombinant antibody microarrays. 2014 , 38, 682-90		13
788	PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1). 2014 , 13, 1231-45		54
787	Molecular Genetics of Chronic Lymphocytic Leukaemia. 2014 ,		
786	The clinical significance of patients' sex in chronic lymphocytic leukemia. 2014 , 99, 1088-94		37
785	Chronic lymphocytic leukemia in young individuals revisited. 2014 , 99, 4-5		5
784	From a 2DE-gel spot to protein function: lesson learned from HS1 in chronic lymphocytic leukemia. 2014 , e51942		2
783	Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. <i>Blood</i> , 2014 , 123, 3247-54	2.2	352
782	Monoclonal B-cell lymphocytosis in healthy blood donors: an unexpectedly common finding. <i>Blood</i> , 2014 , 123, 1319-26	2.2	51
781	Variable induction of PRDM1 and differentiation in chronic lymphocytic leukemia is associated with anergy. <i>Blood</i> , 2014 , 123, 3277-85	2.2	26

780	Trisomy 12 chronic lymphocytic leukemia cells exhibit upregulation of integrin signaling that is modulated by NOTCH1 mutations. <i>Blood</i> , 2014 , 123, 4101-10	2.2	55
779	Chronic Lymphocytic Leukemia with t(14;18)(q32;q21) As a Sole Cytogenetic Abnormality. 2014 , 7, 21-7		2
778	Efficacy and safety of front-line therapy with fludarabine-cyclophosphamide-rituximab regimen for chronic lymphocytic leukemia outside clinical trials: the Israeli CLL Study Group experience. 2015 , 100, 662-9		14
777	Chronic Lymphocytic Leukemia. 2015 , 130-144		1
776	OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells. <i>Blood</i> , 2015 , 125, 284-95	2.2	15
775	Two types of BCR interactions are positively selected during leukemia development in the E μ CLL1 transgenic mouse model of CLL. <i>Blood</i> , 2015 , 125, 1578-88	2.2	35
774	Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations. <i>Blood</i> , 2015 , 125, 856-9	2.2	55
773	Excessive antigen reactivity may underlie the clinical aggressiveness of chronic lymphocytic leukemia stereotyped subset #8. <i>Blood</i> , 2015 , 125, 3580-7	2.2	40
772	Mutations in CHD2 cause defective association with active chromatin in chronic lymphocytic leukemia. <i>Blood</i> , 2015 , 126, 195-202	2.2	38
771	Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling. <i>Blood</i> , 2015 , 125, 3297-305	2.2	107
770	Prognostic relevance of MYD88 mutations in CLL: the jury is still out. <i>Blood</i> , 2015 , 126, 1043-4	2.2	29
769	Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. 2015 , 13, 326-62		37
768	B-cell receptor usage correlates with the sensitivity to CD40 stimulation and the occurrence of CD4+ T-cell clonality in chronic lymphocytic leukemia. 2015 , 100, e307-10		7
767	Regulatory network reconstruction reveals genes with prognostic value for chronic lymphocytic leukemia. 2015 , 16, 1002		3
766	Gene expression and splicing alterations analyzed by high throughput RNA sequencing of chronic lymphocytic leukemia specimens. 2015 , 15, 714		13
765	Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia: Clinical and biologic correlations. 2015 , 54, 818-26		27
764	Low-dose alemtuzumab in refractory/relapsed chronic lymphocytic leukemia: Genetic profile and long-term outcome from a single center experience. <i>American Journal of Hematology</i> , 2015 , 90, 970-4	7.1	2
763	Role of CD38 Expression in Diagnosis and Pathogenesis of Chronic Lymphocytic Leukemia and Its Potential as Therapeutic Target. 2015 , 35, 417-32		20

762	Biological and clinical characteristics of patients with chronic lymphocytic leukemia with the IGHV3-21 and IGHV1-69; analysis of data from a single center. 2015 , 62, 618-26		2
761	Somatic MED12 mutations are associated with poor prognosis markers in chronic lymphocytic leukemia. 2015 , 6, 1884-8		40
760	The Role of CD44 in the Pathophysiology of Chronic Lymphocytic Leukemia. <i>Frontiers in Immunology</i> , 2015 , 6, 177	8.4	14
759	Current concepts in diagnosis and treatment of chronic lymphocytic leukemia. 2015 , 19, 361-7		7
758	Developing Molecular Signatures for Chronic Lymphocytic Leukemia. 2015 , 10, e0128990		8
757	Clustering of Expression Data in Chronic Lymphocytic Leukemia Reveals New Molecular Subdivisions. 2015 , 10, e0137132		6
756	TACI expression and signaling in chronic lymphocytic leukemia. 2015 , 2015, 478753		6
755	. 2015 ,		2
754	Calcium signaling and cell fate: how can Ca ²⁺ signals contribute to wrong decisions for Chronic Lymphocytic Leukemic B lymphocyte outcome?. 2015 , 59, 379-89		12
753	A CD21 low phenotype, with no evidence of autoantibodies to complement proteins, is consistent with a poor prognosis in CLL. 2015 , 6, 32669-80		3
752	New Insights in Prognosis and Therapy of Chronic Lymphocytic Leukaemia. 2015 ,		
751	Molecular pathogenesis of CLL and its evolution. 2015 , 101, 219-28		16
750	The mystery of chronic lymphocytic leukemia (CLL): Why is it absent in Asians and what does this tell us about etiology, pathogenesis and biology?. 2015 , 29, 205-13		39
749	Surrogate molecular markers for IGHV mutational status in chronic lymphocytic leukemia for predicting time to first treatment. 2015 , 39, 840-5		10
748	Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997. <i>Leukemia and Lymphoma</i> , 2015 , 56, 3031-7	1.9	7
747	Del(20q) in patients with chronic lymphocytic leukemia: a therapy-related abnormality involving lymphoid or myeloid cells. 2015 , 28, 1130-7		6
746	microRNA: Cancer. 2015 ,		1
745	miR-377-dependent BCL-xL regulation drives chemotherapeutic resistance in B-cell lymphoid malignancies. 2015 , 14, 185		32

744	Mutacje TP53 w nowotworach hematologicznych. 2015 , 46, 327-338		
743	microRNA and Chronic Lymphocytic Leukemia. 2015 , 889, 23-40		10
742	Chronic lymphocytic leukemia cells express CD38 in response to Th1 cell-derived IFN- γ by a T-bet-dependent mechanism. 2015 , 194, 827-35		28
741	Clonal evolution in chronic lymphocytic leukemia: impact of subclonality on disease progression. 2015 , 8, 71-8		5
740	SOX11 expression in chronic lymphocytic leukemia correlates with adverse prognostic markers. 2015 , 36, 4433-40		13
739	Increased chronic lymphocytic leukemia proliferation upon IgM stimulation is sustained by the upregulation of miR-132 and miR-212. 2015 , 54, 222-34		22
738	High-throughput sequencing using the Ion Torrent personal genome machine for clinical evaluation of somatic hypermutation status in chronic lymphocytic leukemia. 2015 , 17, 145-54		6
737	High levels of CD160 expression up-regulated counts of chronic lymphocytic leukemia cells and were associated with other clinical parameters in Chinese patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2015 , 56, 529-32	1.9	2
736	Human organic cation transporter 1 (hOCT1) as a mediator of bendamustine uptake and cytotoxicity in chronic lymphocytic leukemia (CLL) cells. 2015 , 15, 363-71		15
735	Molecular basis of chronic lymphocytic leukemia diagnosis and prognosis. 2015 , 38, 93-109		28
734	IgM peak independently predicts treatment-free survival in chronic lymphocytic leukemia and correlates with accumulation of adverse oncogenetic events. <i>Leukemia</i> , 2015 , 29, 337-45	10.7	13
733	Basal Ca(2+) signaling is particularly increased in mutated chronic lymphocytic leukemia. <i>Leukemia</i> , 2015 , 29, 321-8	10.7	13
732	Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase β but not SYK or BTK in chronic lymphocytic leukemia cells. 2015 , 194, 2439-46		22
731	Subjects with chronic lymphocytic leukaemia-like B-cell clones with stereotyped B-cell receptors frequently show MDS-associated phenotypes on myeloid cells. <i>British Journal of Haematology</i> , 2015 , 168, 258-67	4.5	5
730	Molecular evidence for antigen drive in the natural history of mantle cell lymphoma. 2015 , 185, 1740-8		12
729	Integrated CLL Scoring System, a New and Simple Index to Predict Time to Treatment and Overall Survival in Patients With Chronic Lymphocytic Leukemia. 2015 , 15, 612-20.e1-5		19
728	A new piece to the stereotypy "puzzle" in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2015 , 56, 3008-9	1.9	
727	Non-coding recurrent mutations in chronic lymphocytic leukaemia. 2015 , 526, 519-24		565

726	Phenotypic heterogeneity in IGHV-mutated CLL patients has prognostic impact and identifies a subset with increased sensitivity to BTK and PI3K inhibition. <i>Leukemia</i> , 2015 , 29, 744-7	10.7	19
725	CD14HLA-DR expression: A novel prognostic factor in chronic lymphocytic leukemia. 2015 , 9, 1167-1172		26
724	Lymphoma. 2015 , 433-454.e3		
723	Immunoglobulin transcript sequence and somatic hypermutation computation from unselected RNA-seq reads in chronic lymphocytic leukemia. 2015 , 112, 4322-7		31
722	Management of chronic lymphocytic leukemia (CLL) in the era of B-cell receptor signal transduction inhibitors. <i>American Journal of Hematology</i> , 2015 , 90, 657-64	7.1	9
721	[Chronic lymphocytic leukemia : treatment concepts in transition]. 2015 , 56, 374-80		
720	KLKB1 mRNA overexpression: A novel molecular biomarker for the diagnosis of chronic lymphocytic leukemia. 2015 , 48, 849-54		23
719	Expression and role of RIP140/NRIP1 in chronic lymphocytic leukemia. 2015 , 8, 20		15
718	Hypermorphic mutation of phospholipase C, β acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation. <i>Blood</i> , 2015 , 126, 61-8	2.2	106
717	Prognosis and therapy of chronic lymphocytic leukemia and small lymphocytic lymphoma. 2015 , 165, 147-75		10
716	Molecular Pathogenesis of B Cell Lymphomas. 2015 , 399-416		
715	Inhibition of type 4 cyclic nucleotide phosphodiesterase blocks intracellular TLR signaling in chronic lymphocytic leukemia and normal hematopoietic cells. 2015 , 194, 101-12		11
714	LEF1: a highly specific marker for the diagnosis of chronic lymphocytic B cell leukaemia/small lymphocytic B cell lymphoma. 2015 , 68, 473-8		32
713	The complex interplay between cell-intrinsic and cell-extrinsic factors driving the evolution of chronic lymphocytic leukemia. 2015 , 34, 22-35		30
712	IGHV gene usage and mutational status in follicular lymphoma: Correlations with prognosis and patient age. 2015 , 39, 702-8		6
711	The biology behind PI3K inhibition in chronic lymphocytic leukaemia. 2015 , 6, 25-36		7
710	Association between gene and miRNA expression profiles and stereotyped subset #4 B-cell receptor in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2015 , 56, 3150-8	1.9	17
709	Total proteome analysis identifies migration defects as a major pathogenetic factor in immunoglobulin heavy chain variable region (IGHV)-unmutated chronic lymphocytic leukemia. 2015 , 14, 933-45		25

708	Prognostic signature and clonality pattern of recurrently mutated genes in inactive chronic lymphocytic leukemia. 2015 , 5, e342		8
707	ARResT/AssignSubsets: a novel application for robust subclassification of chronic lymphocytic leukemia based on B cell receptor IG stereotypy. 2015 , 31, 3844-6		23
706	Characterization of a new human plasma cell leukemia cell line UHKT-944. 2015 , 95, 352-60		
705	Epstein-Barr Virus MicroRNAs are Expressed in Patients with Chronic Lymphocytic Leukemia and Correlate with Overall Survival. 2015 , 2, 572-82		34
704	Enhanced Chemokine Receptor Recycling and Impaired S1P1 Expression Promote Leukemic Cell Infiltration of Lymph Nodes in Chronic Lymphocytic Leukemia. 2015 , 75, 4153-63		32
703	Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2015 , 26 Suppl 5, v78-84		269
702	PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL). 2016 , 393, 123-142		38
701	Applied Protein and Molecular Techniques for Characterization of B Cell Neoplasms in Horses. 2015 , 22, 1133-45		9
700	CD38 in Hairy Cell Leukemia Is a Marker of Poor Prognosis and a New Target for Therapy. 2015 , 75, 3902-11		24
699	TLR-9 and IL-15 Synergy Promotes the In Vitro Clonal Expansion of Chronic Lymphocytic Leukemia B Cells. 2015 , 195, 901-23		25
698	Emerging therapies for refractory chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2015 , 56, 285-92	1.9	2
697	The genomic landscape of chronic lymphocytic leukaemia: biological and clinical implications. <i>British Journal of Haematology</i> , 2015 , 169, 14-31	4.5	22
696	Clinical relevance of vascular endothelial growth factor type A (VEGFA) and VEGF receptor type 2 (VEGFR2) gene polymorphism in chronic lymphocytic leukemia. 2015 , 54, 139-43		7
695	Novel agents in the treatment of chronic lymphocytic leukemia: a review about the future. 2015 , 15, 314-22		12
694	Immunoglobulin heavy variable (IGHV) genes and alleles: new entities, new names and implications for research and prognostication in chronic lymphocytic leukaemia. 2015 , 67, 61-6		19
693	Loss of cooperativity of secreted CD40L and increased dose-response to IL4 on CLL cell viability correlates with enhanced activation of NF-kB and STAT6. 2015 , 136, 65-73		11
692	Paradigm shifts in the management of poor-risk chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2015 , 56, 1626-35	1.9	
691	A B-cell epigenetic signature defines three biologic subgroups of chronic lymphocytic leukemia with clinical impact. <i>Leukemia</i> , 2015 , 29, 598-605	10.7	92

690	Chronic Lymphocytic Leukemia, the Prototypic Chronic Leukemia for Flow Cytometric Analysis. 2016 , 226-234		
689	. 2016 ,		2
688	11. Chronic lymphocytic leukemia. 2016 , 205-228		
687	Identifying High-Risk Chronic Lymphocytic Leukemia: A Pathogenesis-Oriented Appraisal of Prognostic and Predictive Factors in Patients Treated with Chemotherapy with or without Immunotherapy. 2016 , 8, e2016047		5
686	Low expression of CD200 predicts shorter time-to-treatment in chronic lymphocytic leukemia. 2016 , 7, 13551-62		18
685	Activated Allogeneic NK Cells Preferentially Kill Poor Prognosis B-Cell Chronic Lymphocytic Leukemia Cells. <i>Frontiers in Immunology</i> , 2016 , 7, 454	8.4	18
684	To treat or not to treat: metabolomics reveals biomarkers for treatment indication in chronic lymphocytic leukaemia patients. 2016 , 7, 22324-38		14
683	Targeting B-cell receptor signaling in leukemia and lymphoma: how and why?. 2016 , 5, 37-53		4
682	Chronic lymphocytic leukaemia. 2016 , 104, 169-82		85
681	Double IGHV DNA gene rearrangements in CLL: influence of mixed-mutated and -unmutated rearrangements on outcomes in CLL. 2016 , 6, e440		3
680	The prognostic significance of surface dipeptidylpeptidase IV (CD26) expression in B-cell chronic lymphocytic leukemia. 2016 , 47, 166-71		9
679	Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations. 2016 , 9, 88		26
678	SLP76 integrates into the B-cell receptor signaling cascade in chronic lymphocytic leukemia cells and is associated with an aggressive disease course. 2016 , 101, 1553-1562		10
677	High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia. <i>Blood</i> , 2016 , 128, 2931-2940	2.2	75
676	Prognostication of chronic lymphocytic leukemia in the era of new agents. 2016 , 2016, 149-155		24
675	[Flow-cytometric immunophenotyping in clinical diagnostics]. 2016 , 141, 1569-1574		
674	Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors. 2016 , 101, 959-67		41
673	Mimicking the tumour microenvironment of chronic lymphocytic leukaemia in vitro critically depends on the type of B-cell receptor stimulation. 2016 , 114, 704-12		3

672	Longitudinal copy number, whole exome and targeted deep sequencing of 'good risk' IGHV-mutated CLL patients with progressive disease. <i>Leukemia</i> , 2016 , 30, 1301-10	10.7	32
671	Preclinical modeling of novel therapeutics in chronic lymphocytic leukemia: the tools of the trade. 2016 , 43, 222-32		20
670	What does it mean I have a monoclonal B-cell lymphocytosis?: Recent insights and new challenges. 2016 , 43, 201-8		13
669	B Cell Energy Modulated by TLR1/2 and the miR-17~92 Cluster Underlies the Indolent Clinical Course of Chronic Lymphocytic Leukemia Stereotyped Subset #4. 2016 , 196, 4410-7		20
668	Epigenetic silencing of miR-26A1 in chronic lymphocytic leukemia and mantle cell lymphoma: Impact on EZH2 expression. 2016 , 11, 335-43		17
667	Chronic lymphocytic leukemia and proteomics: protein profiles and links with disease progression still need validation. <i>Leukemia and Lymphoma</i> , 2016 , 57, 985-6	1.9	
666	Loss of a chromosomal region with synteny to human 13q14 occurs in mouse chronic lymphocytic leukemia that originates from early-generated B-1 B cells. <i>Leukemia</i> , 2016 , 30, 1510-9	10.7	16
665	El estado mutacional de las inmunoglobulinas en pacientes con leucemia linfocítica crónica: significado y pronóstico. 2016 , 15, 86-92		
664	CD49d prevails over the novel recurrent mutations as independent prognosticator of overall survival in chronic lymphocytic leukemia. <i>Leukemia</i> , 2016 , 30, 2011-2018	10.7	33
663	Combination of bendamustine and rituximab as front-line therapy for patients with chronic lymphocytic leukaemia: multicenter, retrospective clinical practice experience with 279 cases outside of controlled clinical trials. 2016 , 60, 154-65		16
662	An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. 2016 , 17, 779-790		379
661	Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. <i>Blood</i> , 2016 , 127, 208-15	2.2	442
660	Should IGHV status and FISH testing be performed in all CLL patients at diagnosis? A systematic review and meta-analysis. <i>Blood</i> , 2016 , 127, 1752-60	2.2	53
659	Surface IgM expression and function are associated with clinical behavior, genetic abnormalities, and DNA methylation in CLL. <i>Blood</i> , 2016 , 128, 816-26	2.2	39
658	The genetics of mature B-cell malignancies. 2016 , 265-311		
657	Chronic lymphocytic leukemia immunoglobulins display bacterial reactivity that converges and diverges from auto-/poly-reactivity and IGHV mutation status. 2016 , 172, 44-51		8
656	Hypomethylation coordinates antagonistically with hypermethylation in cancer development: a case study of leukemia. 2016 , 10 Suppl 2, 18		25
655	lncRNA profiling in early-stage chronic lymphocytic leukemia identifies transcriptional fingerprints with relevance in clinical outcome. 2016 , 6, e468		33

654	Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. 2016 , 22, 2117-2125		70
653	Hematopoietic Cell Transplantation for Chronic Lymphocytic Leukemia. 2016 , 714-726		
652	Lipoprotein lipase in chronic lymphocytic leukemia: function and prognostic implications. 2016 , 97, 409-415		6
651	Molecular Pathology: Predictive, Prognostic, and Diagnostic Markers in Lymphoid Neoplasms. 2016 , 9, 489-521		3
650	The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: Independent validation in a prospective cohort of early stage patients. <i>American Journal of Hematology</i> , 2016 , 91, 1090-1095	7.1	43
649	Prognostic indices in chronic lymphocytic leukaemia: where do we stand how do we proceed?. 2016 , 279, 347-57		34
648	CD49d (ITGA4) expression is a predictor of time to first treatment in patients with chronic lymphocytic leukaemia and mutated IGHV status. <i>British Journal of Haematology</i> , 2016 , 172, 48-55	4.5	16
647	Prospective validation of predictive value of abdominal computed tomography scan on time to first treatment in Rai 0 chronic lymphocytic leukemia patients: results of the multicenter O-CLL1-GISL study. 2016 , 96, 36-45		6
646	Monoclonal antibodies targeting CD38 in hematological malignancies and beyond. 2016 , 270, 95-112		197
645	Metaphase Cytogenetics in Chronic Lymphocytic Leukemia. 2016 , 4, 65-73		
644	Biomarkers in chronic lymphocytic leukemia: Clinical applications and prognostic markers. 2016 , 29, 79-89		22
643	Molecular Biomarkers in Hematopoietic Neoplasms. 2016 , 187-223		
642	Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia. 2016 , 197, 2522-31		23
641	Molecular Cytopathology. 2016 ,		1
640	Genetic evolution in chronic lymphocytic leukaemia. 2016 , 29, 67-78		1
639	Present and future of personalized medicine in CLL. 2016 , 29, 100-110		8
638	Key Molecular Drivers of Chronic Lymphocytic Leukemia. 2016 , 16, 593-606		14
637	Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia. 2016 , 101, 77-85		37

636	Rewired NFB signaling as a potentially actionable feature of activated B-cell-like diffuse large B-cell lymphoma. 2016 , 97, 499-510		14
635	t(14;18)(q32;q21) in chronic lymphocytic leukemia patients: Report of two cases and a literature review. 2016 , 12, 4351-4356		6
634	PI3K signaling pathway in normal B cells and indolent B-cell malignancies. 2016 , 43, 647-654		24
633	Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia. 2016 , 38, 346-357		17
632	IL-4 enhances expression and function of surface IgM in CLL cells. <i>Blood</i> , 2016 , 127, 3015-25	2.2	55
631	Integration of innate into adaptive immune responses in ZAP-70-positive chronic lymphocytic leukemia. <i>Blood</i> , 2016 , 127, 436-48	2.2	20
630	IL-4 rescues surface IgM expression in chronic lymphocytic leukemia. <i>Blood</i> , 2016 , 128, 553-62	2.2	25
629	Toll-like receptors signaling: A complex network for NF- κ B activation in B-cell lymphoid malignancies. 2016 , 39, 15-25		48
628	Chromatin accessibility maps of chronic lymphocytic leukaemia identify subtype-specific epigenome signatures and transcription regulatory networks. 2016 , 7, 11938		95
627	Real-world clinical experience in the Connect chronic lymphocytic leukaemia registry: a prospective cohort study of 1494 patients across 199 US centres. <i>British Journal of Haematology</i> , 2016 , 175, 892-903 ^{4,5}		37
626	The mutational signature of chronic lymphocytic leukemia. 2016 , 473, 3725-3740		3
625	Global DNA methylation profiling reveals new insights into epigenetically deregulated protein coding and long noncoding RNAs in CLL. 2016 , 8, 106		34
624	UGT2B17 expression: a novel prognostic marker within IGHV-mutated chronic lymphocytic leukemia?. 2016 , 101, e63-5		10
623	Integrating multiple immunogenetic data sources for feature extraction and mining somatic hypermutation patterns: the case of "towards analysis" in chronic lymphocytic leukaemia. 2016 , 17 Suppl 5, 173		1
622	Determination of HLA-G Expression and Evaluation of Its Role as a Prognostic Factor in Chronic Lymphocytic Leukemia. 2016 , 30, 399-403		4
621	Template for Reporting Results of Biomarker Testing of Specimens From Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. 2016 , 140, 1228-1230		3
620	Neue Therapiekonzepte bei der chronisch-lymphatischen Leukämie. 2016 , 22, 283-294		3
619	A ribosome-related signature in peripheral blood CLL B cells is linked to reduced survival following treatment. 2016 , 7, e2249		20

618	SF3B1 and IGHV gene mutation status predict poor prognosis in Japanese CLL patients. 2016 , 103, 219-26		4
617	Transformation in Low-grade B-cell Neoplasms. 2016 , 9, 79-92		12
616	Characteristics of chronic lymphocytic leukemia in Senegal. 2016 , 16, 10		9
615	Trends in survival of chronic lymphocytic leukemia patients in Germany and the USA in the first decade of the twenty-first century. 2016 , 9, 28		32
614	The outcome of Chronic lymphocytic leukaemia patients with 97% IGHV gene identity to germline is distinct from cases with . <i>British Journal of Haematology</i> , 2016 , 173, 127-36	4.5	12
613	CD38 is a putative functional marker for side population cells in human nasopharyngeal carcinoma cell lines. 2016 , 55, 300-11		6
612	Clonality Analysis of Immunoglobulin Gene Rearrangement by Next-Generation Sequencing in Endemic Burkitt Lymphoma Suggests Antigen Drive Activation of BCR as Opposed to Sporadic Burkitt Lymphoma. 2016 , 145, 116-27		26
611	Pitting new treatments for chronic lymphocytic leukemia against old ones: how do they fare?. 2016 , 9, 245-54		1
610	A progression-risk score to predict treatment-free survival for early stage chronic lymphocytic leukemia patients. <i>Leukemia</i> , 2016 , 30, 1440-3	10.7	21
609	Analysis of clinical prognostic variables for Chronic Lymphocytic Leukemia decision-making problems. 2016 , 60, 342-51		12
608	Differential methylation tests of regulatory regions. 2016 , 15, 237-51		3
607	Chronic lymphocytic leukemia (CLL)-Then and now. <i>American Journal of Hematology</i> , 2016 , 91, 330-40	7.1	83
606	Humanized mouse G6 anti-idiotypic monoclonal antibody has therapeutic potential against IGHV1-69 germline gene-based B-CLL. 2016 , 8, 787-98		6
605	Prognostic factors and risk stratification in chronic lymphocytic leukemia. 2016 , 43, 233-40		48
604	The molecular pathogenesis of chronic lymphocytic leukaemia. 2016 , 16, 145-62		170
603	Evolving Strategies for the Treatment of Chronic Lymphocytic Leukemia in the Upfront Setting. 2016 , 11, 61-70		5
602	Combined CXCR3/CXCR4 measurements are of high prognostic value in chronic lymphocytic leukemia due to negative co-operativity of the receptors. 2016 , 101, e99-102		21
601	Immunoglobulin heavy chain variable region gene repertoire and B-cell receptor stereotypes in Indian patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2016 , 57, 2389-400	1.9	4

600	Catalog of genetic progression of human cancers: non-Hodgkin lymphoma. 2016 , 35, 109-27		7
599	Prognostic Factors for Chronic Lymphocytic Leukemia. 2016 , 11, 37-42		17
598	B Cell Receptor Signaling. 2016 ,		
597	Chronic Lymphocytic Leukemia and Other Lymphoproliferative Disorders. 2016 , 32, 175-89		6
596	mRNA overexpression of kallikrein-related peptidase 14 (KLK14) is an independent predictor of poor overall survival in chronic lymphocytic leukemia patients. 2016 , 54, 315-24		11
595	CTLA-4 affects expression of key cell cycle regulators of G0/G1 phase in neoplastic lymphocytes from patients with chronic lymphocytic leukaemia. 2016 , 16, 317-32		8
594	Indole-3-Carbinol Synergizes with and Restores Fludarabine Sensitivity in Chronic Lymphocytic Leukemia Cells Irrespective of p53 Activity and Treatment Resistances. 2016 , 22, 134-45		4
593	Antigen Selection Shapes the T-cell Repertoire in Chronic Lymphocytic Leukemia. 2016 , 22, 167-74		28
592	Autocrine Signaling by Wnt-5a Deregulates Chemotaxis of Leukemic Cells and Predicts Clinical Outcome in Chronic Lymphocytic Leukemia. 2016 , 22, 459-69		37
591	Protein profiles distinguish stable and progressive chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2016 , 57, 1033-43	1.9	6
590	New strategies to maximize therapeutic opportunities for NAMPT inhibitors in oncology. 2016 , 3, e1052180		31
589	Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment. 2016 , 1863, 401-413		125
588	The BAFF receptor TACI controls IL-10 production by regulatory B cells and CLL B cells. <i>Leukemia</i> , 2016 , 30, 163-72	10.7	56
587	COBLL1, LPL and ZAP70 expression defines prognostic subgroups of chronic lymphocytic leukemia patients with high accuracy and correlates with IGHV mutational status. <i>Leukemia and Lymphoma</i> , 2017 , 58, 70-79	1.9	9
586	Coevolution of Leukemia and Host Immune Cells in Chronic Lymphocytic Leukemia. 2017 , 7,		16
585	Chronic lymphocytic leukaemia. 2017 , 3, 16096		219
584	Characterization of treatment and outcomes in a population-based cohort of patients with chronic lymphocytic leukemia referred for cytogenetic testing in British Columbia, Canada. 2017 , 55, 79-90		6
583	Leukemia-cell proliferation and disease progression in patients with early stage chronic lymphocytic leukemia. <i>Leukemia</i> , 2017 , 31, 1348-1354	10.7	18

582	Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI. <i>American Journal of Hematology</i> , 2017 , 92, 375-380	7.1	60
581	Mechanisms of Resistance to Targeted Therapies in Chronic Lymphocytic Leukemia. 2018 , 249, 203-229		5
580	Current Treatment of Chronic Lymphocytic Leukemia. 2017 , 18, 5		14
579	Early stages in the ontogeny of small B-cell lymphomas: genetics and microenvironment. 2017 , 282, 395-414		8
578	Hematopoietic Cell Transplantation. 2017 , 1-13		1
577	Milestones in Chronic Lymphocytic Leukemia: An exciting decade of progress-10th anniversary of. 2017 , 10, 8-12		
576	Cortactin, a Lyn substrate, is a checkpoint molecule at the intersection of BCR and CXCR4 signalling pathway in chronic lymphocytic leukaemia cells. <i>British Journal of Haematology</i> , 2017 , 178, 81-93	4.5	16
575	Quantitative miR analysis in chronic lymphocytic leukaemia/small lymphocytic lymphoma - proliferation centres are characterized by high miR-92a and miR-155 and low miR-150 expression. 2017 , 58, 39-42		9
574	High-Throughput Immunogenetics for Clinical and Research Applications in Immunohematology: Potential and Challenges. 2017 , 198, 3765-3774		46
573	Rituximab and Alemtuzumab for Chronic Lymphocytic Leukemia: Clinical Pharmacology and Therapeutic Results. 2017 , 99-122		
572	Numerous Ontogenetic Roads to Mantle Cell Lymphoma: Immunogenetic and Immunohistochemical Evidence. 2017 , 187, 1454-1458		9
571	Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: updated ERIC recommendations. <i>Leukemia</i> , 2017 , 31, 1477-1481	10.7	75
570	mRNA overexpression of the hypoxia inducible factor 1 alpha subunit gene (HIF1A): An independent predictor of poor overall survival in chronic lymphocytic leukemia. 2017 , 53, 65-73		20
569	MicroRNA: Defining a new niche in Leukemia. 2017 , 31, 129-138		12
568	Genetic landscape and deregulated pathways in B-cell lymphoid malignancies. 2017 , 282, 371-394		41
567	IGHV mutational status testing in chronic lymphocytic leukemia. <i>American Journal of Hematology</i> , 2017 , 92, 1393-1397	7.1	15
566	Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes. 2017 , 23, 5292-5301		20
565	Evaluation of Interleukin-9 Expression as a Potential Therapeutic Target in Chronic Lymphocytic Leukemia in a Cohort of Egyptian Patients. 2017 , 33, 477-482		4

564	Immunoglobulin genes in chronic lymphocytic leukemia: key to understanding the disease and improving risk stratification. 2017 , 102, 968-971	17
563	Lymphoid Leukaemias of Mature B, T and Natural Killer Cells. 2017 , 417-524	1
562	FcR1b expression in early stage chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2017 , 58, 2642-2648	5
561	Chronic lymphocytic leukemia and small lymphocytic lymphoma: two faces of the same disease. 2017 , 10, 137-146	10
560	Flow cytometry minimal residual disease after allogeneic transplant for chronic lymphocytic leukemia. 2017 , 98, 363-370	8
559	Functional Activation of Osteoclast Commitment in Chronic Lymphocytic Leukaemia: a Possible Role for RANK/RANKL Pathway. 2017 , 7, 14159	11
558	Chronic Lymphocytic Leukemia Patient Clustering Based on Somatic Hypermutation (SHM) Analysis. 2017 , 988, 127-138	3
557	NFAT2 is a critical regulator of the anergic phenotype in chronic lymphocytic leukaemia. 2017 , 8, 755	24
556	Microenvironment regulates the expression of miR-21 and tumor suppressor genes PTEN, PIAS3 and PDCD4 through ZAP-70 in chronic lymphocytic leukemia. 2017 , 7, 12262	16
555	B-cell Receptor Signaling Regulates Metabolism in Chronic Lymphocytic Leukemia. 2017 , 15, 1692-1703	23
554	Flow Cytometry of B-Cell Neoplasms. 2017 , 37, 697-723	8
553	Prognostic and Predictive Markers in CLL. 2017 , 17, S197-S200	1
552	Molecular Diagnostics. 2017 ,	4
551	Targeting B Cell Signaling in Chronic Lymphocytic Leukemia. 2017 , 19, 61	13
550	Calreticulin as a novel B-cell receptor antigen in chronic lymphocytic leukemia. 2017 , 102, e394-e396	8
549	Anti-leukemic activity of microRNA-26a in a chronic lymphocytic leukemia mouse model. 2017 , 36, 6617-6626	16
548	Cell Surface Proteomics of N-Linked Glycoproteins for Typing of Human Lymphocytes. 2017 , 17, 1700156	8
547	Structural Determination of the Broadly Reactive Anti-IGHV1-69 Anti-idiotypic Antibody G6 and Its Idiotope. 2017 , 21, 3243-3255	9

546	Genome-wide DNA methylation profiling integrated with gene expression profiling identifies as a novel prognostic marker in chronic lymphocytic leukemia. 2017 , 9, 57		18
545	Targeted deep sequencing reveals clinically relevant subclonal IgHV rearrangements in chronic lymphocytic leukemia. <i>Leukemia</i> , 2017 , 31, 837-845	10.7	33
544	Health-related quality of life and patient-reported outcomes of ofatumumab plus fludarabine and cyclophosphamide versus fludarabine and cyclophosphamide in the COMPLEMENT 2 trial of patients with relapsed CLL. <i>Leukemia and Lymphoma</i> , 2017 , 58, 1598-1606	1.9	11
543	Molecular Biology of Leukemias. 2017 , 505-559		
542	Lipoprotein Lipase as a Prognostic Marker in Chronic Lymphocytic Leukemia. 2017 , 23, 165-171		5
541	Antigen receptor stereotypy in chronic lymphocytic leukemia. <i>Leukemia</i> , 2017 , 31, 282-291	10.7	74
540	Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation. 2017 , 23, 735-745		62
539	Dynamic variation of CD5 surface expression levels within individual chronic lymphocytic leukemia clones. 2017 , 46, 31-37.e10		6
538	Major prognostic value of complex karyotype in addition to TP53 and IGHV mutational status in first-line chronic lymphocytic leukemia. 2017 , 35, 664-670		24
537	Expression of circulating miRNAs associated with lymphocyte differentiation and activation in CLL-another piece in the puzzle. 2017 , 96, 33-50		20
536	EGR2 mutations define a new clinically aggressive subgroup of chronic lymphocytic leukemia. <i>Leukemia</i> , 2017 , 31, 1547-1554	10.7	34
535	The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia-Microenvironment Interactions in Chronic Lymphocytic Leukemia. 2017 , 23, 1493-1505		28
534	Identification of key miRNA-gene pairs in chronic lymphocytic leukemia through integrated analysis of mRNA and miRNA microarray. 2018 , 15, 361-367		9
533	Preferential Usage of Specific Immunoglobulin Heavy Chain Variable Region Genes With Unmutated Profile and Advanced Stage at Presentation Are Common Features in Patients With Chronic Lymphocytic Leukemia From Senegal. 2017 , 148, 545-554		4
532	Somatic Hypermutational Status and Gene Repertoire of Immunoglobulin Rearrangements in Chronic Lymphocytic Leukemia. 2017 ,		1
531	The mutational landscape of chronic lymphocytic leukemia and its impact on prognosis and treatment. 2017 , 2017, 329-337		39
530	Lipoprotein Lipase Expression in Chronic Lymphocytic Leukemia: New Insights into Leukemic Progression. 2017 , 22,		8
529	Telomere protein complexes and their role in lymphoid malignancies. 2017 , 9, 17-30		2

528	Altered N-Linked Glycosylation in Follicular Lymphoma and Chronic Lymphocytic Leukemia: Involvement in Pathogenesis and Potential Therapeutic Targeting. <i>Frontiers in Immunology</i> , 2017 , 8, 912 ^{8.4}	11
527	MicroRNA-155-5p Overexpression in Peripheral Blood Mononuclear Cells of Chronic Lymphocytic Leukemia Patients Is a Novel, Independent Molecular Biomarker of Poor Prognosis. 2017 , 2017, 2046545	22
526	The role of B cell antigen receptors in mantle cell lymphoma. 2017 , 10, 164	12
525	Lck is a relevant target in chronic lymphocytic leukaemia cells whose expression variance is unrelated to disease outcome. 2017 , 7, 16784	9
524	Next-generation sequencing in chronic lymphocytic leukemia: recent findings and new horizons. 2017 , 8, 71234-71248	18
523	An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness. 2017 , 8, 28008-28020	11
522	Clinical Implications of Novel Genomic Discoveries in Chronic Lymphocytic Leukemia. 2017 , 35, 984-993	37
521	Chronic lymphocytic leukaemia. 2018 , 391, 1524-1537	142
520	Prognostic Factors in the Era of Targeted Therapies in CLL. 2018 , 13, 78-90	7
519	Chronic lymphocytic leukemia and mantle cell lymphoma: crossroads of genetic and microenvironment interactions. <i>Blood</i> , 2018 , 131, 2283-2296	2.2 59
518	Review of targeted therapy in chronic lymphocytic leukemia: what a radiologist needs to know about CT interpretation. 2018 , 18, 13	2
517	Pathology of Non-Hodgkin and Hodgkin Lymphomas. 2018 , 773-826	
516	Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Introduction-Definition, Diagnosis, Cell of Origin. 2018 , 1-33	
515	Lymphoid Leukemias in Adults. 2018 , 422-433	1
514	Proteomics Profiling of CLL Versus Healthy B-cells Identifies Putative Therapeutic Targets and a Subtype-independent Signature of Spliceosome Dysregulation. 2018 , 17, 776-791	31
513	Targeting B cell receptor signalling in cancer: preclinical and clinical advances. 2018 , 18, 148-167	159
512	Epigenetic deregulation in chronic lymphocytic leukemia: Clinical and biological impact. 2018 , 51, 1-11	26
511	Chronic Lymphocytic Leukemia. 2018 ,	2

510	CD38 knockout suppresses tumorigenesis in mice and clonogenic growth of human lung cancer cells. 2018 , 39, 242-251		41
509	Critical molecular pathways in CLL therapy. 2018 , 24, 9		23
508	Role of Bruton's tyrosine kinase in B cells and malignancies. 2018 , 17, 57		225
507	Elevated miR-20b-5p expression in peripheral blood mononuclear cells: A novel, independent molecular biomarker of favorable prognosis in chronic lymphocytic leukemia. 2018 , 70, 1-7		21
506	Chronic Lymphocytic Leukemia-Derived IL-10 Suppresses Antitumor Immunity. 2018 , 200, 4180-4189		24
505	iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. <i>Blood</i> , 2018 , 131, 2745-2760	2.2	607
504	Treatment of Chronic Lymphocytic Leukemia and Related Disorders. 2018 , 117-134		
503	CD49d shows superior performance characteristics for flow cytometric prognostic testing in chronic lymphocytic leukemia/small lymphocytic lymphoma. 2018 , 94, 129-135		9
502	Association between immunoglobulin heavy-chain variable region mutational status and isolated favorable baseline genomic aberrations in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2018 , 59, 59-68	1.9	5
501	Telomere length in poor-risk chronic lymphocytic leukemia: associations with disease characteristics and outcome. <i>Leukemia and Lymphoma</i> , 2018 , 59, 1614-1623	1.9	11
500	Regulation of MAPK signaling and implications in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2018 , 59, 1565-1573	1.9	8
499	The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab. <i>British Journal of Haematology</i> , 2018 , 180, 33-40	4.5	23
498	What is the optimal management of older CLL patients?. 2018 , 31, 83-89		3
497	Advances in chronic lymphocytic leukemia pharmacotherapy. 2018 , 97, 349-358		5
496	Using prognostic models in CLL to personalize approach to clinical care: Are we there yet?. 2018 , 32, 159-166		8
495	Flow Cytometric Principles in Hematopathology. 2018 , 686-711.e1		
494	On the architecture of translational research designed to control chronic lymphocytic leukemia. 2018 , 2018, 1-8		6
493	Clinical outcomes in chronic lymphocytic leukaemia associated with expression of CD5, a negative regulator of B-cell receptor signalling. <i>British Journal of Haematology</i> , 2018 , 183, 747-754	4.5	4

492	From Mice to Men: How B Cell Immunology Helped the Understanding of Leukemia Development. <i>Frontiers in Immunology</i> , 2018 , 9, 2402	8.4	1
491	Evaluation of CD38 expression in Sudanese patients with chronic lymphocytic leukemia. 2018 , 11, 815		3
490	Syndecan-1 (sCD138) levels in chronic lymphocytic leukemia: clinical and hematological correlations. 2018 , 53, 205-209		3
489	Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation. 2018 ,		3
488	MYD88 L265P mutations identify a prognostic gene expression signature and a pathway for targeted inhibition in CLL. <i>British Journal of Haematology</i> , 2019 , 184, 925-936	4-5	7
487	The current role of clinical flow cytometry in the evaluation of mature B-cell neoplasms. 2019 , 96, 20-29		10
486	Chronic lymphocytic leukemia treatment algorithm 2018. 2018 , 8, 93		46
485	Identification of Distinct Unmutated Chronic Lymphocytic Leukemia Subsets in Mice Based on Their T Cell Dependency. <i>Frontiers in Immunology</i> , 2018 , 9, 1996	8.4	6
484	Prognostic and therapeutic stratification in CLL: focus on 17p deletion and p53 mutation. 2018 , 97, 2269-2278		18
483	The Ins and Outs of Autophagy and Metabolism in Hematopoietic and Leukemic Stem Cells: Food for Thought. 2018 , 6, 120		12
482	Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia. Krohem B-CLL 2017. 2018 , 57, 190-215		4
481	Altered patterns of global protein synthesis and translational fidelity in RPS15-mutated chronic lymphocytic leukemia. <i>Blood</i> , 2018 , 132, 2375-2388	2.2	31
480	Combined Influence of B-Cell Receptor Rearrangement and Somatic Hypermutation on B-Cell Class-Switch Fate in Health and in Chronic Lymphocytic Leukemia. <i>Frontiers in Immunology</i> , 2018 , 9, 1784	8.4	14
479	Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). <i>Blood Advances</i> , 2018 , 2, 1705-1718	7.8	9
478	Evolution of CLL treatment - from chemoimmunotherapy to targeted and individualized therapy. 2018 , 15, 510-527		73
477	The reference epigenome and regulatory chromatin landscape of chronic lymphocytic leukemia. 2018 , 24, 868-880		103
476	The International Prognostic Index for Patients with Chronic Lymphocytic Leukemia Has the Higher Value in Predicting Overall Outcome Compared with the Barcelona-Bрно Biomarkers Only Prognostic Model and the MD Anderson Cancer Center Prognostic Index. 2018 , 2018, 9506979		15
475	ZAP-70 expression is associated with increased CD4 central memory T cells in chronic lymphocytic leukemia: cross-sectional study. 2018 , 40, 317-325		2

474	The Light Chain IgLV3-21 Defines a New Poor Prognostic Subgroup in Chronic Lymphocytic Leukemia: Results of a Multicenter Study. 2018 , 24, 5048-5057		21
473	Impact of age and comorbidities on the efficacy of FC and FCR regimens in chronic lymphocytic leukemia. 2018 , 97, 2153-2161		4
472	Balancing efficacy and toxicity of targeted agents currently used for the treatment of patients with chronic lymphocytic leukemia. 2018 , 11, 601-611		8
471	Chronic lymphocytic leukemia with proliferation centers in bone marrow is associated with younger age at initial presentation, complex karyotype, and TP53 disruption. 2018 , 82, 215-231		6
470	CD38 Is Robustly Induced in Human Macrophages and Monocytes in Inflammatory Conditions. <i>Frontiers in Immunology</i> , 2018 , 9, 1593	8.4	86
469	Bioinformatics of Epigenomic Data Generated From Next-Generation Sequencing. 2018 , 65-106		2
468	Immunoglobulin heavy chain variable region gene and prediction of time to first treatment in patients with chronic lymphocytic leukemia: Mutational load or mutational status? Analysis of 1003 cases. <i>American Journal of Hematology</i> , 2018 , 93, E216-E219	7.1	9
467	A History of the Chronic Leukemias. 2018 , 3-8		
466	Update on Fc receptor-like (FCRL) family: new immunoregulatory players in health and diseases. 2018 , 22, 487-502		21
465	Chronic Lymphocytic Leukemia: Diagnosis and Treatment. 2018 , 93, 651-664		18
464	Normal serum protein electrophoresis and mutated IGHV genes detect very slowly evolving chronic lymphocytic leukemia patients. 2018 , 7, 2621-2628		4
463	Morphological, immunophenotypic, and genetic features of chronic lymphocytic leukemia with trisomy 12: a comprehensive review. 2018 , 103, 931-938		20
462	Why Is the Immunoglobulin Heavy Chain Gene Mutation Status a Prognostic Indicator in Chronic Lymphocytic Leukemia?. 2018 , 140, 51-54		12
461	ZAP70 expression enhances chemokine-driven chronic lymphocytic leukemia cell migration and arrest by valency regulation of integrins. 2018 , 32, 4824-4835		11
460	Preferential use of unmutated immunoglobulin heavy variable region genes in Boxer dogs with chronic lymphocytic leukemia. 2018 , 13, e0191205		3
459	Daratumumab at the frontiers of post-transplant refractory T-acute lymphoblastic leukemia-a worthwhile strategy?. 2018 , 53, 1487-1489		25
458	MicroRNA-92a-3p overexpression in peripheral blood mononuclear cells is an independent predictor of prolonged overall survival of patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2019 , 60, 658-667	1.9	13
457	Pathogenic B-cell receptor signaling in lymphoid malignancies: New insights to improve treatment. 2019 , 291, 190-213		40

456	Predicting the outcome of patients with chronic lymphocytic leukemia: Progress and uncertainty. 2019 , 125, 3699-3705		8
455	Constitutive Activation of the B Cell Receptor Underlies Dysfunctional Signaling in Chronic Lymphocytic Leukemia. 2019 , 28, 923-937.e3		5
454	Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia. 2019 , 19, 715-722.e6		22
453	Molecular pathogenesis of chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2019 , 186, 668-684	4.5	7
452	Prognostic risk score for patients with relapsed or refractory chronic lymphocytic leukaemia treated with targeted therapies or chemoimmunotherapy: a retrospective, pooled cohort study with external validations. 2019 , 6, e366-e374		36
451	Chronic lymphocytic leukaemia: from genetics to treatment. 2019 , 16, 684-701		85
450	Detection of Differentially Methylated Regions Using Bayes Factor for Ordinal Group Responses. 2019 , 10,		1
449	Lymphoma genetics. 2019 , 101-110		
448	Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. <i>American Journal of Hematology</i> , 2019 , 94, 1353-1363	7.1	152
447	Ectonucleotidases in Blood Malignancies: A Tale of Surface Markers and Therapeutic Targets. <i>Frontiers in Immunology</i> , 2019 , 10, 2301	8.4	15
446	Proteomics insights into the pathology and prognosis of chronic lymphocytic leukemia. 2019 , 40, 317-327		7
445	Immunophenotyping. <i>Methods in Molecular Biology</i> , 2019 ,	1.4	0
444	[Biological diagnosis of mature B cell malignancies]. 2019 , 48, 816-824		
443	Refining prognosis after first-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy in chronic lymphocytic leukaemia. 2019 , 20, 1478-1479		1
442	BCR-associated factors driving chronic lymphocytic leukemia cells proliferation ex vivo. 2019 , 9, 701		11
441	Genetic mutations in chronic lymphocytic leukemia: impact on clinical treatment. 2019 , 12, 89-98		3
440	New roles for B cell receptor associated kinases: when the B cell is not the target. <i>Leukemia</i> , 2019 , 33, 576-587	10.7	14
439	Another step forward in the 20-year history of mutations in chronic lymphocytic leukemia. 2019 , 104, 219-221		5

438	Computational Methods for Detection of Differentially Methylated Regions Using Kernel Distance and Scan Statistics. 2019 , 10,	1
437	Precision Medicine in Cancer Therapy. 2019 ,	1
436	Immunoglobulin gene rearrangement IGHV3-48 is a predictive marker of histological transformation into aggressive lymphoma in follicular lymphomas. 2019 , 9, 52	4
435	Genomics-Enabled Precision Medicine for Cancer. 2019 , 178, 137-169	6
434	Hedgehog activation in CLL. <i>Blood</i> , 2019 , 133, 2628-2630	2.2
433	Distinct immunoglobulin heavy chain variable region gene repertoire and lower frequency of del(11q) in Taiwanese patients with chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2019 , 187, 82-92	4.5 2
432	Combined analysis of ZAP-70 and CD38 expression in sudanese patients with B-cell chronic lymphocytic leukemia. 2019 , 12, 282	1
431	Laboratory Diagnosis of Chronic Lymphocytic Leukaemia. 2019 , 21-35	2
430	Chronic Lymphocytic Leukemia: Who, How, and Where?. 2019 , 3-17	2
429	Study of gene expressions' correlation structures in subgroups of Chronic Lymphocytic Leukemia Patients. 2019 , 95, 103211	2
428	Fc receptor-like 2 (FCRL2) is a novel marker of low-risk CLL and refines prognostication based on IGHV mutation status. 2019 , 9, 47	5
427	Corrupted coordination of epigenetic modifications leads to diverging chromatin states and transcriptional heterogeneity in CLL. 2019 , 10, 1874	38
426	Guidelines for Diagnosis, Indications for Treatment, Response Assessment, and Supportive Management of Chronic Lymphocytic Leukemia: The 2018 Update. 2019 , 69-77	
425	Analysis of basal chromosome instability in patients with chronic lymphocytic leukaemia. 2019 , 34, 245-252	2
424	Chronic Lymphocytic Leukemia. 2019 ,	
423	Prognostic and Predictive Effect of IGHV Mutational Status and Load in Chronic Lymphocytic Leukemia: Focus on FCR and BR Treatments. 2019 , 19, 678-685.e4	12
422	CRISPR/Cas9: a powerful tool for identification of new targets for cancer treatment. 2019 , 24, 955-970	32
421	New advances in chronic lymphocytic leukemia treatment: Biodegradable ZnO hybrid cluster nanoparticle as antineoplastic agents. 2019 , 409-430	

420	Role of long non-coding RNAs in disease progression of early stage unmutated chronic lymphocytic leukemia. 2019 , 10, 60-75		5
419	Targeting CD38 Enhances the Antileukemic Activity of Ibrutinib in Chronic Lymphocytic Leukemia. 2019 , 25, 3974-3985		16
418	Identification of a novel tRNA-derived RNA fragment exhibiting high prognostic potential in chronic lymphocytic leukemia. 2019 , 37, 498-504		21
417	Dissecting CLL through high-dimensional single-cell technologies. <i>Blood</i> , 2019 , 133, 1446-1456	2.2	1
416	Molecular Players in Hematologic Tumor Cell Trafficking. <i>Frontiers in Immunology</i> , 2019 , 10, 156	8.4	25
415	Time to Treatment Prediction in Chronic Lymphocytic Leukemia Based on New Transcriptional Patterns. <i>Frontiers in Oncology</i> , 2019 , 9, 79	5.3	5
414	Lymphoma. <i>Methods in Molecular Biology</i> , 2019 ,	1.4	
413	Case 7-2019: A 73-Year-Old Woman with Swelling of the Right Groin and Fever. 2019 , 380, 859-868		0
412	Flow Cytometry for Non-Hodgkin and Hodgkin Lymphomas. <i>Methods in Molecular Biology</i> , 2019 , 1956, 35-60	1.4	3
411	Stereotyped B Cell Receptor Immunoglobulins in B Cell Lymphomas. <i>Methods in Molecular Biology</i> , 2019 , 1956, 139-155	1.4	9
410	Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials. 2019 , 2019, 476-481		2
409	New Protein Markers of Chronic Lymphocytic and Acute Lymphocytic Leukemia. 2019 ,		
408	Treatment-naive CLL: lessons from phase 2 and phase 3 clinical trials. <i>Blood</i> , 2019 , 134, 1796-1801	2.2	8
407	Optimized Xenograft Protocol for Chronic Lymphocytic Leukemia Results in High Engraftment Efficiency for All CLL Subgroups. 2019 , 20,		4
406	Chronic Lymphocytic Leukemia: Rapidly Changing Treatment Landscape. 2019 ,		
405	Loss of NFAT2 expression results in the acceleration of clonal evolution in chronic lymphocytic leukemia. 2019 , 105, 531-538		7
404	AKT/mTORC2 Inhibition Activates FOXO1 Function in CLL Cells Reducing B-Cell Receptor-Mediated Survival. 2019 , 25, 1574-1587		9
403	The importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemia. <i>Leukemia</i> , 2019 , 33, 287-298	10.7	22

402	Poly(ADP-Ribose) Polymerases in Host-Pathogen Interactions, Inflammation, and Immunity. 2019 , 83,		21
401	Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact. <i>Blood</i> , 2019 , 133, 1205-1216	2.2	94
400	Acalabrutinib and its use in treatment of chronic lymphocytic leukemia. 2019 , 15, 579-589		18
399	Integrated epigenomic and transcriptomic analysis reveals TP63 as a novel player in clinically aggressive chronic lymphocytic leukemia. 2019 , 144, 2695-2706		12
398	Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials. <i>Leukemia and Lymphoma</i> , 2019 , 60, 1438-1446	1.9	11
397	Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab. <i>Blood</i> , 2019 , 133, 494-497	2.2	18
396	Altered expression of metabolic pathways in CLL detected by unlabelled quantitative mass spectrometry analysis. <i>British Journal of Haematology</i> , 2019 , 185, 65-78	4.5	3
395	Real-world testing and treatment patterns in chronic lymphocytic leukemia: A SEER patterns of care analysis. 2019 , 125, 135-143		15
394	Chronic Lymphocytic Leukemia. <i>Methods in Molecular Biology</i> , 2019 ,	1.4	
393	High-Throughput Sequencing of the T-Cell Receptor Beta Chain Gene Repertoire in Chronic Lymphocytic Leukemia. <i>Methods in Molecular Biology</i> , 2019 , 1881, 355-363	1.4	0
392	Immunoglobulin Gene Analysis in Chronic Lymphocytic Leukemia. <i>Methods in Molecular Biology</i> , 2019 , 1881, 51-62	1.4	0
391	Activation-induced deaminase and its splice variants associate with trisomy 12 in chronic lymphocytic leukemia. 2019 , 98, 423-435		2
390	Ibrutinib Therapy Releases Leukemic Surface IgM from Antigen Drive in Chronic Lymphocytic Leukemia Patients. 2019 , 25, 2503-2512		14
389	Accumulation of DNA damage and alteration of the DNA damage response in monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2019 , 60, 795-804	1.9	6
388	SLAMF6 in health and disease: Implications for therapeutic targeting. 2019 , 204, 3-13		8
387	Flow Cytometry in Hematology. 2019 , 253-275		1
386	Molecular Diagnostics in Cytopathology. 2019 ,		
385	Overview of non-coding mutations in chronic lymphocytic leukemia. 2019 , 13, 99-106		6

384	TLR Signaling Is Activated in Lymph Node-Resident CLL Cells and Is Only Partially Inhibited by Ibrutinib. 2019 , 79, 360-371	23
383	Molecular Diagnostics in Hematologic Malignancies. 2019 , 405-424	
382	Updates in the management of chronic lymphocytic leukemia/small lymphocytic leukemia. 2020 , 26, 146-155	2
381	Chronic Myelogenous Leukemia Diagnosed in the Setting of Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. 2020 , 28, 216-224	1
380	The Impact and Prognostic Significance of Chronic Lymphocytic Leukemia Upregulated 1 (CLLU1) Gene Expression in Patients with Chronic Lymphocytic Leukemia: A Single Center Experience. 2020 , 51, 259-264	
379	Is Cd11c and Fmc7 Negativity in Chronic Lymphocytic Leukemia Poor Prognostic?. 2020 , 36, 84-90	
378	Current Immunotherapeutic Strategies in Cancer. 2020 ,	4
377	Current Development of Monoclonal Antibodies in Cancer Therapy. 2020 , 214, 1-70	9
376	98% IGHV gene identity is the optimal cutoff to dichotomize the prognosis of Chinese patients with chronic lymphocytic leukemia. 2020 , 9, 999-1007	2
375	Chronic Lymphocytic Leukemia. 2020 , 1850-1871.e5	1
374	The Good, the Bad and the Unknown of CD38 in the Metabolic Microenvironment and Immune Cell Functionality of Solid Tumors. 2019 , 9,	26
373	Diagnosis and Treatment of Chronic Lymphocytic Leukemia: Recommendations of the French CLL Study Group (FILO). 2020 , 4, e473	9
372	SOHO State of the Art Updates and Next Questions: Clonal Evolution in Chronic Lymphocytic Leukemia. 2020 , 20, 779-784	2
371	Driver Mutations and Single Copy Number Abnormalities Identify Binet Stage A Patients with Chronic Lymphocytic Leukemia with Aggressive Progression. 2020 , 9,	2
370	Macrophage Polarization in Chronic Lymphocytic Leukemia: Nurse-Like Cells Are the Caretakers of Leukemic Cells. 2020 , 8,	1
369	Chemotherapy-free frontline therapy for CLL: is it worth it?. 2020 , 2020, 24-32	5
368	Roles for the FCRL6 Immunoreceptor in Tumor Immunology. <i>Frontiers in Immunology</i> , 2020 , 11, 575175	8.4 5
367	Editorial: Structure, Isotypes, Targets, and Post-translational Modifications of Immunoglobulins and Their Role in Infection, Inflammation and Autoimmunity. <i>Frontiers in Immunology</i> , 2020 , 11, 1761	8.4 0

366	The complex karyotype and chronic lymphocytic leukemia: prognostic value and diagnostic recommendations. <i>American Journal of Hematology</i> , 2020 , 95, 1361-1367	7.1	7
365	Chemokine Receptors CCR1 and CCR2 on Peripheral Blood Mononuclear Cells of Newly Diagnosed Patients with the CD38-Positive Chronic Lymphocytic Leukemia. 2020 , 9,		0
364	Prognostic models for newly-diagnosed chronic lymphocytic leukaemia in adults: a systematic review and meta-analysis. 2020 , 7, CD012022		10
363	Treatment of Chronic Lymphocytic Leukemia. 2020 , 383, 460-473		75
362	Monoclonal gammopathy and serum immunoglobulin levels as prognostic factors in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2020 , 190, 901-908	4.5	8
361	Assessing prognosis of chronic lymphocytic leukemia using biomarkers and genetics. 2020 , 8, 329-342		2
360	Clinicopathological characterization of chronic lymphocytic leukemia with MYD88 mutations: L265P and non-L265P mutations are associated with different features. 2020 , 10, 86		5
359	Distinct evolutionary paths in chronic lymphocytic leukemia during resistance to the graft-versus-leukemia effect. 2020 , 12,		7
358	Recent progress of prognostic biomarkers and risk scoring systems in chronic lymphocytic leukemia. 2020 , 8, 40		10
357	Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2020 , 12,	6.6	0
356	Importance of Crosstalk Between Chronic Lymphocytic Leukemia Cells and the Stromal Microenvironment: Direct Contact, Soluble Factors, and Extracellular Vesicles. <i>Frontiers in Oncology</i> , 2020 , 10, 1422	5.3	11
355	A reduced panel of eight genes (ATM, SF3B1, NOTCH1, BIRC3, XPO1, MYD88, TNFAIP3, and TP53) as an estimator of the tumor mutational burden in chronic lymphocytic leukemia. 2021 , 43, 683-692		3
354	A Novel SEC22B-NOTCH2 Fusion in Chronic Lymphocytic Leukemia. 2020 , 21, 200408		1
353	Frequency of MYD88 L256P mutation and its correlation with clinico-hematological profile in mature B-cell neoplasm. 2021 , 14, 231-239		1
352	Role of Specific B-Cell Receptor Antigens in Lymphomagenesis. <i>Frontiers in Oncology</i> , 2020 , 10, 604685	5.3	4
351	Targeting CD38 is lethal to Breg-like chronic lymphocytic leukemia cells and Tregs, but restores CD8+ T-cell responses. <i>Blood Advances</i> , 2020 , 4, 2143-2157	7.8	14
350	Unsupervised machine learning and prognostic factors of survival in chronic lymphocytic leukemia. 2020 , 27, 1019-1027		9
349	Mechanisms of B Cell Receptor Activation and Responses to B Cell Receptor Inhibitors in B Cell Malignancies. <i>Cancers</i> , 2020 , 12,	6.6	15

348	International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. <i>Blood</i> , 2020 , 135, 1859-1869	2.2	45
347	Analysis of the Targets and Glycosylation of Monoclonal IgAs From MGUS and Myeloma Patients. <i>Frontiers in Immunology</i> , 2020 , 11, 854	8.4	5
346	Evaluation of Somatic Hypermutation Status in Chronic Lymphocytic Leukemia (CLL) in the Era of Next Generation Sequencing. 2020 , 8, 357		3
345	Immunoglobulin gene analysis in chronic lymphocytic leukemia in the era of next generation sequencing. <i>Leukemia</i> , 2020 , 34, 2545-2551	10.7	15
344	Chronic Lymphocytic Leukaemia in 2020: the Future Has Arrived. 2020 , 22, 36		14
343	Serum Expression of Seven MicroRNAs in Chronic Lymphocytic Leukemia Patients. 2020 , 11, 97-102		2
342	The Many Facets of CD38 in Lymphoma: From Tumor-Microenvironment Cell Interactions to Acquired Resistance to Immunotherapy. 2020 , 9,		11
341	Tracing CLL-biased stereotyped immunoglobulin gene rearrangements in normal B cell subsets using a high-throughput immunogenetic approach. 2020 , 26, 25		9
340	Precision Medicine Management of Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2020 , 12,	6.6	16
339	Prognostic and Predictive Molecular Biomarkers in Chronic Lymphocytic Leukemia. 2020 , 22, 1114-1125		8
338	IgCaller for reconstructing immunoglobulin gene rearrangements and oncogenic translocations from whole-genome sequencing in lymphoid neoplasms. 2020 , 11, 3390		8
337	B cell signalling pathways-New targets for precision medicine in chronic lymphocytic leukaemia. 2020 , 92, e12931		4
336	Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies. 2020 , 105, 2205-2217		21
335	T-Cell Dynamics in Chronic Lymphocytic Leukemia under Different Treatment Modalities. 2020 , 26, 4958-4969		9
334	Is There a Role for Chemotherapy in the Era of Targeted Therapies?. 2020 , 15, 72-82		2
333	Celebrating 20 Years of IGHV Mutation Analysis in CLL. 2020 , 4, e334		10
332	Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG). 2020 , 105, 2598-2607		20
331	B Cell Receptor Immunogenetics in B Cell Lymphomas: Immunoglobulin Genes as Key to Ontogeny and Clinical Decision Making. <i>Frontiers in Oncology</i> , 2020 , 10, 67	5.3	12

330	is an inherited risk factor for CLL through the acquisition of a single-point mutation enabling autonomous BCR signaling. 2020 , 117, 4320-4327		24
329	Do we need to analyse everything at diagnosis in chronic lymphocytic leukaemia?. <i>British Journal of Haematology</i> , 2020 , 189, 603-604	4.5	1
328	Genomic and Epigenomic Alterations in Chronic Lymphocytic Leukemia. 2020 , 15, 149-177		8
327	Machine learning can identify newly diagnosed patients with CLL at high risk of infection. 2020 , 11, 363		36
326	Impact of using leader primers for IGHV mutational status assessment in chronic lymphocytic leukemia. <i>Leukemia</i> , 2020 , 34, 2257-2259	10.7	2
325	Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results. <i>Blood</i> , 2020 , 135, 1204-1213	2.2	81
324	An Updated Perspective on Current Prognostic and Predictive Biomarkers in Chronic Lymphocytic Leukemia in the Context of Chemoimmunotherapy and Novel Targeted Therapy. <i>Cancers</i> , 2020 , 12,	6.6	13
323	Diagnose und Behandlung der chronischen lymphatischen Leukämie. 2020 , 15, 8-16		
322	DAPK3 participates in the mRNA processing of immediate early genes in chronic lymphocytic leukaemia. 2020 , 14, 1268-1281		0
321	CLL intraclonal fractions exhibit established and recently acquired patterns of DNA methylation. <i>Blood Advances</i> , 2020 , 4, 893-905	7.8	1
320	A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia. 2020 , 105, 1613-1620		6
319	Prognosis Assessment of Early-Stage Chronic Lymphocytic Leukemia: Are We Ready to Predict Clinical Evolution Without a Crystal Ball?. 2020 , 20, 548-555.e4		5
318	Chronic Lymphocytic Leukemia. 2021 , 11,		11
317	Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL. <i>Blood</i> , 2021 , 137, 1365-1376	2.2	26
316	Reading the B-cell receptor immunome in chronic lymphocytic leukemia: revelations and applications. 2021 , 93, 14-24		2
315	Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2021 , 32, 23-33		92
314	IGLV3-21R110 identifies an aggressive biological subtype of chronic lymphocytic leukemia with intermediate epigenetics. <i>Blood</i> , 2021 , 137, 2935-2946	2.2	12
313	T Cells in Chronic Lymphocytic Leukemia: A Two-Edged Sword. <i>Frontiers in Immunology</i> , 2020 , 11, 612244.4		10

312	Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases. 2021 , 106, 493-499		1
311	IFN- γ and CD38 in Hyperprogressive Cancer Development. <i>Cancers</i> , 2021 , 13,	6.6	7
310	The Pivotal Role of Viruses in the Pathogeny of Chronic Lymphocytic Leukemia: Monoclonal (Type 1) IgG K Cryoglobulinemia and Chronic Lymphocytic Leukemia Diagnosis in the Course of a Human Metapneumovirus Infection. 2021 , 13,		
309	Recurrent XPO1 mutations alter pathogenesis of chronic lymphocytic leukemia. 2021 , 14, 17		4
308	Duvelisib (Copiktra) in relapsed or refractory chronic lymphocytic leukemia: safety and efficacy. 2021 , 21, 481-488		4
307	Assessing technical and biological variation in SWATH-MS-based proteomic analysis of chronic lymphocytic leukaemia cells. 2021 , 11, 2932		2
306	Therapeutic Options for Patients with TP53 Deficient Chronic Lymphocytic Leukemia: Narrative Review. 2021 , 13, 1459-1476		0
305	Prognostic factors and effectiveness of the first-line therapy for chronic lymphocytic leukemia: results of 10-year follow-up. 2021 , 27, 80-96		1
304	A hotspot mutation in transcription factor IKZF3 drives B cell neoplasia via transcriptional dysregulation. 2021 , 39, 380-393.e8		7
303	Integrative prognostic models predict long-term survival after immunochemotherapy in chronic lymphocytic leukemia patients. 2021 ,		1
302	The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action. 2021 , 11, 57		5
301	T-cell dysfunction in chronic lymphocytic leukemia from an epigenetic perspective. 2021 , 106, 1234-1243		2
300	Oral PI3K- γ Inhibitor for the Management of People with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: A Narrative Review on Duvelisib. 2021 , 14, 2109-2119		3
299	Intensity of antigen expression reflects IGHV mutational status and Dohner-defined prognostic categories in chronic lymphocytic leukemia, monoclonal B-cell lymphocytosis, and small lymphocytic lymphoma. <i>Leukemia and Lymphoma</i> , 2021 , 62, 1828-1839	1.9	
298	References. 2021 , 301-427		
297	B-cell receptor signaling and genetic lesions in TP53 and CDKN2A/CDKN2B cooperate in Richter transformation. <i>Blood</i> , 2021 , 138, 1053-1066	2.2	6
296	Extracellular vesicles and their associated miRNAs as potential prognostic biomarkers in chronic lymphocytic leukemia. 2021 , 23, 66		1
295	The DNx Mouse Model of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Recapitulates the Biased IGHV Gene Usage, Stereotypy, and Antigen-Specific HCDR3 Selection of Its Human Counterpart. <i>Frontiers in Immunology</i> , 2021 , 12, 627602	8.4	1

294	From Biomarkers to Models in the Changing Landscape of Chronic Lymphocytic Leukemia: Evolve or Become Extinct. <i>Cancers</i> , 2021 , 13,	6.6	1
293	Subgroup-specific gene expression profiles and mixed epistasis in chronic lymphocytic leukemia.		1
292	Temporal multiomic modeling reveals a B-cell receptor proliferative program in chronic lymphocytic leukemia. <i>Leukemia</i> , 2021 , 35, 1463-1474	10.7	1
291	The future of laboratory testing in chronic lymphocytic leukaemia. 2021 , 53, 377-384		0
290	The Evolving Landscape of Chronic Lymphocytic Leukemia on Diagnosis, Prognosis and Treatment. 2021 , 11,		2
289	Clinical outcome and prognostic factors in dogs with B-cell chronic lymphocytic leukemia: A retrospective study. 2021 , 35, 1918-1928		2
288	Challenges with Approved Targeted Therapies against Recurrent Mutations in CLL: A Place for New Actionable Targets. <i>Cancers</i> , 2021 , 13,	6.6	1
287	Identification of Clinically Relevant Subgroups of Chronic Lymphocytic Leukemia Through Discovery of Abnormal Molecular Pathways. 2021 , 12, 627964		0
286	Immune Gene Rearrangements: Unique Signatures for Tracing Physiological Lymphocytes and Leukemic Cells. 2021 , 12,		0
285	TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target. <i>Blood</i> , 2021 , 137, 3064-3078	2.2	2
284	Chemoimmunotherapy in the First-Line Treatment of Chronic Lymphocytic Leukaemia: Dead Yet, or Alive and Kicking?. <i>Cancers</i> , 2021 , 13,	6.6	1
283	Exploring the pathways to chronic lymphocytic leukemia. <i>Blood</i> , 2021 , 138, 827-835	2.2	3
282	Towards Control Of Chronic Lymphocytic Leukemia With Targeted Agents. 2021 , 39,		1
281	Multivariate transcriptome analysis identifies networks and key drivers of chronic lymphocytic leukemia relapse risk and patient survival. 2021 , 14, 171		1
280	Proteomics-based identification of cancer-associated proteins in chronic lymphocytic leukaemia. 2021 , 52, 1-12		0
279	Repertoire of Rearranged Immunoglobulin Heavy Chain Genes in Russian Patients With B-Cell Lymphoproliferative Diseases. 2021 , 21, e938-e945		1
278	Temporal variation in lymphocyte proteomics.		
277	Multi-omics reveals clinically relevant proliferative drive associated with mTOR-MYC-OXPPOS activity in chronic lymphocytic leukemia. 2021 , 2, 853-864		2

276	ENDOG Impacts on Tumor Cell Proliferation and Tumor Prognosis in the Context of PI3K/PTEN Pathway Status. <i>Cancers</i> , 2021 , 13,	6.6	2
275	CD4+ T cells sustain aggressive chronic lymphocytic leukemia in E μ TCL1 mice through a CD40L-independent mechanism. <i>Blood Advances</i> , 2021 , 5, 2817-2828	7.8	0
274	Expression patterns of CD180 in the lymph nodes of patients with chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2021 , 195, e131-e134	4.5	
273	Mining the Microenvironment for Therapeutic Targets in Chronic Lymphocytic Leukemia. 2021 , 27, 306-313		0
272	The Biology of Chronic Lymphocytic Leukemia: Diagnostic and Prognostic Implications. 2021 , 27, 266-274		0
271	Perspectives on Precision Medicine in Chronic Lymphocytic Leukemia: Targeting Recurrent Mutations-NOTCH1, SF3B1, MYD88, BIRC3. 2021 , 10,		0
270	Potential Relevance of B-cell Maturation Pathways in Defining the Cell(s) of Origin for Chronic Lymphocytic Leukemia. 2021 , 35, 665-685		1
269	The Extracellular NADome Modulates Immune Responses. <i>Frontiers in Immunology</i> , 2021 , 12, 704779	8.4	5
268	Altered DNA Methylation Profiles in Mutated CLL Patients. 2021 , 22,		0
267	High Bax/Bcl-2 ratio is associated with good prognosis and better survival in patients with B cell chronic lymphocytic leukemia. 2021 , 107, 106604		2
266	The Significance of B-cell Receptor Stereotypy in Chronic Lymphocytic Leukemia: Biological and Clinical Implications. 2021 , 35, 687-702		0
265	CRIS: complete reconstruction of immunoglobulin sequences from RNA-seq data. 2021 , 1, vbab021		0
264	From Descriptive to Functional Genomics of Leukemias Focusing on Genome Engineering Techniques. 2021 , 22,		2
263	Old Prognostic Markers Still Have a Role in CLL Management. 2021 , 21, S139-S141		
262	Chronic lymphocytic leukemia in a young population. 2021 , 110, 106668		0
261	Immunomolecular evaluation of dihydroartemisinin effects on apoptosis in chronic lymphocytic leukemia cell lines. 2021 , 110, 106702		
260	The signs of negative selection in IGHV framework regions are associated with worse overall survival of chronic lymphocytic leukemia patients. 2021 , 110, 106686		
259	Aberrant expression profile of miR-32, miR-98 and miR-374 in chronic lymphocytic leukemia. 2021 , 111, 106691		1

258	Relapsed Chronic Lymphocytic Leukaemia with Concomitant Extensive Chronic Graft versus Host Disease after Allogeneic Haematopoietic Stem Cell Transplantation Successfully Treated with Oral Venetoclax. 2021 , 2021, 8831125		1
257	Musashi 2 influences chronic lymphocytic leukemia cell survival and growth making it a potential therapeutic target. <i>Leukemia</i> , 2021 , 35, 1037-1052	10.7	2
256	Incorporating molecular biomarkers into the continuum of care in chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2021 , 62, 1289-1301	1.9	0
255	Mature B-Cell Neoplasms. 2021 , 339-359		
254	Building a network of TP53 and IGHV testing reference centers across Spain: the Red53 initiative. 2021 , 100, 825-830		1
253	Lymphoid Malignancies.		3
252	Chronic Lymphocytic Leukemia. 211-227		1
251	Chronic lymphocytic leukaemia: clinical translations of biological features. 2005 , 294, 165-85		6
250	New insights into the phenotype and cell derivation of B cell chronic lymphocytic leukemia. 2005 , 294, 31-49		27
249	Clinical and laboratory parameters that define clinically relevant B-CLL subgroups. 2005 , 294, 109-33		10
248	Gene expression profiling in malignant lymphomas. 2007 , 593, 134-46		5
247	B cell receptor and antigens in CLL. 2013 , 792, 1-24		6
246	Regulation of Immune Responses by CD38 and cADPR. 2002 , 217-240		3
245	Retinoid-Mediated Signaling and CD38 Expression. 2002 , 409-425		2
244	Determining the Origin of Human Germinal Center B Cell-Derived Malignancies. <i>Methods in Molecular Biology</i> , 2017 , 1623, 253-279	1.4	1
243	Clinical Flow-Cytometric Testing in Chronic Lymphocytic Leukemia. <i>Methods in Molecular Biology</i> , 2019 , 2032, 311-321	1.4	5
242	Staging of Chronic Lymphocytic Leukemia. 2004 , 193-199		1
241	Guidelines for Clinical Management of CLL. 2004 , 219-240		1

240	Young Patients With Chronic Lymphocytic Leukemia. 2004 , 401-413		3
239	Molecular Biology of Chronic Lymphocytic Leukemia. 2004 , 77-94		1
238	Cutaneous B-Cell Lymphomas. 2011 , 247-262		2
237	CD5 and other superantigens may select and maintain rabbit self-renewing B-lymphocytes and human B-CLL cells. 2000 , 252, 87-96		5
236	Chronic lymphocytic leukemia: a proliferation of B cells at two distinct stages of differentiation. 2000 , 252, 285-92		6
235	The AID dilemma: infection, or cancer?. 2012 , 113, 1-44		29
234	Normal Lymphoid Organs and Tissues. 2011 , 97-117		3
233	The Flow Cytometric Evaluation of Hematopoietic Neoplasia. 2011 , 656-673		3
232	Chronic lymphocytic leukemia/small lymphocytic lymphoma. 81-102		1
231	Historical aspects of chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2000 , 111, 1023-34	4.5	2
230	Autologous T lymphocytes recognize the tumour-derived immunoglobulin VH-CDR3 region in patients with B-cell chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2000 , 111, 230-8	4.5	25
229	Association of CD38 Antigen Expression with Other Prognostic Parameters in Early Stages of Chronic Lymphocytic Leukemia. <i>Leukemia and Lymphoma</i> , 2001 , 42, 1315-1321	1.9	24
228	Genome-wide mutational signatures revealed distinct developmental paths for human B cell lymphomas. 2021 , 218,		6
227	CD38 contributes to human natural killer cell responses through a role in immune synapse formation.		7
226	Impact of Genetics on Mature Lymphoid Leukemias and Lymphomas. 2020 , 10,		1
225	Redefining the prognostic likelihood of chronic lymphocytic leukaemia patients with borderline percentage of immunoglobulin variable heavy chain region mutations. <i>British Journal of Haematology</i> , 2020 , 189, 853-859	4.5	6
224	Immunoglobulin heavy variable somatic hyper mutation status in chronic lymphocytic leukaemia: on the threshold of a new era?. <i>British Journal of Haematology</i> , 2020 , 189, 809-810	4.5	4
223	Remarkably similar antigen receptors among a subset of patients with chronic lymphocytic leukemia. 2004 , 113, 1008-16		162

222	The IL-12R α gene functions as a tumor suppressor in human B cell malignancies. 2004 , 113, 1651-1659		49
221	Ig V region restrictions in human chronic lymphocytic leukemia suggest some cases have a common origin. 2004 , 113, 952-4		8
220	In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. 2005 , 115, 755-64		453
219	HS1 protein is differentially expressed in chronic lymphocytic leukemia patient subsets with good or poor prognoses. 2005 , 115, 1644-50		58
218	Immunoglobulin diversity gene usage predicts unfavorable outcome in a subset of chronic lymphocytic leukemia patients. 2008 , 118, 306-15		19
217	Drug-perturbation-based stratification of blood cancer. 2018 , 128, 427-445		72
216	Implications of new prognostic markers in chronic lymphocytic leukemia. 2012 , 2012, 76-87		38
215	Mutational Status of Ig VH Genes Provides Clinically Valuable Information in B-Cell Chronic Lymphocytic Leukemia. <i>Blood</i> , 1999 , 94, 1837-1839	2.2	1
214	Expression of unmutated VH genes is a detrimental prognostic factor in chronic lymphocytic leukemia. <i>Blood</i> , 2000 , 96, 377-379	2.2	4
213	High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH. <i>Blood</i> , 2000 , 96, 1505-1511	2.2	1
212	Obinutuzumab is Effective in Chronic Lymphocytic Leukemia and Rheumatoid Arthritis After Rituximab Failure: A Case Report. 2017 , 18, 516-519		3
211	Differential bone marrow homing capacity of VLA-4 and CD38 high expressing chronic lymphocytic leukemia cells. 2011 , 6, e23758		34
210	Clinical and biological relevance of genomic heterogeneity in chronic lymphocytic leukemia. 2013 , 8, e57356		4
209	IGHV1-69-encoded antibodies expressed in chronic lymphocytic leukemia react with malondialdehyde-acetaldehyde adduct, an immunodominant oxidation-specific epitope. 2013 , 8, e65203		10
208	VDJSeq-Solver: in silico V(D)J recombination detection tool. 2015 , 10, e0118192		11
207	Insulin growth factor 1 receptor expression is associated with NOTCH1 mutation, trisomy 12 and aggressive clinical course in chronic lymphocytic leukaemia. 2015 , 10, e0118801		12
206	The Number of Overlapping AID Hotspots in Germline IGHV Genes Is Inversely Correlated with Mutation Frequency in Chronic Lymphocytic Leukemia. 2017 , 12, e0167602		2
205	Spleen Tyrosine Kinase Is Involved in the CD38 Signal Transduction Pathway in Chronic Lymphocytic Leukemia. 2016 , 11, e0169159		4

204	Dysregulation of H/ACA ribonucleoprotein components in chronic lymphocytic leukemia. 2017 , 12, e0179883	7
203	Subtype assignment of CLL based on B-cell subset associated gene signatures from normal bone marrow - A proof of concept study. 2018 , 13, e0193249	5
202	Biological prognostic markers in chronic lymphocytic leukemia. 2009 , 52, 3-8	9
201	Use of V H, D and J H immunoglobulin gene segments in Brazilian patients with chronic lymphocytic leukaemia (CLL). 2008 , 31, 643-648	3
200	Genetic subclonal complexity and miR125a-5p down-regulation identify a subset of patients with inferior outcome in low-risk CLL patients. 2014 , 5, 140-9	9
199	The long noncoding RNA, treRNA, decreases DNA damage and is associated with poor response to chemotherapy in chronic lymphocytic leukemia. 2017 , 8, 25942-25954	19
198	Clinicopathological features and outcome of chronic lymphocytic leukaemia in Chinese patients. 2017 , 8, 25455-25468	7
197	CK2 and PI3K are direct molecular targets of quercetin in chronic lymphocytic leukaemia. 2017 , 8, 42571-42587	31
196	Cell lines generated from a chronic lymphocytic leukemia mouse model exhibit constitutive Btk and Akt signaling. 2017 , 8, 71981-71995	14
195	Efficient lysis of B-chronic lymphocytic leukemia cells by the plant-derived sesquiterpene alcohol Ebisabolol, a dual proapoptotic and antiautophagic agent. 2018 , 9, 25877-25890	5
194	Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells. 2015 , 6, 29833-46	25
193	Comprehensive assessment of potential multiple myeloma immunoglobulin heavy chain V-D-J intraclonal variation using massively parallel pyrosequencing. 2012 , 3, 502-13	16
192	Heightened BTK-dependent cell proliferation in unmutated chronic lymphocytic leukemia confers increased sensitivity to ibrutinib. 2016 , 7, 4598-610	34
191	Immunoglobulin gene rearrangements in Chinese and Italian patients with chronic lymphocytic leukemia. 2016 , 7, 20520-31	24
190	Validation of oligonucleotide microarray data using microfluidic low-density arrays: a new statistical method to normalize real-time RT-PCR data. 2005 , 38, 785-92	78
189	CD38 as an immunomodulator in cancer. 2020 , 16, 2853-2861	2
188	ZAP-70 and CD38 expression are independent prognostic factors in patients with B-cell chronic lymphocytic leukaemia and combined analysis improves their predictive value. 2008 , 46, 147-52	7
187	THE SPECTRUM OF TP53, SF3B1, AND NOTCH1 MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS EXPOSED TO IONIZING RADIATION DUE TO THE CHORNOBYL NPP ACCIDENT. 2018 , 23, 283-301	2

186	Chronic lymphocytic leukaemia in Norway--incidence and prognostic markers at diagnosis. 2012 , 132, 2056-9	7
185	Recent advances in chronic lymphocytic leukemia therapy. 2020 , 55, S72-S82	3
184	Expression of miR-15a and miR-16-1 in patients with chronic lymphocytic leukemia. 2013 , 157, 284-93	12
183	ZAP70 Expression Within del6q21, del11q13 and del17p13 Cytogenetic Subgroups of Iranian Patients with Chronic Lymphocytic Leukemia. 2014 , 16, e22528	1
182	Molecular diagnostics on lymphoid malignancies. 2004 , 128, 1379-84	3
181	A case of chronic lymphocytic leukemia with unmutated variable region of the immunoglobulin heavy chain gene with markedly high lactate dehydrogenase responding to ibrutinib. 2021 , 12, 172	
180	Driving Out Chronic Lymphocytic Leukemia With CAR T Cells. 2021 , 28, 5-5	0
179	The Hydropathy Index of the HCDR3 Region of the B-Cell Receptor Identifies Two Subgroups of IGHV-Mutated Chronic Lymphocytic Leukemia Patients With Distinct Outcome. <i>Frontiers in Oncology</i> , 2021 , 11, 723722	5.3
178	Molecular pathogenesis of B-cell chronic lymphocytic leukemia: analysis of 13q14 chromosomal deletions. 2000 , 252, 275-84	8
177	Somatic mutation of bcl-6 genes can occur in the absence of VH mutations in chronic lymphocytic leukemia. <i>Blood</i> , 2000 , 95, 3534-3540	2.2 3
176	Chronic Lymphocytic Leukemia. 2002 , 497-503	
175	La Leucémie Lymphoïde Chronique : une maladie unique ou deux maladies distinctes ?. 2002 , 186, 1251-1268	
174	Chronic Lymphocytic Leukemia. 2003 , 231-242	
173	Chronisch lymphatische Leukämie vom B-Zell-Typ (B-CLL). 2003 , 393-410	
172	The Heterogeneous Origin of the B-CLL Cell. 2004 , 95-107	
171	Prognostic Indicators of Chronic Lymphocytic Leukemia. 2004 , 201-215	1
170	Autologous and Allogeneic Transplantations for Chronic Lymphocytic Leukemia. 2004 , 255-268	
169	Genetics of B-Cell Chronic Lymphocytic Leukemia. 2004 , 57-75	

168 Molecular Diagnostics in Neoplastic Hematopathology. **2004**, 233-259

167 New Applications of Flow Cytometry in Cancer Diagnosis and Therapy. **2004**, 199-232

166 Chronische lymphatische Leukämie. **2004**, 1975-2000

165 Molecular Pathology of Hematological Malignancies. **2004**, 239-277

164 Immunotoxin Therapy of Chronic Lymphocytic Leukemia. **2004**, 299-314

163 Nodal B-Cell Lymphoma. **2004**, 19-120

3

162 Chronic lymphoid leukemias. **2004**, 521-542

161 Chronische lymphatische Leukämie/lymphoplasmozytoides Lymphom. **2006**, 2845-2886

160 Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia. **2006**, 406-414

159 Gene expression profiling data in lymphoma and leukemia: review of the literature and extrapolation of pertinent clinical applications. **2006**, 130, 483-520

24

158 Diseases of the haematological system. **2007**, 773-834

157 Chronic Lymphocytic Leukaemia.

156 Lymphoid leukemias. **2008**, 1131-1149

155 Inmunofenotipado. **2008**, 287-304

154 Chronic Lymphoid Leukemias. **2008**, 2293-2308

153 Differential diagnosis [chromosomal/molecular changes. **2008**, 542-566

152 Chronic Lymphocytic Leukemia and the B-Cell Receptor. **2008**, 45-67

151 Origin and Nature of Chronic Lymphocytic Leukemia B Cells. **2008**, 1-18

1

- 150 Stem Cell Transplantation in CLL. **2008**, 185-200
- 149 Gene Expression Profiling in the Study of Chronic Lymphocytic Leukemia. **2008**, 19-33
- 148 CLL-Specific Complications. **2008**, 231-260
- 147 Differential Diagnosis, Staging and Prognostic Factors. **2008**, 103-119 2
- 146 Stem Cells in Leukemia and Other Hematological Malignancies. **2009**, 111-136
- 145 Biologic Therapies for Chronic Lymphocytic Leukemia. **2009**,
- 144 Hematopoietic Progenitor Cell Transplantation for Treatment of Chronic Lymphocytic Leukemia. **2010**, 43-52
- 143 Gene Expression Profiling. **2010**, 177-189
- 142 Prognostic Markers. **2010**, 65-72
- 141 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. **2010**, 211-220
- 140 Myelodysplastic Syndromes and Chronic Myeloproliferative Neoplasms. **2010**, 293-312
- 139 Bone marrow. **2011**, 1927-2012
- 138 Diagnosis of Leukemias: New Diagnostic Modalities and Implications for Classification. 43-55
- 137 The Role of Stem-Cell Transplantation in Chronic Lymphocytic Leukemia. 315-326
- 136 Chronic Lymphocytic Leukemia: Pathophysiology, Diagnosis and Manifestations, and Prognostic Markers. 297-307
- 135 T(11;18)(q21;q21)-positive gastrointestinal MALT lymphomas are heterogeneous with respect to the V(H) gene mutation status. **2011**, 3, 24-32
- 134 Special Situations: Management of Elderly Patients and Chronic Lymphocytic Leukemia in Transformation. 327-337
- 133 Molecular Biology of Chronic Lymphoproliferative Disorders. 191-210

132 Lymphoid Leukaemias of Mature T, B and Natural Killer Cells. 301-376

131 Diseases. 160-300

130 High-dose therapy with autologous stem cell transplantation for patients with chronic lymphocytic leukaemia.

129 B-Cell Leukemias of Mature Lymphocytes. **2012**, 387-402

128 Chronic Lymphocytic Leukemia: From Pathobiology to Targeted Therapy. **2012**, 43-52

127 Flow Cytometric Principles in Hematopathology. **2012**, 655-678

126 Bone Marrow Involvement in Primary Mature B and T Cell Leukemias. **2012**, 171-189

125 Immunophenotyping. **2012**, 353-371

3

124 Transplant in chronic lymphocytic leukemia: to do it or not and if so, when and how?. **2012**, 399-404

123 Where Do We Stand in the Genomics of Lymphomas?. **2013**, 495-541

122 Prognostic Factors in B-Cell Lymphomas. **2013**, 101-139

121 Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia. **2013**, 65-82

120 Lymphoid leukemias. **2013**, 946-961

119 Chronic Lymphocytic Leukaemia.

118 Ancillary studies on neoplastic cytologic specimens. **2014**, 160, 13-29

117 Chronische lymphatische Leukämie. **2014**, 1-10

116 Lymphoma, Non-Hodgkin. **2014**,

115 Molecular Testing in Hematologic Malignancies. **2014**, 135-167

114 Chronic Lymphocytic Leukemia. **2014**, 1958-1978.e7

113 High-dose therapy with autologous stem cell transplantation for patients with chronic lymphocytic leukaemia.

112 Clinical Flow Cytometry for Hematopoietic Neoplasms. **2016**, 279-316

111 Cytogenetics: Applications. **2016**, 67-82

110 Somatic Mutation in Immunoglobulin Gene Variable Region in Patients With Chronic Lymphoid Leukemia and Its Influence on Disease Prognosis. **2016**, 3,

109 Molecular Diagnostics of Lymphoid Malignancies. **2017**, 103-129

108 Effect of IGHV Gene Mutation Status and BCR Structure Stereotypy on Effectiveness of BR Regimen in First-Line Therapy of Chronic Lymphocytic Leukemia. **2017**, 10, 141-149

107 Phenotypic Markers. **2017**, 115-125

106 MULTITARGET ANTI-PD-1/PD-L1/CD19/CD25/CD38 THERAPY USING CHELATE NANOCOMPLEX MSC-428 IN ONCOPATHOLOGY. **2018**, 2, 161

105 B-Cell Leukemias of Mature Lymphocytes. **2018**, 397-413.e2

104 B-Cell Receptors. **2018**, 61-89

103 Prognostic Indicators in CLL: Clinical, Cytogenetics, Novel Mutations, MicroRNAs, Hierarchal Classification. **2018**, 35-60 1

102 Clonal Evolution: Driver/Passenger Mutation Model in CLL. **2018**, 111-132

101 Minimal Residual Disease and IGHV-Genes Mutational Status as the Main Predictors of Response to Bendamustine-Rituximab Therapy in Previously Untreated Chronic Lymphocytic Leukemia. **2018**, 11, 167-174

100 Clinical Evaluation and Management of Chronic Lymphocytic Leukemia. **2019**, 401-409

99 Telomere dynamics in adult hematological malignancies. **2019**, 163, 1-7 3

98 HSP90 overexpression potentiates the B-cell receptor and fibroblast growth factor receptor survival signals in chronic lymphocytic leukemia cells. **2020**, 11, 2037-2046 1

97 Bio-informatic Analysis of Missense Single Nucleotide Polymorphisms (SNPs) in Human CD38 Gene Associated with B-Chronic Lymphocytic Leukemia.

96	HLA allele repertoire in Russian chronic lymphocytic leukemia patients with an unfavorable prognosis. 2020 , 65, 312-320		
95	Profiling of biological and environmental risk factors in immunogenetic subgroups of chronic lymphocytic leukemia - Czech national study. 2020 , 164, 425-434		
94	EXPRESSION OF LIPOPROTEIN LIPASE AND c-MYC ONCOGENE IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AFFECTED BY THE CHORNOBYL ACCIDENT. 2020 , 25, 421-429		
93	Small B-Cell Lymphomas With and Without Plasmacytic Differentiation. 2020 , 87-121		
92	Distinctive Signaling Profiles With Distinct Biological and Clinical Implications in Aggressive CLL Subsets With Stereotyped B-Cell Receptor Immunoglobulin. <i>Frontiers in Oncology</i> , 2021 , 11, 771454	5.3	3
91	Targeted Therapy in Chronic Lymphocytic Leukemia. 2008 , 61-86		
90	Lymph nodes and spleen. 688-812		1
89	Understanding Monoclonal B Cell Lymphocytosis: An Interplay of Genetic and Microenvironmental Factors. <i>Frontiers in Oncology</i> , 2021 , 11, 769612	5.3	0
88	How to Diagnose and Treat CD5-Positive Lymphomas Involving the Spleen.. 2021 , 28, 4611-4633		0
87	B-cell receptor isotypes differentially associate with cell signaling, kinetics, and outcome in chronic lymphocytic leukemia. 2021 ,		1
86	Outcomes of patients diagnosed with chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation: Results from a tertiary care center. 2021 ,		
85	Identification of CD105 (endoglin) as novel risk marker in CLL.. 2022 , 101, 773		0
84	Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies.. <i>Leukemia and Lymphoma</i> , 2022 , 1-12	1.9	2
83	Are we finally getting personal? Moving towards a personalized approach in chronic lymphocytic leukemia.. 2022 ,		0
82	B cell receptor antigen expression and phosphatidylinositol 3-kinase signaling regulate genesis and maintenance of mouse chronic lymphocytic leukemia.. 2022 ,		1
81	Biological and Clinical Insight from Analysis of the Tumor B-Cell Receptor Structure and Function in Chronic Lymphocytic Leukemia.. <i>Cancers</i> , 2022 , 14,	6.6	1
80	CLL update 2022: A continuing evolution in care.. 2022 , 100930		1
79	Inferring tumor-specific cancer dependencies through integrating ex-vivo drug response assays and drug-protein profiling.		

78	Druggable Molecular Pathways in Chronic Lymphocytic Leukemia.. 2022 , 12,		
77	TGF- β /SMAD Pathway Is Modulated by miR-26b-5p: Another Piece in the Puzzle of Chronic Lymphocytic Leukemia Progression.. <i>Cancers</i> , 2022 , 14,	6.6	0
76	Unmutated IGHV1-69 CLL Clone Displays a Distinct Gene Expression Profile by a Comparative qRT-PCR Assay.. 2022 , 10,		0
75	The Immune Microenvironment Shapes Transcriptional and Genetic Heterogeneity in Chronic Lymphocytic Leukemia.. <i>Blood Advances</i> , 2022 ,	7.8	0
74	Memory B-cell like chronic lymphocytic leukaemia is associated with specific methylation profile of promoter and undetectable expression of gene.. 2022 , 1-8		0
73	CD34+ cell of origin for immunoglobulin heavy chain variable region unmutated, but not mutated, chronic lymphocytic leukemia.. <i>Leukemia and Lymphoma</i> , 2022 , 1-7	1.9	0
72	Lymphoma: New Diagnosis and Current Treatment Strategies.. 2022 , 11,		
71	Proteomic profiling based classification of CLL provides prognostication for modern therapy and identifies novel therapeutic targets.. 2022 , 12, 43		1
70	Cyclin-dependent kinase inhibitor fadraciclib (CYC065) depletes anti-apoptotic protein and synergizes with venetoclax in primary chronic lymphocytic leukemia cells.. <i>Leukemia</i> , 2022 ,	10.7	2
69	Up to 8 Years Follow-up From RESONATE-2: First-Line Ibrutinib Treatment for Patients With Chronic Lymphocytic Leukemia.. <i>Blood Advances</i> , 2022 ,	7.8	8
68	Clonal Evolution of High-Risk Chronic Lymphocytic Leukemia: A Contemporary Perspective.. <i>Frontiers in Oncology</i> , 2021 , 11, 790004	5.3	2
67	The Determinants of B Cell Receptor Signaling as Prototype Molecular Biomarkers of Leukemia.. <i>Frontiers in Oncology</i> , 2021 , 11, 771669	5.3	0
66	Anti CD38 monoclonal antibodies for multiple myeloma treatment.. 2022 , 1-9		0
65	Molecular pathology of lymphoma. 257-276		
64	Network analysis reveals a major role for 14q32 cluster miRNAs in determining transcriptional differences between IGHV-mutated and unmutated CLL.		
63	Lower access to risk stratification tests and drugs, and worse survival of chronic lymphocytic leukaemia patients treated in public as compared to private hospitals in Brazil: A retrospective analysis of the Brazilian registry of chronic lymphocytic leukaemia. <i>EJHaem</i> ,	0.9	
62	Activated CLL cells regulate IL17F producing Th17 cells in miR155 dependent and outcome specific manners.. <i>JCI Insight</i> , 2022 ,	9.9	0
61	TRAF3 alterations are frequent in del-3'IGH chronic lymphocytic leukemia patients and define a specific subgroup with adverse clinical features.. <i>American Journal of Hematology</i> , 2022 ,	7.1	0

60	ROR1 - An Orphan Becomes Apparent.. <i>Blood</i> , 2022 ,	2.2	4
59	Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: the 2022 update of the recommendations by ERIC, the European Research Initiative on CLL. <i>Leukemia</i> ,	10.7	1
58	Immunoglobulin Gene Mutational Status Assessment by Next Generation Sequencing in Chronic Lymphocytic Leukemia. <i>Methods in Molecular Biology</i> , 2022 , 153-167	1.4	0
57	High surface IgM levels associate with shorter response to ibrutinib and BTK bypass in CLL patients. <i>Blood Advances</i> ,	7.8	0
56	Real-world Clinical Outcomes of First-Line Ibrutinib or Chemoimmunotherapy in Patients with Chronic Lymphocytic Leukemia by Risk Status. <i>Advances in Therapy</i> ,	4.1	1
55	Molecular Basis and Role of Siglec-7 Ligand Expression on Chronic Lymphocytic Leukemia B Cells. <i>Frontiers in Immunology</i> , 13,	8.4	1
54	T-helper cell regulation of CD45 phosphatase activity by galectin-1 and CD43 governs chronic lymphocytic leukaemia proliferation. <i>British Journal of Haematology</i> ,	4.5	
53	Acute and chronic leukemias. 2023 , 403-411		
52	Immunoglobulin Gene Sequence as an Inherited and Acquired Risk Factor for Chronic Lymphocytic Leukemia. <i>Cancers</i> , 2022 , 14, 3045	6.6	
51	Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group. <i>Leukemia and Lymphoma</i> , 1-14	1.9	0
50	Stem Cell Theory of Cancer: Implications for Translational Research from Bedside to Bench. <i>Cancers</i> , 2022 , 14, 3345	6.6	
49	MiR-146b-5p regulates il-23 receptor complex expression in chronic lymphocytic leukemia cells. <i>Blood Advances</i> ,	7.8	0
48	Impact of the Types and Relative Quantities of IGHV Gene Mutations in Predicting Prognosis of Patients With Chronic Lymphocytic Leukemia. <i>Frontiers in Oncology</i> , 12,	5.3	0
47	Left truncation in linked data: A practical guide to understanding left truncation and applying it using SAS and R. <i>Pharmaceutical Statistics</i> ,	1	
46	Myeloma and Leukemia. 2023 , 503-528		
45	Expression of lipoprotein lipase and SORL1 genes in patients with chronic lymphocytic leukemia. 2021 , 251-255		
44	Genetic Testing at Diagnosis Has Prognostic Value in Patients with Chronic Lymphocytic Leukemia including at Early Stages. 2022 , 12, 1802		
43	Spatial organization and early signaling of the B-cell receptor in CLL. 13,		

- 42 Enhanced Co-Stimulatory Signaling Improves CAR T cell Effector Responses in CLL. ○
- 41 Genomic Profiling for Clinical Decision Making in Lymphoid Neoplasms. 1
- 40 A gene expression assay based on chronic lymphocytic leukemia activation in the microenvironment to predict progression.
- 39 Inferring tumor-specific cancer dependencies through integrating ex vivo drug response assays and drug-protein profiling. **2022**, 18, e1010438
- 38 The spectrum of subclonal TP53 mutations in chronic lymphocytic leukemia: A next generation sequencing retrospective study.
- 37 CD38 as a multifaceted immunotherapeutic target in CLL. 1-11 ○
- 36 Integrative epigenomics in chronic lymphocytic leukaemia: Biological insights and clinical applications. ○
- 35 EXABS-176-CLL Clinical Significance of B-Cell Receptor Stereotype in CLL. **2022**, 22, S78-S80 ○
- 34 Role of Social Status and Social Environment on Net Survival in Patients with Chronic Lymphocytic Leukemia: A High-Resolution Population-Based Study. ○
- 33 Surface CD3-negative monomorphic epitheliotropic intestinal T-cell lymphoma. **2022**, 62, 169-174 ○
- 32 Loss of AID exacerbates the malignant progression of CLL. **2022**, 36, 2430-2442 ○
- 31 The end of the beginning: Application of single cell sequencing to chronic lymphocytic leukemia (CLL). ○
- 30 Rapid amplification of cDNA ends (5'RACE): A simpler method to analyze immunoglobulin genes and discover the value of the light chain in chronic lymphocytic leukemia. **2022**, 106952 ○
- 29 Molecular Determinants Underlying the Anti-Cancer Efficacy of CD38 Monoclonal Antibodies in Hematological Malignancies. **2022**, 12, 1261 ○
- 28 Super-Enhancer-Associated nine-gene prognostic score model for prediction of survival in chronic lymphocytic leukemia patients. 13, ○
- 27 Clonal evolution in chronic lymphocytic leukemia is associated with an unmutated IGHV status and frequently leads to a combination of loss of TP53 and TP53 mutation. ○
- 26 Advancements on the Multifaceted Roles of Sphingolipids in Hematological Malignancies. **2022**, 23, 12745 ○
- 25 Targeting CD38 for acute leukemia. 12, 1

24	Clinical and economic burden of first-line chemoimmunotherapy by risk status in chronic lymphocytic leukemia. 1-13	0
23	Chronic Lymphocytic Leukemia. 1-11	0
22	Anti-cancer activity of Biochanin A against multiple myeloma by targeting the CD38 and cancer stem-like cells. 2022 , 123, 11-26	1
21	Modern Approach to Prognostication and Therapy of Chronic Lymphocytic Leukemia. 2022 ,	0
20	Biological relevance of ZNF224 expression in chronic lymphocytic leukemia and its implication IN NF-kB pathway regulation. 9,	0
19	Old and New Facts and Speculations on the Role of the B Cell Receptor in the Origin of Chronic Lymphocytic Leukemia. 2022 , 23, 14249	1
18	Role of social status and social environment on net survival in patients with chronic lymphocytic leukemia: A high-resolution population-based study. 2023 , 82, 102292	0
17	Distinct Immunogenetic Profiles of Chronic Lymphocytic Leukemia in Asia: A Taiwan Cooperative Oncology Group Registry Study. 2022 , 6, e803	0
16	Different prognostic impact of recurrent gene mutations in chronic lymphocytic leukemia depending on IGHV gene somatic hypermutation status: a study by ERIC in HARMONY.	0
15	Evidence of somatic hypermutation in the antigen binding sites of patients with CLL harboring IGHV genes with 100% germline identity. 12,	0
14	High-throughput proteomics identifies THEMIS2 as independent biomarker of treatment-free survival in untreated CLL.	0
13	A novel next-generation sequencing capture-based strategy to report somatic hypermutation status using genomic regions downstream to immunoglobulin rearrangements.	0
12	Recent revelations and future directions using single-cell technologies in chronic lymphocytic leukemia. 13,	0
11	Cost-Effectiveness Analysis of Rituximab for Chronic Lymphocytic Leukemia Using A Semi-Markovian Model Approach in R. 2023 , 36, 10-17	0
10	STEREOTYPED CASES IN UKRAINIAN COHORT OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS DEPENDING ON THE IONIZING RADIATION EXPOSURE. 2022 , 27, 307-323	0
9	Prediction of Clinical Outcomes with Explainable Artificial Intelligence in Patients with Chronic Lymphocytic Leukemia. 2023 , 30, 1903-1915	0
8	Chronic Lymphocytic Leukemia: Current Knowledge and Future Advances in Cytogenomic Testing. 93-106	0
7	Next-CLL. 2023 ,	0

- 6 Genetic Lesions in Russian CLL Patients with the Most Common Stereotyped Antigen Receptors. **2023**, 14, 532
- 5 Current Landscape of Ancillary Diagnostic Testing in Chronic Lymphocytic Leukemia. **2023**,
- 4 B cell M-CLL clones retain selection against replacement mutations in their immunoglobulin gene framework regions. 13,
- 3 CLL stereotyped B-cell receptor immunoglobulin sequences are recurrent in the B-cell repertoire of healthy individuals: Apparent lack of central and early peripheral tolerance censoring. 13,
- 2 Precision diagnostics in chronic lymphocytic leukemia: Past, present and future. 13,
- 1 Clonal Characterization and Somatic Hypermutation Assessment by Next-Generation Sequencing in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. **2023**,